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ABSTRACT 
Peroxisome proliferator-activated receptor alpha (PPARα) and delta 
(PPARδ) belong to the nuclear receptor superfamily. PPARα is a target of 
lipid-lowering drugs and PPARδ promotes fatty acid utilization and is a 
promising anti-diabetic drug target.  However, evidence is growing that 
PPARδ-agonism can stimulate fat accumulation in liver, which may aggravate 
the toxic situation in diabetics.  
The aim of the study was to characterise the hepatic transcriptional and 
lipid response of humanized mouse models to PPARδ-agonists.  
In our studies of mice conditionally-expressing human PPARδ (hPPARδ), 
or the dominant-negative derivative of hPPARδ (hPPARδΔAF2) or wild-type 
animals, we demonstrated that GW501516, a potent PPARδ activator, 
promoted up-regulation of the genes involved in lipid turnover, stimulated 
significant weight loss and promoted hepatic steatosis in these mouse models. 
There was time-dependent accumulation of hepatic triglycerides observed in 
wild-type and in conditionally-expressing hPPARδ mice fed a diet containing 
PPARδ synthetic ligand. This was not seen in animals conditionally-
expressing hPPARδΔAF2, neither in PPARα-KO or PPARδ-KO animals. 
Concurrently, activation of PPARδ in humanised animals caused significant 
depletion, as compared with controls, of adipose tissue deposits when fed 
normal or high fat diet. This effect was completely absent in PPARα-KO or 
PPARδ-KO mice, fed diet containing GW501516.  Genome-wide 
transcriptional profiling of GW501516 effects in the livers of these different 
mouse strains was performed.  In PPARα-KO mice fed PPARδ-agonist, some 
XVI 
 
direct PPARδ target genes were still up-regulated, demonstrating that they are 
not sufficient for the observed phenotype.  In addition the blood HDL-raising 
effects of GW501516 were preserved in the PPARα-KO mice.  
This suggests a novel finding that both PPARδ and PPARα receptors are 
essential for GW501516-driven weight loss and hepatic steatosis, with PPARα 
working downstream of PPARδ. 
1 
 
Chapter 1 Introduction to fatty liver disease 
 
1.1 Liver lipid metabolism 
The liver is an organ that performs a diverse array of biochemical 
functions necessary for whole-body metabolic homeostasis. One of them is 
turnover of lipids. Fatty acids (FA) are the most frequently stored and circulating 
forms of energy, and triacylglycerols (TG) are the non-toxic form of fatty acids. 
Fatty acids/triacylglycerols may appear in liver from four sources. De novo fatty 
acids synthesis (de novo lipogenesis), cytoplasmic triacylglycerol stores, fatty 
acids derived from triacylglycerols of lipoprotein remnants directly taken up by 
the liver, and plasma free fatty acids released by adipose tissue [1]. In addition, 
the amount of TG present in hepatocytes represents a complex interaction 
among these 4 sources and fatty acid oxidation (FAO) and FA export within 
very low-density lipoprotein (VLDL)-TG [2].  
 
1.1.1 Lipid absorption by the liver 
The lipids taken up by liver may derive from the diet followed by the 
transport in the circulation, which requires specific transporters. Free fatty acids 
are very poorly soluble in the water and most of the fatty acids in plasma are 
transported loosely bound to the plasma protein albumin [3]. While dietary lipids 
in the form of triacylglycerol (TG) are transported by chylomicrons and very low 
density lipoprotein (VLDL) [4]. Chylomicrons are the largest and least dense 
lipoprotein particles found in plasma and contain the highest proportion (about 
85%) of triacylglycerol. They are derived from dietary sources of triacylglycerol 
2 
 
only, are produced by intestinal epithelia, and are delivered to the circulation via 
the lymphatic system [5]. 
Circulating triacylglycerols (in the form of chylomicrons or VLDL) are not 
taken up directly into the cells by the liver or any other organ. The triacylglycerol 
molecules must first by hydrolyzed enzymatically outside the cell to fatty acids 
and glycerol; this is carried out by lipoprotein lipase, which is attached to the 
outer surface of e.g. hepatocyte [6]. In the liver, specific transporters (FAT and 
L-FABP) are involved in the uptake and intracellular traffic of these molecules 
[7]. The hepatocyte then converts TG to diacylglycerol (carried out by 
microsomal lipase) and then to fatty acids, which are then activated and 
combined with coenzyme A, which allows their transport into the reticulum 
luminal space by intraluminal carnitine acyltransferase, where they are again re-
esterified by TG diacylglycerol acyltransferase 2, and become a part of nascent 
hepatic VLDL, or are stored within lipid droplets [6]. VLDLs are similar in 
composition to chylomicrons but considerably smaller in size. Although 
chylomicrons carry up to 80% of the TAG during the post-prandial period they 
are significantly outnumbered by the smaller VLDL particles at all times [8]. 
Although VLDL receptor mRNA is mainly expressed in the muscle, heart , 
adipose tissue [9], VLDL can still be taken up by the liver through VLDL 
receptor, forming a route of re-absorption of VLDL formed in the liver itself [10].    
Non-esterified fatty acids (NEFA of FFA) enter cells via transporters (fatty acid 
transport protein (FATP) or fatty acid translocase (FAT), CD36) or diffusion [11]. 
Non-esterified fatty acids and fatty acyl-CoA are bound to FABP and acyl CoA 
binding protein which transport them to intracellular compartments (for export or 
oxidation) or the nucleus (to be used as signalling molecules for transcription 
3 
 
factors) [12]. Cells exposed to exogenous fatty acids rapidly assimilate the fatty 
acids into neutral and polar lipids, and part of the fatty acids pool is oxidized. 
The result of these metabolic pathways leads to low levels of intracellular NEFA 
and fatty acyl-CoA [13]. 
 
1.1.2 De novo synthesis of fatty acids.  
The liver and the adipose are two major tissues that can produce fatty 
acids in the body. Fatty acids synthesized in the liver are destined for export 
through lipoprotein production, and thus provide an energy source and 
components needed for membrane structures building. In adipose tissue, de 
novo synthesis of fatty acids is aimed for fat deposition and long-term energy 
storage [14,15].  Synthesis of fatty acids occurs in the cytosol and it is an 
extension of an alkanoic chain, two carbons at a time, in which acetyl units 
(derived from either glucose or acetate) are added successively to acetyl-CoA. 
The rate-limiting step in this pathway is catalyzed by acetyl-CoA carboxylase A, 
which is considered to be the chain extender substrate (donor of acetyl units) in 
the elongation process. Formation of a new C–C bond by condensation of the 
acetyl and malonyl moieties is coupled with an energetically favourable 
decarboxylation, so that the carbon originating from CO2 introduced in the 
reaction catalyzed by acetyl- CoA carboxylase is recycled [16].  
Activity of fatty acid synthase (FAS) a key multifunctional enzyme that 
catalyzes the entire pathway of palmitate synthesis is closely associated with 
the rate of fatty acid synthesis and its expression can serve as a marker of in 
situ lipogenesis [17,18,19]. Fatty acid synthase is expressed in the two major 
sites of fatty acid production in the body, liver and adipose tissue, but the 
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relative contribution of these sites to de-novo lipogenesis is species dependent 
with liver in humans being the main organ for fatty acid synthesis while in rodent 
both liver and adipose tissue being equally important [13]. FAS is regulated 
positively by insulin and nutritional state (abundance of carbohydrates) [18], 
whereas glucagon and catecholamines inhibit its activity. Increased 
concentration of fatty acyl-CoA in the cytosol also inhibits the acetyl-CoA 
carboxylation. Regulation of FAS is also largely determined by intracellular fatty 
acid concentration (especially polyunsaturated fatty acids), an increase of which 
lowers FAS activity [20]. The regulation of lipogenic gene expression by insulin 
and fatty acids is mainly mediated by transcription factors, such as sterol 
regulatory element binding proteins SREBPs and in part by nuclear receptors 
such as liver X receptors (LXRs) [21]. 
 
1.1.3 Fatty acid oxidation in the liver 
Fatty acid oxidation occurs in mitochondria, peroxisomes and 
microsomes. The β-oxidation occurs in the mitochondria and the peroxisomes, 
whereas ω-oxidation occurs in the microsomes [22]. Carnitine 
palmitoyltransferase-1 (CPT1), the rate limiting step of mitochondrial fatty acid 
β-oxidation in cells, is located in the outer mitochondrial membrane. CPT1 
controls the transport of long-chain acyl-CoA into the mitochondria [23,24]. 
Mitochondrial oxidation may be either complete or incomplete. During 
incomplete oxidation ketone bodies are being formed [25]. Ketogenesis 
therefore allows the liver to metabolize about five times more fatty acids (for the 
same ATP yield), and conversion of fatty acids into water-soluble particles is a 
short-term way for redistribution of energy [10,26]. Ketogenesis is controlled 
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indirectly by CPT1 and directly by the activity of the mitochondrial key regulatory 
enzyme 3-hydroxy-3-methylglutaryl-CoA synthase (HMG-CoAs), which also 
plays important role in cholesterol synthesis [27]. There are differences between 
the peroxisomal and mitochondrial fatty acid oxidation. In peroxisomes, very 
long chain fatty acids are being oxidised, while mitochondrial β-oxidation is 
responsible for the oxidation of short, medium and long chain fatty acids [13]. 
 
1.1.4 Triacylglycerol export (VLDL turnover) 
The triglycerides are bound to apolipoprotein B (Apo B) to form the 
mature lipoprotein particle to be secreted as VLDL. Apo B synthesis is 
stimulated by elevated FFA and TG levels, as well as by the microsomal 
transfer protein (MTP), whereas it is inhibited by insulin [28]. Elevated FFA 
afflux to the liver, and normal or decreased insulin concentrations stimulate 
secretion of mature VLDL-Apo B. The majority of triglyceride incorporated into 
VLDL originate from intracellular storage pools rather than from de novo 
synthesis [29]. For example, in obese mice, de novo lipogenesis in the liver 
does not stimulate VLDL output [30], whereas in rats, high carbohydrate diets 
enhance secretion of VLDL-triacylglycerols, but this increased hepatic output of 
triacylglycerols is accomplished by enhanced formation of VLDL triglyceride 
from exogenous NEFA rather than from fatty acids synthesis in the liver [28]. 
 
1.1.5 Alterations in hepatic lipid and glucose metabolism 
In last few decades, obesity has risen to considerable proportions in 
Western societies. It is present in literally all age and socioeconomic groups. It 
is a complex condition produced and accompanied by many factors, which high 
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calorie diet and lack of exercise are most significant [31]. Obesity results as a 
direct imbalance between energy intake and energy expenditure. The excess of 
calories is principally stored in adipose tissue in form of triglyceride. However, 
obesity often leads to storage of the fat in tissues other then adipose tissue 
such as liver and skeletal muscle. Obesity and the metabolic syndrome promote 
alterations in hepatic lipid and glucose metabolism and are linked to formation 
and pathogenesis of fatty liver disease [32,33,34]. 
 
 
1.2 Features of non-alcoholic fatty liver disease. 
 
1.2.1 Characterization of the fatty liver disease. 
Liver abnormality known as non-alcoholic fatty liver disease (NAFLD) is 
characterized by an increase in intrahepatic triglyceride (IHTG) content 
(steatosis) with or without inflammation (steatohepatitis) or fibrotic components 
(cirrhosis). In the past, excess alcohol consumption was the primary reason for 
the majority of cases of NAFLD, but in recent years, non-alcoholic causes of 
NAFLD have attracted considerable attention [35,36,37]. Both alcoholic fatty 
liver disease (AFLD) and NAFLD generally begin as simple hepatic steatosis, 
and if the cause persists, this steatosis subsequently progresses to 
steatohepatitis, cirrhosis, and possibly to liver cancer [34]. Hepatic steatosis is 
defined as excess accumulation of fat (triglyceride) in hepatic parenchymal cells 
(hepatocytes) of the liver, and its aetiology is usually diverse [38,39,40]. 
Morphologically, hepatic steatosis appears as accumulation of large 
(macrovesicular) or small (microvesicular) cytosolic fat droplets in liver 
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parenchymal cells. A patient can be diagnosed with hepatic steatosis when lipid 
content in the liver exceeds 5–10% by weight [41,42]. In most cases hepatic 
steatosis is macrovesicular in type in the alcoholic, obese, and diabetic states. 
Macrovesicular steatosis, appears when hepatocytes contain a large, single 
vacuole of fat, which fills the cytosol and pushes the nucleus to the periphery 
(Fig. 1.1A). In microvesicular steatosis, hepatocytes are occupied by numerous 
small lipid droplets that do not displace the centrally located nucleus (Fig. 1.1B) 
[23]. 
 
 
Figure 1.1 Histopathological features of non-alcoholic fatty liver disease. Human liver 
biopsies from: A: macrovesicular hepatic steatosis with a large lipid vacuole in the 
hepatocyte. B: microvesicular steatosis where small fat droplets fill the hepatocyte 
cytoplasm with a central or peripheral location of the nucleus (stained blue). Adapted 
from Reddy et al, 2006. 
 
Generally genetic or toxin-related abnormalities in mitochondrial and 
peroxisomal β-oxidation of fatty acids might induce microvesicular hepatic 
steatosis, and this type tends to be rapidly progressive and more severe. Some 
hepatocytes with microvesicular steatosis may also reveal a macrovesicular 
fatty change, suggesting that the progression of disease can lead to fusion of 
8 
 
small lipid vacuoles to become large droplet [43]. In AFLD and longstanding 
NAFLD, hepatic steatosis is generally macrovesicular and, but in some cases, 
the phenotype of the droplets might be intermediate [34,44].  
The steatotic liver is vulnerable to secondary insults, which lead to 
hepatocellular inflammation and fibrosis. However, the exact cause of 
progression to non-alcoholic steatohepatitis (NASH) is not entirely defined. 
Currently the leading theory is that an in initial insult leads to fatty deposition in 
hepatocytes, while a second mechanism triggers the inflammation  that targets 
lipid-loaded hepatocytes (steatohepatitis). This is known as two hit hypothesis 
[45].  A variety of endogenous and exogenous factors have been implicated to 
produce a second “hit,” including hormones derived from adipose tissue (like 
adipocytokines), oxidative stress or bacterial-borne  endotoxin [45]. A small 
subset of patients with NAFLD (5-10%) develop NASH, which can potentially 
progress to more serious liver injury ending in liver cirrhosis. However, the 
occurence of NAFLD is nearly 50% in people with diabetes, 76% in those with 
obesity, and 100% morbidly obese with diabetes [41]. Moreover, older patients  
and those with hypertension and diagnosed obesity are at greater risk of 
developing NASH [32]. 
 
1.2.2 Non-alcoholic steatohepatitis. 
NASH has been defined as part of the spectrum of fatty liver disease, but 
the characteristic distinguishing feature is necroinflamatory damage to the 
tissue. In the diagnosis of NASH, a daily alcohol intake exceeding 20 g/day 
must be excluded due to the known hepatotoxicity of such alcohol use [32]. 
Hepatic injury is characterized in NASH by hepatocyte necrosis and 
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inflammatory infiltrates. Unlike NAFLD, NASH is a progressive liver disease, 
and if it is not reversed might lead to cirrhosis, liver failure and need for liver 
transplantation [34]. Histologic features of NASH are virtually very close to 
those seen in alcoholic steatohepatitis (although some differences exist like 
sclerosing hyaline necrosis, the veno-occlusive lesion first described and 
alcoholic foamy degeneration) [34]. And lipid peroxidation and oxidative stress 
appears to be responsible from the production of reactive oxygen species and 
inflammation in NASH [23]. Histological markers used to distinguish NASH from 
fatty acids accumulations vary in the literature, but when diagnosing NASH 
based on histopathology, degree of steatosis, the presence of hepatocellular 
ballooning and the lobular and portal inflammation is usually assessed. Typical 
look of NASH diagnosed liver biopsy is shown on Fig. 1.2. 
 
 
Fig 1.2 Characteristic features of non-alcoholic steatohepatitis. Zone 3 accentuation of 
the lesions of steatosis (large and small droplet type), ballooning and lobular 
inflammation. Adapted from Brunt E. 2007. 
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1.2.3 Liver cirrhosis 
If the causes persist, NASH may progress to later stages of liver disease 
with fibrosis and cirrhosis. This medical condition is characterized by 
replacement of functional hepatocytes by fibrotic, scar tissue, which greatly 
weakens liver functionality.  Although a some regression has been shown in 
animal models, cirrhosis is generally thought to be irreversible, and treatment 
usually focuses on stopping progression and disease-associated complications 
[46]. However, fibrosis progression in patients with NAFLD appears to be slow, 
sometimes it might take several decades for developing liver cirrhosis [42]. 
Currently, cirrhosis is being diagnosed primarily on histological evidence of late 
stage fibrosis  showing the end stage of the wound healing process, but without 
adequately signifying the complexity of its pathogenesis [47]. Histopathology of 
the fibrotic changes in the liver is shown in Fig. 1.3. 
 
 
Figure 1.3 Fibrosis in non-alcoholic steatohepatitis (NASH). Left: trichrome stain of liver 
showing both macrovesicular lipid droplets and fibrosis, most prominent in zone 3 near 
the central vein (CV). Right: Necrosis and inflammation in NASH. Hematoxylin and 
eosin stain of liver with injured ballooned hepatocytes (B) and mild infiltration of 
neutrophiles (N). Adapted from Adams et al 2005. 
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1.2.4 Liver carcinoma 
The last stage that NAFLD can turn into is development of hepatocellular 
carcinoma (HCC). Primary liver carcinoma including both HCC and intrahepatic 
cholangiocarcinoma often occur in patients with NASH, especially in those with 
advanced fibrosis and cirrhosis, and the occurrence of HCC is strong predictor 
of death in patients with old age and well developed liver fibrosis [48]. It is worth 
mentioning that obesity and NAFLD alone can induce proliferation and 
decrease the rate of apoptosis in hepatocytes in a mouse model, resulting in 
hepatic hyperplasia also in the absence of inflammation or cirrhosis [49]. 
 
1.2.5 Clinical characteristics of NAFLD 
NAFLD and NASH is usually an asymptomatic condition [32]. First the 
exact prevalence of both NAFLD and NASH is unclear because confirmation of 
the diagnosis requires liver biopsy. For obvious ethical consideration, no large 
screening studies have used this invasive technique. However, liver 
biochemistry abnormalities are common, and usually drag attention where 
otherwise unexplained elevations in liver tests or abnormal hepatic imaging 
(e.g. incidental finding) are found [33]. Although, fatty change of the liver can be 
well characterized by ultrasonography [50], computed topographic scanning [33] 
or magnetic resonance imaging [35,51] it does not differentiate NAFLD from 
NASH, and therefore it cannot replace biopsy-based liver histology. Recently 
many studies were undertaken to discover and evaluate non-invasive markers 
for NAFLD [52]. Serum-derived gene expression and proteomic markers attract 
attention along with fibrosis and apoptosis biomarkers allowing distinguishing 
between stages of fatty liver disease. In order to assess the utility of a 
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combination of individual markers in diagnosing and staging various forms of 
NAFLD a range of useful algorithm tests has been also proposed [52]. 
 
1.3 Causes of non-alcoholic fatty liver disease 
A reasonable correlation has been found between the risk for NAFLD or 
NASH and increasing body weight [53,54]. However, non-obese people have 
also a risk of developing non-alcoholic fatty liver disease. The risk factors for 
NAFLD among people who are not obese and in non-diabetics are: impaired 
fasting glycemia, hypertriglyceridemia, hyperuricemia, hypertension or levels of 
high-density lipoprotein cholesterol (HDL) [41]  and to some extent genetics [55] 
and others causes [56]. In the next part of this introduction some of the most 
common causes of NAFLD will be shortly characterized.  
 
1.3.1 Nutrition and de novo lipogenesis. 
Intake of the dietary calories is closely linked with de novo fatty acids in 
the liver. After the meal, both ingested fat and de novo lipogenesis increase and 
can provide more than 50% of the fatty acids entering the liver [57]. Dietary 
glucose and fat are important regulators of lipogenesis via activation of SREBP-
1c. Glucose also is an activator of carbohydrate response element-binding 
protein (ChREBP), which exerts, similarly to SREBP-1c, stimulatory effects on 
the expression of genes involved in lipogenesis and triglyceride synthesis [58]. 
Therefore during fasting lipogenesis accounts for less than 5% of hepatic fatty 
acids supply in healthy subjects, but lipogenesis may substantially increase in 
subjects with fatty liver creating positive feedback loop [18]. Expression of 
lipogenic gene SREBP-1c also depends on saturation of fatty acids.  Saturated 
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and trans-unsaturated FFAs are known to increase and mono and 
polyunsaturated FFAs decrease its expression and activity [21,24]. This was 
confirmed in human studies, where individuals with fatty liver had higher intake 
of calories as well as saturated fat and cholesterol when compared with healthy 
controls. This was confirmed in human studies, where individuals with fatty liver 
had higher intake of calories as well as saturated fat and cholesterol when 
compared with healthy controls. Apart from that, they also have lower intake of 
polyunsaturated fatty acids, fibre, and antioxidant vitamins [59,60]. Some 
studies also suggest, that iron overload can play some role in pathogenesis of 
in NASH [32]. Additionally there are studies showing that low carbohydrate, 
ketogenic diet is correlated with a greater weight loss, a better lipid profile, and 
clearly improved steatosis than low fat diets [61]. Among the carbohydrates, 
fructose appears to have the strongest effects on lipogenesis [62]. Because use 
and consumption of high fructose corn syrup has massively increased in the last 
decades in the western world, its contribution to the increase of the occurrence 
of fatty liver disease might be significant [63]. 
 
 
1.3.2 Body fat composition and liver fatty acids influx. 
Liver fat measured by proton magnetic resonance spectroscopy (1H-
MRS) is positively correlated with total adiposity expressed as body mass index 
(BMI) or percentage body fat. Furthermore, the association of liver fat with 
visceral adiposity, measured as waist circumference, is also positive [38]. 
However according to some studies visceral adipose index (VAI) cannot be 
adequate predictor of liver histology in patients with NAFLD [35].  A proposed 
14 
 
mechanism explaining the relationship of overall and visceral obesity with liver 
fat is as follows.  When adipose tissue expands, macrophages infiltrate it and 
eventually adipose tissue is highly exposed to proinflammatory cytokines and 
probably, therefore, can become insulin resistant [64]. In normal healthy 
condition insulin mediates suppression of lipolysis [15]. When the tissue is non-
responsive to insulin, it increases release of free fatty acids (FFAs) from 
adipocytes. In this case visceral adipose tissue (VAT) is more important than 
subcutaneous adipose tissue because it is metabolically more active [65]. 
Additionally, increased lipolysis in VAT is thought to result in an elevated flux of 
FFAs directly into the portal vein and therefore to the liver, a physiological 
phenomenon that is commonly defined  as the “portal hypothesis” [66]. FFAs 
are then taken up by the hepatocytes. However, during fasting the main origin 
of the FFAs in the systemic circulation is considered to be subcutaneous fat 
[33]. Although in the fasting state liver fatty acids are taken up predominantly 
from the systemic plasma FFA pool, the portal FFA route of supply to the liver 
may be more relevant postprandially as in obese individuals state of fasting is of 
course not the dominant one. Another factor associated with overgrown adipose 
tissue, which contributes to NAFLD is inflamed adipose tissue in obesity. High 
levels of proinflammatory cytokines as TNF-α and interleukins, particularly IL-6, 
suppresses the production of the insulin-sensitizing adiponectin [67]. Therefore, 
the imbalance in the secretion pattern of these adipocytokines is considered to 
represent another link between obesity and fatty liver. Circulating adiponectin 
closely and reversely correlates with liver fat content and hepatic insulin 
resistance [68]. Apart from hypothalamic effects that leptin has in the regulation 
of food intake, this adipokine is considered another important regulator of liver 
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fat. Although the mechanisms of the protective effect are not fully understood, 
the most probable explanation of leptin anti-steatotic effects lies in enhancing 
lipid oxidation and inhibiting lipogenesis in liver tissue [69]. In the animal studies 
where recombinant adenovirus-receptor constructs containing the normal leptin 
receptor were injected into obese Zucker diabetic rats, the marked hepatic 
triglyceride reduction was observed. It is known that most of the adenovirus-
receptor constructs is taken up by the liver [69]. 
 Surprisingly the reverse situation, where the total body adiposity is very 
low, can also result in ectopic lipid accumulation including liver steatosis. The 
lipoatrophy is a group of syndromes with various aetiology, characterised by 
paucity of adipose tissue. In lipoatrophy, adipocytes can by non-functional or 
normally functioning but lacking lipids to be stored. The latter situation reflects 
conditions such as extreme exercise, starvation, or treatment with 
pharmacological doses of leptin [55]. However, when adipocytes are present 
but non-functional, e.g. caused by autoimmune mechanisms or defects in 
adipogenesis, it results in ectopic fat accumulation as a way the body’s attempt 
to compensate for the overall lack of storage sites for lipids. Therefore, hepatic 
steatosis is uniformly present in severely affected patients, some of whom 
develop steatohepatitis and cirrhosis [55,70].  
 
1.3.3 Decreased hepatic lipid export 
Microsomal triglyceride transfer protein (MTP) mediates TAG association 
with apolipoprotein B (ApoB). Inhibition of MTP in mice results in inefficient lipid 
attachment to ApoB, which leads to impaired TAG transfer out of the liver [71].  
Additionally, hyperinsulinaemia can alter the synthesis of ApoB, leading to 
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decreased VLDL production. This finding was also confirmed in some of the 
NASH patients who were reported to have tempered synthesis of ApoB, which 
almost certainly contributes to hepatic fat accumulation [72]. However, in the 
subjects with high intrahepatic TG content, apart from having impaired insulin 
action in liver, they also have elevated hepatic VLDL-TG secretion rate. 
Moreover, intrahepatic TG content is the best independent predictor of 
increased VLDL-TG secretion rate [73]. 
 
1.3.4 Defects in the liver fat oxidation 
Some reports indicate that physical activity can be negatively associated 
with liver fat, and this effect is independent of BMI [53]. Mechanisms linking 
fitness and liver fat most likely include factors regulating hepatic lipid oxidation. 
Fitness is known to cause enlargement of and increase in mitochondria in 
skeletal muscle and the generation of type I fibers [74]. Mitochondria play an 
essential role in hepatocyte metabolism, representing the primary site for the 
oxidation of fatty acids. Hepatocytes are particularly rich in mitochondria, 
occupying approximately 18% of the liver cell volume [75]. Disruption of the 
straight-chain acyl-CoA oxidase gene in the mouse leads to the development of 
severe hepatic steatosis. These animals accumulate high levels of very long-
chain fatty acids (>C22) in plasma and hepatomegaly with accompanied by 
steatohepatitis. In later stages, hepatocyte death and hepatocellular carcinomas 
develop in these mice [76]. Very long-chain fatty acids (>C20) are not 
processed by the mitochondrial β-oxidation system, and they require 
peroxisomal β-oxidation to shorten the chain length for further completion of 
oxidation in mitochondria [23]. The well known master of genes involved in liver 
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lipid oxidation is peroxisome proliferator activated receptor α (PPARα). Genetic 
ablation of the PPARα causes massive fatty acid accumulation in response to 
fasting in these animals [77]. PPARα-KO mice fail to up-regulate genes involved 
in fatty acid oxidation systems in the liver and are unable oxidize the influxed 
fatty acids and thus develop severe hepatic steatosis. Furthermore, the 
administration of PPARα agonists to rats with induced fatty liver by methionine 
and choline-deficient diet prevents development of steatohepatitis [78]. 
Summary of potential causes for NAFLD is shown on Fig 1.3 
 
 
Figure 1.4 Major determinants of fatty liver. Adapted from Stefan et al, 2008 
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1.3.5 Treatment strategies for NAFLD 
The aim of treatment for NAFLD is to slow the progression of the disease 
and to prevent liver-related illness and death. There are currently 3 types of 
approach to treat NAFLD: life style modification, pharmacology and liver 
transplantation. Liver transplantation may be necessary when the disease has 
progressed to cirrhosis and is complicated by liver failure or hepatocellular 
carcinoma. However, recurrence of steatosis after transplantation happens in 
60%–100% of transplant recipients and progression to steatohepatitis is 
reported in one-third of cases [41]. Both weight loss and exercise are highly 
recommended for ameliorating some aspects of metabolic syndrome therefore 
these life style modifications are also useful for NAFLD treatment. Diets aim at 
reducing total daily energy intake, based on either a low processed 
carbohydrate, or low-fat diet, aimed at achieving about a 10% weight reduction. 
They should improve both metabolic and histopathological abnormalities in a 
diverse group of NAFLD patients. However, great care needs to be taken some 
studies suggested that too rapid a weight loss may worsen the histopathology of 
patients with NAFLD. This happens likely due to massive lipolysis of WAT and 
infflux of free fatty acids to the liver, where, in such a situation the liver’s 
oxidative capabilities are exceeded [10,53]. Moderate exercise is also effective 
way of improvement in the metabolic profiles of patients with NAFLD [79]. 
 Pharmacologic therapy of NAFLD is evolving.  To relieve oxidative stress 
in NASH,  powerful scavengers of free radicals were tried [32].  α-Tocopherol or 
vitamin E have an excellent safety profile and their use helped to lower the 
levels of  aspartate transaminase (AST), alanine transaminase (ALT). Betaines 
are trimethyl amino acids derived either from choline or from the diet. Betaines 
are essential to form phosphatidyl choline (PC), a component of VLDL, which is 
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the key molecule to export lipids from liver. Administration of betaine improves 
the export of lipids from hepatocytes [80]. 
Given that insulin resistance is central to the pathogenesis of NAFLD, 
insulin sensitizing agents find their application for pharmacotherapy for NAFLD. 
Metformin an inhibitor of gluconeogenesis has shown some results in human 
trials where it helped to improve ALT parameters but not histology. And another 
antidiabetic agents statins, inhibitors of cholesterol synthesis may reduce 
hepatic fat content in patients with hyperlipidemia and NASH [79]. 
Other groups of drugs which have been successfully applied in treatment 
of metabolic syndrome are peroxisome proliferator activated receptors (PPAR) 
ligands. PPARα was partly mentioned in the context of its abilities to control 
fatty oxidation in the liver, and agonists for another PPAR member, peroxisome 
proliferator activated receptor gamma (PPARγ), like pioglitazone or 
rosiglitazone also have some success in ameliorating some parameters of 
NAFLD. Another member of PPAR family PPARδ, is one of the promising drug 
target known for its anti-obesity actions [81] and therefore it is thought that 
modulation of its activity with small molecule would have great potential for 
treating NAFLD. 
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1.4 PPARS as drug targets for NAFLD 
 
1.4.1 PPARs as nuclear receptors 
Superfamily of nuclear receptors includes endocrine receptors that 
mediate the actions of steroid hormones, thyroid hormones, and the fat-soluble 
vitamins A and D, but also a number of so called orphan nuclear receptors [82]. 
The name indicates that their activators, target genes, and physiological 
functions were initially unknown. With the progress of research, some of orphan 
receptors become "adopted" orphan receptors - with partially characterized 
ligands or target genes [83]. PPARs are examples of adopted orphan receptors.  
The structural organization of PPARs is similar to other nuclear receptors and 
consists of six regions. These proteins are build from an NH2-terminal region 
that holds a ligand-independent transcriptional activation function (AF-1); core 
DNA-binding domain, containing two highly conserved zinc finger motifs that 
target the receptor to specific DNA sequences known as putative response 
element (PPRE) with the sequence AGGTCA N AGGTCA (direct repeat with a 
single nucleotide spacer (DR-1)) [84,85]. In the middle there is a hinge region 
that confers the protein flexibility needed for simultaneous receptor dimerization 
and DNA binding. And in the COOH-terminal region, ligand-binding domain 
(which also serves as dimerization interface) and a ligand-dependent activation 
function (AF-2) are localized. Typical structure of PPAR receptor is shown on 
Fig 1.4. X-ray crystal structures of the ligand binding domains exposed that 
PPARs contain a relatively large to other nuclear receptors hydrophobic-binding 
pocket. This large structural cavity is most likely the reflection of variety of 
putative ligands that can bind and activate PPARs [86,87]. 
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Figure 1.5 Structure of PPAR receptor. 
 
 
1.4.2 Characterization of PPARs 
There are three closely related members of the family: PPARα (NR1C1), 
PPARβ/δ (NR1C2) and PPARγ (NR1C3). There are two forms of PPARγ, (γ1 
and γ2, with differing amino termini) [88]. Messenger RNA of these three 
isoforms RNA’s are transcribed  from different genes: PPARα gene is located 
on chromosome 22 in the general region22q12-q13.1, the PPARγ gene is 
mapped on chromosome 3 at position 3p25, and the PPARδ is found on 
chromosome 6, at position 6p211.1-p21.2 [85]. Studies with fluorescently 
labelled PPARα and PPARγ fusion proteins show that PPARs are primarily 
found in the nucleus, independent of the presence of ligands [89]. PPARα is 
well expressed in metabolically active tissues such as liver, brown adipose 
tissue, muscle, and heart. PPARδ is ubiquitously expressed with high levels 
especially in skin, brain muscle and macrophages. PPARγ is most highly 
expressed in adipose tissue, yet reasonable levels of PPARγ mRNA can also 
be found in other organs including, colon, and especially lung [89]. 
Prior to DNA binding, PPARs form heterodimers with retinoid X receptors 
(RXR). The heterodimerization between PPARs and RXR has been 
experimentally demonstrated as ligand-independent. In living cells, PPARs can 
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efficiently heterodimerize with RXR in both absence and presence of ligand 
[88]. In the absence of the ligand, PPAR-RXR heterodimers are actively 
repressed by recruitment of co-repressor complex which possesses histone 
deacetylation activity (HDAC) and chromatin modifying factors, which results in 
silencing of the target genes [31]. Upon ligand binding, nuclear receptors 
undergo a conformational change that co-ordinately dissociates co-repressors 
and facilitates recruitment of co-activators proteins to enable transcriptional 
activation [88]. It is known that, the RXR ligand, 9-cis retinoic acid, enhances 
PPAR action. Retinoids may therefore modulate the action of peroxisome 
proliferators and also PPARs may interfere with retinoid action [90]. The 
peroxisome proliferator-activated receptors are activated by polyunsaturated 
fatty acids, eicosanoids, and various synthetic ligands [91]. However, their 
distinct expression patterns and gene knockout experiments have unravelled 
that each PPAR subtype performs a specific function in fatty acid homeostasis. 
 
 
1.4.3 PPARα function. 
The transcription factor PPARα modulates metabolism through activation 
of a set of target genes in a variety of metabolically active tissues, particularly 
under fasting conditions. Cross-species prognostics are not always possible 
due to differences in metabolism or expression levels. Generally, the effect of 
activation by the PPARα synthetic agonist WY14643 is more pronounced in 
mice than in humans [92,93,94]. Long-term treatment of rodent with peroxisome 
proliferators like fibrates or WY14643, results in hepatomegaly and in increased 
incidence of hepatocellular carcinomas, which is not found in humans. Ablation 
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of PPARα immunises mouse to fibrates-related effects in the liver, but in the 
same time makes them prone to fasting-induced hepatic triglyceride 
accumulation [95].   However, in both species PPARα regulates many identical 
gene ontology classes, including lipid metabolism. Genes encoding for 
mitochondrial proteins of the β-oxidation pathway are induced by PPARα 
activation, such as acyl-CoA synthetase (Acs) coding for an enzyme which 
activates FA to their fatty acyl-CoA derivatives. Also genes of the short, 
medium, long and very long-chain acyl-CoA dehydrogenases coding for 
proteins that catalyze the first step in FA oxidation in a chain length-specific 
manner, are under the control of PPARα. PPARα also has important role in 
governing fatty acid oxidation in perixosomes. The first characterized PPARα 
target gene, acyl-CoA oxidase 1 (Acox1) encodes the rate-limiting enzyme of 
this process in perixosomes [96]. Peroxisomal β-oxidation becomes increasingly 
important during periods of increased delivery of fatty acids into the liver, which 
is typical in NAFLD. In addition to mitochondrial and peroxisomal β- oxidation, 
ω-hydroxylation occurs in smooth endoplasmic reticulum. In both mice and 
humans activation of PPARα modulates the expression of cytochrome P450 4A 
genes. CYP4A enzymes,  such as the human enzyme CYP4A11, catalyse the 
ω-hydroxylation of medium and long-chain fatty acids [97]. Other crucial 
processes regulated by PPARα activation are lipoprotein synthesis and 
assembly. The VLDL abundance in plasma is influenced by lipoprotein lipase 
(LPL) activity in peripheral cells. The hepatic expression of this hydrolase, which 
is required for VLDL triglyceride particles lipolysis, is up-regulated by PPARα 
[98]. Additionally, activity of LPL is stimulated by Apolipoprotein A5 (ApoA5) and 
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inhibited by ApoC3. Activation of PPARα increases ApoA5 and decreases 
ApoC3 mRNA, which results in a plasma TAG lowering effect [98]. 
 
 
1.4.4 PPARα in treatment therapy for NAFLD 
Pharmacological management of NAFLD by PPARα action benefits 
mainly from its ability of promoting fat burning in the liver and ameliorating 
general aspects of type 2 diabetes and obesity-related problems. Although 
natural PPARα ligand was recently identified [17], clinically utilized PPARα 
agonists belong to fibrates  class such as gemfibrozil, clofibrate, fenofibrate and 
ciprofibrate, which have been used for decades in the treatment of dyslipidemia. 
This abnormality is characterized by low HDL and high TG levels. The ability of 
PPARα to increase HDL levels comes as a result of the stimulation of 
expression of ApoAI and ApoA2 expression, the major apolipoproteins of HDL 
[99]. However, fibrates are weak agonists of PPARα (EC50 values 20-500µM), 
and high doses are required for effective treatment [100]. On the other hand, 
fibrates are considered as safe drugs, with few side effects, such as an increase 
in myopathy, and possible lithogenicity rarely reported in humans. 
Animal studies show that PPARα-KO mice fed the methionine and 
choline-deficient diet (MCD) display greater levels of steatohepatitis compared 
to wild-type mice on the same diet. And delivery of the PPARα agonist 
WY14643 reduces or even reverses MCD-induced steatohepatitis and fibrosis 
in wild-type mice [101]. Apart from promoting lipid oxidation, PPARα activation 
also exhibits anti-inflammatory effects via inhibition of IL-6 and C-reactive 
protein. These effects are at least in part mediated by reduced expression of 
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NF-κB as well as an increase in IκB-R leading to prevention of NF-κB nuclear 
translocation [102]. This property of PPARα signalling might be of particular 
interests when liver steatosis progresses to NASH stage. In addition to 
regulating fat oxidation and lipoproteins turnover, PPARα influences glucose 
homeostasis. Under fasting conditions, PPARα-KO mice apart from hepatic lipid 
accumulation, suffer from hypoglycaemia and hyperinsulinaemia. In these 
animals glucose synthesis from lactate and lactate production, are strongly 
reduced, whereas the hyperinsulinemia found in fasted PPARα-KO animals 
results from impaired repression of insulin secretion in the pancreas [103]. 
 
 
1.4.5 PPARγ as a drug target for NAFLD 
PPARγ can be activated by various fatty acids, prostaglandins, 
arachidonic acid metabolites or components of oxidized LDLs. However, the 
affinity of the receptor for many of these ligands is low [104].  
Target genes of PPAR-γ include the adipocyte fatty acid binding protein, 
lipoprotein lipase, the uncoupling protein UCP1, the scavenger receptor CD36 
[104]. In contrast to PPARα, PPARγ activation promotes fat storage by 
increasing adipocyte differentiation and induction of a number of important 
proteins involved in lipogenesis [105]. This subsequently leads to increased 
fatty acid uptake by adipose tissue cells. PPARγ is the important molecular 
target for drugs of the thiazolidinedione (TZDs) or glitazones class [105]. These 
drugs sensitize cells to insulin and therefore are in use for their anti-diabetic 
effects in the liver, adipose tissue and skeletal muscle [99]. On the other hand, 
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mice with PPARγ adipose-specific knockout are insulin-resistant and 
unresponsive to TZDs [106]. 
TZD treatment leads to adipose tissue remodelling. The mechanism 
consists of two physiological events. First is selective pre-adipocyte 
differentiation in subcutaneous depots and second is promotion of apoptosis of 
older and larger insulin-resistant visceral adipocytes. The new adipocytes are 
smaller in size, they are more sensitive to insulin and therefore can take up 
more fats [107]. Activation of PPARγ by TZDs enhances lipolysis of circulating 
TGs by lipoprotein lipase and their storage in adipose tissue. Furthermore, 
TZDs stimulate the use of glycerol for TG production, thereby reducing FFA 
release from adipocytes. This reduction in FFAs removes the burden of fatty 
acids in skeletal muscle, liver and pancreas, leading to a reduction in hepatic 
glucose production. This hypoglycemic effects of TZDs improves glucose 
utilization in skeletal muscle [108].  
The important overall therapeutic effect of PPARγ activation in NAFLD is 
thus promotion of "new" storage space in adipocytes. It helps to relieve other 
organs from excessive fatty acids load. An increase in insulin sensitivity and 
glycemic control, coupled with a reduction in circulating free fatty acids helps to 
ameliorate type 2 diabetes-associated abnormalities. 
Additional function of PPARγ in the aspects of treatment of NAFLD 
emerges from macrophage biology. The physiological consequences of 
macrophage-specific deletion of PPARγ in BALB/c mice are increased insulin 
resistance in skeletal muscle and liver, and exacerbation of diet-induced 
obesity. In the absence of functional PPARγ, macrophages cannot appropriately 
suppress inflammatory cytokine production [109]. This is particularly important 
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taking under consideration that increased systemic levels of pro-inflammatory 
cytokines can speed up progression from simple steatosis to NASH. Other 
studies also confirm that administration of PPARγ ligands can ameliorate 
inflammatory responses in multiple organs [104].  
Hepatic stellate cells play role in NASH progression to cirrhosis by 
promoting hepatic fibrogenesis after transdifferentiation [110]. PPARγ activation 
was also found to preserve hepatic stellate cells in dormancy and thus prevent 
or even reverse hepatic fibrosis. The possible mechanism for this phenomenon 
might be the fact that the quiescent stellate cell has cytoplasm rich in lipids and 
thus shares some phenotypic features of adipocytes [111]. 
Despite being extensively used in type 2 diabetes patients, TZDs are not 
free of adverse effects such as pulmonary oedema and weight gain (2–3 kg per 
1% glycosylated haemoglobin that is lowered), anaemia, congestive cardiac 
failure, or increased risk of myocardial infarction or bladder cancer [106]. 
Bearing in mind the dominant role of PPARγ in adipocyte formation, it is not 
surprising that its agonists promote weight gain. Therefore treatment with 
PPARγ ligands cannot be considered as a preferred long-term treatment in 
NAFLD. The best pharmacological agent in NAFLD management would 
promote fatty acids burning and utilization and would exhibit action in multiple 
organs. The last member of PPAR family, PPARδ is not yet targeted by any 
drugs on the market, however the recent extensive research indicates great 
potential of PPARδ selective agonists in treatment of fatty liver disease. 
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1.4.6 Functions of PPARδ receptor 
PPARδ has a relatively large (1300 Å3) in comparison to other nuclear 
receptors ligand binding pocket [112]. It is believed that this large pocket can 
bind easily various sizes of fatty acids and others amphipathic acids through 
hydrophobic interactions and hydrogen bond. Natural or synthetic eicosanoids 
(twenty-carbon essential fatty acids) like prostaglandin A1 or carbaprostacylin 
can also serve as PPARδ activators [113]. Although the exact natural ligands of 
PPARδ are so far unknown, the discovery of many synthetic activators (like 
GW501516), which serve as a potent full agonists, has allowed investigations 
on the functions of this receptor to progress [87]. 
Generally, it is thought that PPARδ is involved in lipid metabolism 
[74,114]. In animal models, most of the PPARδ-/- embryos die at an early stage 
due to placental and myelination defects and small numbers of survivors 
exhibits a reduction in fat mass/adiposity [85]. However, no change in fat mass 
is seen in adipose tissue specific knockouts of PPARδ [115]. On the other hand, 
in one study, a construct involving a viral fusion protein (VP16-PPARδ) was 
made and it turned out to be a potent ligand-independent transactivator of 
PPARδ target genes. When constitutively expressed in adipose tissue in murine 
model, it resulted in 40% decrease in the reproductive white fat depot [81].  
Adipose tissue under expression of the transgene shows morphological 
changes: adipocytes are smaller and heterogeneous in size indicating that the 
reduction in total mass may results in fall of triglyceride accumulation. 
Therefore, it suggests that activation of PPARδ in adipose tissue promotes fatty 
acids combustion [81,116]. This indicates that the physiological actions of this 
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receptor may be complex [22]. PPARδ was also shown that it plays an 
important role in epidermal maturation and skin wound healing and could even 
serve as drug target for psoriasis [117,118,119].   
It is known that exercise mediates up-regulation of PPARδ and creates a 
requirement for external or serum derived source of triacylglycerol as an energy 
substrate. It suggests induction of modification of lipoproteins by PPARδ activity 
[120]. There is a tendency for HDL cholesterol to drop in lack of physical 
exercise and vice versa: increase with the exercise. The administration of 
synthetic PPARδ ligands can mimics the exercise rise in the HDL levels while 
lowering triglyceride levels in animal models [81]. Muscle is a major place of 
metabolism of glucose and fatty acid oxidation. It is also an important regulator 
of cholesterol homeostasis and HDL levels. Muscle is also a major site of 
expression for PPARδ [22,121]. This nuclear receptor is predominantly found in 
oxidative rather than glycolytic myofibres. Some of the studies have 
demonstrated that constitutive activation of PPARδ can increase the number of 
oxidative myofibres and slow atherosclerotic lesion progression in obese 
dyslipidaemic rhesus monkeys [122]. Tanaka et al showed that activation of 
PPARδ in skeletal muscle by the selective, synthetic ligand (GW501516) 
increases the expression of the molecules involved in fatty acid oxidation, 
energy expenditure, related to fatty acid oxidation, mitochondrial respiration, 
oxidative metabolism and slow-twitch contractile apparatus as well as in 
adaptive thermogenesis [123]. The GW501516 treatment therefore improves 
fatty acid β-oxidation in the skeletal muscle, protects against diet-induced 
obesity, and improves glucose tolerance and insulin sensitivity [123,124]. 
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PPARδ is also expressed in macrophages. However, the number of 
studies involving  PPARδ and its role in inflammation is limited [125]. So far it 
has been shown that treatment with different PPARδ drugs promotes lipid 
accumulation in macrophages exposed to oxidized LDL or THP-1 cells exposed 
to serum [126]. This suggests promotion of atherosclerosis. On the other hand, 
in a study which low density lipoprotein receptor (LDLR)-/- mice were fed 
hypercholesterolemic diet with addition of PPARδ ligand has shown decrease in 
inflammatory gene expression when compared to controls. The main 
suppressed genes were: VCAM-1, MCP-1, IFN-γ, which are correlated with the 
development and progression of the arthrosclerosis [125]. Also study where 
treatment of THP-1 human monocytes with the highly-specific agonist 
(GW501616) showed both an increased level of expression of ABCA1, an 
important reverse cholesterol transporter, and stimulated apoAI specific 
cholesterol efflux [127]. 
 
 
1.4.7 PPARδ in hepatic lipid metabolism 
Although in the liver PPARδ is not the most highly expressed member of 
PPAR family (eg PPARα protein is much more abundant than PPARδ in  rodent 
liver), evidence is growing that it still play an important role in liver lipid 
metabolism.  
In a study where db/db mice (model for diabetes with mutated leptin 
receptor) were treated GW501516 – high affinity PPARδ ligand, authors found 
that while GW501516 treatment significantly increased β-oxidation rate in 
muscle, 20% increase in liver triglyceride content was observed (cholesterol 
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and glycogen levels wwere not affected) [124]. It has been suggested that 
PPARδ regulates metabolic homeostasis through production of additional fat in 
the liver from the glucose to counterbalance fat burning in muscle. This work 
indicates that stimulation with PPARδ agonists gives control of the substrate 
utilization through regulation of diverse transcriptional programs in different 
tissues. Such metabolic shift resulting in reduction of hepatic glucose output 
improves insulin sensitivity [124]. Triglyceride increase following GW501516 
stimulation may raise concerns if the long term drug treatment could be counter-
productive and facilitate disease progression to NASH. However, there were no 
signs of fatty liver up to 6 months treatment in C57BL/6 mice [124]. Another 
work showing association of PPARδ activity with hepatic lipid deposition, 
utilized adenovirus-mediated liver restricted expression of PPARδ. The author 
found that although these mice exhibits reduced fasting glucose levels on chow 
or on high fat fed diet, this effect is accompanied by hepatic glycogen and lipid 
accumulation. However, despite observed elevated triglyceride levels, livers of 
these mice showed less damage and a reduction in JNK stress signalling [128]. 
 On the other hand, in the study where mice fed a MCD diet (model of 
NASH) were given GW501516, treatment prevented the livers weights to be 
increased in comparison to MCD control mice [129]. It also decreased the 
numbers of lipid droplets when compared to MCD untreated animals and 
increased the levels of hepatic mRNAs associated with β-oxidation (acyl CoA 
oxidase, carnitine palmitoyltransferase-1, liver fatty acid binding protein and 
reduced the levels of a number of mRNAs associated with inflammatory 
response. In summary, in this study stimulation of PPARδ improved 
steatohepatitis [129]. 
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 Similarly, in a study done by Qin et al, it was shown that GW0742 and 
GW501516 treatment (both PPARδ agonists) of db/db mice markedly reduced 
the hepatocyte intracellular lipid accumulation. The proposed mechanism is as 
following: treatment induced the insulin-induced gene-1 (Insig-1), which is an 
endoplasmic reticulum (ER) protein retarding SREBP-1 activation at both the 
RNA and the protein levels. Inhibition of the processing the SREBP-1 into a 
mature form prevented the expression of lipogenic genes such as FAS. Results 
revealed direct binding of the PPARδ upstream of the transcription initiation site 
of Insig-1. It suggests that Insig-1 is a direct PPARδ target gene in hepatocytes 
[130]. Another study supporting a protective role for PPARδ showed that when 
Otsuka Long Evans Tokushima Fatty (OLETF) rats (rat model of type 2 
diabetes) were treated with other PPARδ agonists GW0742 from 26 to 36 
weeks a marked improvement in fatty infiltration of the liver occured. Authors 
also observed that GW0742 had inhibitory effects on palmitic acid-induced 
triglyceride accumulation and inflammatory markers in HepG2 and Raw264.7 
cells [131]. 
 Since there is contradicting evidence that PPARδ can either stimulate 
accumulation or promote disposal of fatty acids in mouse liver, a 
comprehensive understanding of its biological role in hepatic lipid metabolism is 
of vital importance. 
 
 
 
 
 
33 
 
 
1.5 Aims and objectives 
PPARα and PPARγ have been proven as effective modulators of lipid 
metabolism and their ligands are used in clinical management of metabolic 
syndrome. Additionally, evidence implicating PPARδ as a key regulator of lipid 
homeostasis and glucose disposal is also growing. Although there are currently 
no available drugs targeting PPARδ, the compounds that selectively target 
PPARδ are being proposed to be used in obese, diabetic humans.  However, 
the role of PPARδ signalling in liver lipid homeostasis is so far controversial with 
evidence both supporting and against the benefit of PPARδ agonism in 
treatment of the NAFLD. Therefore, we sought to test the hypothesis that 
PPARδ agonism may carry a risk of promoting hepatic fatty accumulation 
similar to Non-Alcoholic Fatty Liver Disease (NAFLD).  The aim of this thesis 
was to characterise the hepatic lipid and transcriptional response using different 
strains of transgenic or knockout animal models and non-transgenic mice to 
selective PPARδ agonist and different diets. This project will therefore provide a 
solid understanding of the role of PPARδ agonists in hepatic and whole body 
lipid homeostasis, which can then be evaluated for potential risk of fatty liver 
toxicity in type 2 diabetic patients who may be treated with such agents. 
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Chapter 2 Materials and methods  
 
2.1 Reagents used 
Agarose gel running buffer (TAE) (50X) 
242 g Tris base (2-amino-2-hydroxymethyl-propane-1,3-diol) (= 2 mole) was 
added to 500 ml of water and then 57.1 ml glacial acetic acid (= 100% acetic 
acid) (57.19 ml = 1 mole) was added followed up by addition of  100 ml 0.5 M 
Na2 EDTA (pH 8.0) Buffer was made up to 1L with water 
To prepare 0.5 M Na2 EDTA (pH 8.0) 186.1 g of disodium 
ethylenediaminetetraacetate x 2H2O was added to 800 ml of H2O. Mixture was 
stirred vigorously. Solution was then adjusted to pH 8.0 with NaOH (ca. 20 g of 
NaOH (pellets)). Hint: The disodium salt of EDTA does not go into solution until 
the pH of the solution is adjusted to ca. 8.0 by the addition of NaOH. 
Add 20 ml of stock was mixed with 980 ml of water to get 1X solution. 
 
Histology 
Tissue fixing buffers (cryosectioning) 
1% Paraformaldehyde/PBS/2mM MgCl2: 
2g Paraformaldehyde (PFA) 
0.0812g MgCl2 
200 ml PBS 
The mixture was to be warmed above 55°C (but temperature cannot exceed 
60°C) to dissolve PFA. 
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Dehydration solution (30% sucrose): 
0.0812g MgCl2 
60g sucrose 
200 ml PBS 
 
Glycerine Jelly Mounting Medium 
      Gelatin (Kitchen grade)    10 g 
       Distilled Water                60 ml 
      Glycerol                           70 ml 
       Phenol                            0.25 g 
       Gelatine was dissolved in the distilled water using sufficient heat to melt the 
gelatine, glycerol and phenol was then added. Mixture was mixed well and 
transferred to a small capped bottle and refrigerated. 
 
1% Dextrin solution:  
1g of dextrin was mixed in 100ml of sterile water (sterile glassware) gently 
heating the mixture (dextrin will not entirely go into the solution). Mixture was 
not autoclaved and not filtered. Solution was stored in 4°C. 
 
DNA extraction buffers 
Lysis buffer: 
15ml NaCl salt solution (5M): 75mM 
50ml EDTA (0.5M) ph 8.0: 25mM 
100ml 10% (w/v) SDS: 1% (w/v) 
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The buffer was made up to 1L with 835 ml dH2O 
TE buffer 
50 ml TrisCL (0.1M) ph 8.0: 10mM 
1ml EDTA (0.5M) pH 8.0: 25mM 
The buffer was made up to 500ml with 449 ml dH2O 
 
Lipid buffer 
Lipid buffer used for dilution of liver lipid extracts was composed as follows: 
Isopropanol : TritonX1000 : tert-butanol (2:1:1) 
 
PPARδ agonist 
PPARδ ligand:2-[2-methyl-4-([4-methyl-2-[4-(trifluoromethyl)phenyl)-1,3-thiazol-
5-yl]methylsulfanyl]phenoxy]acetic acid (GW501516), was synthesised by AF 
ChemPharm Ltd, Sheffield, UK. 
 
 
2.2 Animals 
2.2.1 Mice used in experimental procedures 
Non-transgenic C57BL/6 female mice were obtained from Harlan 
Laboratories (Harlan, UK). PPARα knockout mice (B6.129S4-Pparatm1Gonz/J) 
were purchased from Jackson laboratory (Bar Harbor, Maine, USA). PPARδ 
null animals were obtained from University of Lausanne, Switzerland, through 
the courtesy of Walter Wahli.  
Human PPARδ transgenic mice were generated by cloning full-length 
human PPARδ downstream of the rat CYP1A1 promoter. The PPARδ coding 
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sequence was amplified using primers PRMG15 (5´-CTA GTC TAG AAT GGA 
GCA GCC ACA GGA GGA AGC -3´) and PRMG3 (5´-CTA GTC TAG ATT AGT 
ACA TGT CCT TGT AGA TC TCC TG-3´), respectively (ATG start codon in 
bold). PCR products were cleaved with XbaI and cloned in plasmid pUHD10-3 
(M. Gossen, unpublished, Genbank accession number U89931) creating 
pMGD7 (PPARδ). The integrity of the inserts was confirmed by sequencing and 
cleaved out using BamHI and ligated into plasmid pAHIR1-b-gal [132] cleaved 
with BglII, resulting in the plasmid pMGD72 (PPARδ). Proper insert orientation 
was confirmed by restriction endonuclease analysis and sequencing. 
Transgenic mice were generated by microinjection of the expression unit (NotI 
fragment) of the plasmid pMGD72 into pro-nuclei of C57BL/J6 x CBA F1 
fertilized eggs. 
To generate mice conditionally over-expressing a derivative of hPPARδ 
lacking the eleven carboxyterminal aminoacids residues (hPPARδΔAF2), the 
coding sequence of hPPARδ was amplified using primer PRMG15 (5´-
CTAGTCTAGAATGGAGCAGCCACAGGAGGAAGC- 3´) and PRMG16 (5´ -
CTAGTCTAGATTAGTGCAGCGAGGTCTCGGTTTC-3´), (XbaI-sites 
underlined, ATG start codon in bold). This PCR product was cleaved with XbaI 
and cloned into plasmid pUHD10-3 (M. Gossen, unpublished, Genbank 
accession number U89931) creating pMGD10. The integrity of the insert ion 
was confirmed by sequencing and cleaved out using BamHI and ligated into 
pAHIR1-β-gal [132], digested with BglII resulting in plasmid pMGD18 
(hPPARδΔAF2). The correct orientation was confirmed by sequencing. Four 
founder lines on a C57BL/6 background were generated for each transgene and 
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analysed for induction of transgene expression and suitable lines selected and 
brought forward for experimental analysis. 
The expression of the transgene of choice is dependent on the activation 
of the mouse endogenous aryl hydrocarbon receptor (AhR). Activation is 
achieved by dietary administration of the AhR agonist (Indole-3-carbinol (I3C) - 
0.25% (w/w)). Basal transcription from the Cyp1a1 promoter in the absence of 
AhR agonist is very low, allowing for tight control of transgene expression. 
All mice were fed ad libitum, and were kept under 12 hour light/dark 
cycles in humidity and temperature controlled environment. All procedures were 
done in accordance with regulations contained in the Animals and Scientific 
Procedures Act (1996) of the United Kingdom, and with the approval of the 
University of Dundee ethical committee. 
 
2.2.2 Diets and administration of the compound 
The animals were fed normal chow (standard RM1 laboratory animal 
feed SDS Ltd, Wickam, UK) or High Fat Diet (60% energy from fat, TestDiet, 
Richmond, USA).  
GW501516 compound was administered to the mice in their diet. 
GW501516 was dissolved in DMSO and mixed with water, which was 
subsequently added to RM1 powder. The mass was formed into pellets, dried 
and used for experimental procedures with the final concentration of GW501516 
0.0025% (w/w). The same method was used to incorporate I3C into the 
appropriate diets. 
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2.2.3 Measured parameters  
Body weights were measured on a twice weekly basis and food intake was 
calculated weekly weigh-ins of the food pellets, before being refilled with fresh 
food.  
 
2.3.4 Animals sacrifice and sample collection 
At the termination of each experiment, animals were sacrificed using 
increasing concentration of CO2. Blood was removed using cardiac puncture, 
followed by organ removal (liver, muscle (quadriceps), adipose tissue (visceral 
fat pad)). Collected tissues were snap frozen in liquid nitrogen and stored in -
80ºC until further processing. Blood was collected in heparin coated tubes 
(Sarsted, Germany) and plasma separated by centrifugation and stored at -
80ºC until further processing. 
 
 
2.3 Determination of transgene detection. 
Ear skin biopsy was taken from the animals which needed confirmation of 
presence of transgene expression.  
 
2.3.1 DNA extraction  
Skin biopsy specimens were suspended in 250μl of lysis buffer and 4μl of 
proteinase K (Qiagen) was added and whole mixture was incubated on heating 
block or in water bath at 55° overnight. After the incubation 365μl 
Of chloroform was added along with 78.5 μl of NaCl (5M) and the samples were 
incubated on rotator at room temperature (RT) for 45 minutes. After this, 
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samples were centrifuged at 13000RPM for 10 min at room temperature. The 
upper aqueous phase was collected and added to 250 μl of isopropanol. 
Mixture was mixed by inversion and incubated at RT for 30 minutes. Samples 
were then centrifuged for 12 min at 13K RPM and the supernatant was 
discarded. Remaining pellet was washed with 70% ethanol and centrifuged 
again for 12 min at 13K RPM. Samples were then dried in the concentrator 
(Eppendorf) or dried under fume hood. Each pellet was re-suspended in TE 
buffer and stored in 4°C until needed. 
 
2.3.2 Amplification of DNA 
HotStarTaq Plus kit (Qiagen) was used to amplify DNA. 
Reaction mixes contained 50-100ng of template DNA, 3 μl of Q solution 1.5 μl 
of Coral loading buffer, 0.6 μl of primers mix (from 10μM stock), 0.3 μl dNTPs 
mix (Promega), 0.12μl of DNA taq polymerase and the whole mixture was made 
up to 15μl with 8.28μl ddH2O. The primers set used for detection of hPPARδ 
and hPPARδΔAF2 transgene were as follows: PRMG159 (5´-CCA ACC ACC 
CTG TCC CAG CTT G-3´) and PRMG160 (5´-ACA AAC TCT GCC CTG CTC 
TAT G-3´). The primers set used for detection of PPARδ-KO homozygotes were 
as follows: wild type allele: PBX9 (5´-AGA CAA TGA TGG TGT GCT CA-3´) 
and AB029 (5´-CTT TGG GGT GAG ACA GAC TGC GCA -3´). Mutant allele: 
PBX10 (5´-GCA GCT GCT CAG CTG CCT GC-3´) and UMS1 (5´-GCT CCT 
GAA GTC CAC AAT TCA CAG TCC -3´). The cycling parameters were as 
follows: 95°C for 5 min then 39 cycles of 94°C for 30 seconds, 60°C for 30 
seconds, 72°C for 2 min and 72° for 10 min. 
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2.3.3 Agarose gel electrophoresis 
DNA was routinely examined for the presence of the transgene by 
electrophoresis in 0.8% (w/v) agarose gel that contained TAE buffer with 
0.5μg/ml ethidium bromide. The electrophoresis was performed at 120V for 48 
min in TAE buffer. The 100bp or 1kb (New England Biolabs) markers were 
routinely run alongside analysis samples. DNA was visualised by UV 
illumination at 302nm. 
 
2.4 Hepatic lipid analysis 
2.4.1 Extraction of liver lipids 
Total lipids from liver were extracted using Folch method [133]. 100mg of liver 
tissue was placed in 1.5ml eppendorf tube. 633μl of methanol was added and 
the tissue was homogenized using Polytron PT2100 homogenizer (Kinematica 
Luzern, Switzerland). After the dispersion, 1266μl of chloroform was add to get 
the final volume 20 times the volume of tissue sample (chloroform : methanol 
(2:1)). The mixture was agitated for 2 hours in an orbital shaker at room 
temperature. After the incubation, 0.2 volume of methanol (for 100mg of tissue 
400l of methanol) was added to lower the gravity of the mixture and the 
sample was centrifuged at 3000 RPM for 5 min. Supernatant was collected and 
placed in a clean 15ml centrifuge tube. Volume of chloroform was then added to 
restore 2:1 proportions of chloroform/methanol (e.g. for 100mg of tissue 800μl 
of chloroform). Mixture was vortexed for several seconds. Exact volume of the 
mixture was determined and 0.2 volume of 0.9% NaCl solution was added. 
Mixture was shaken on vortex for several seconds and centrifuged at 2000rpm 
for 20 minutes. After the centrifugation upper phase was removed and 
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discarded. The bottom organic phase was transferred in the 2 ml eppendorf 
tubes and evaporated under nitrogen stream at 60°C. The lipids were then 
either analyzed through Liquid chromatography mass spectrometry or re-
suspended in lipid buffer and stored -80ºC until further analysis. 
 
2.4.2 Liquid chromatography mass spectrometry analysis (LC MS) of 
phosphatidylcholine (GPC) 
LC MS analysis of the lipid specimens extracted from the liver was carried out 
by Dr Jeffrey Huang (Biomarker and Drug Analysis Core Facility, University of 
Dundee, Ninewells Hospital) as follows: LC-MS analysis of GPC was performed 
on a Thermo Finnigan TSQ Quantum Ultra triplequadrupole mass spectrometer 
(ThermoFinnigan, San Jose, CA) in conjunction with a Thermo Dionex Ultimate 
3000 LC and an electrospray source. The system was tuned using GPC 
(16:0/18:1)(Aventi). Five microliters of lipid extracts was injected to a 
Phenominex C18 column (50 x 2.1 mm). A 6 minute binary LC gradient elution 
from 50:50 CH3CN/H2O (solution A) to 90:10 isopropanol/CH3CN (solution B) 
was employed. Both mobile phase solutions contained 0.1% formic acid. The 
lipids species containing phosphocholine were analyzed in a precursor ion scan 
(positive ion mode, mass range=740-820) monitoring neutral loss of 184.1, 
which corresponds to phosphocholine. The relative abundance of m/z 760 
(representing 16:0/18:1-GPC) to m/z 758 (representing 16:0/18:2-GPC) was 
calculated. 
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2.4.3 Total cholesterol, TG, HDL and FFA biochemical assay. 
Analysis of plasma and liver lipids was performed using RX Daytona 
clinical analyser (Randox, UK) with accordance to manufacturer’s instructions.  
 
 
2.5 Gene expression analysis 
2.5.1 Preparation of cDNA from animal tissues. 
Total RNA from the liver and muscle was prepared using the RNeasy or 
RNeasy Mini Fibrous tissue or RNeasy Lipid tissue Mini kit (Qiagen) following 
manufacturer instructions (Qiagen, UK). The procedure was performed also 
using automated extraction system Qiaqube (Qiagen, UK). During the extraction 
DNase treatment was performed to remove any possible traces of genomic 
DNA. To examine the integrity of RNA, sample of the RNA extracts was 
denaturated at 55°C for 5min and then run on agarose gel electrophoresis. 
When the bands were clearly visible, the RNA concentration of the samples 
were determined by NanoDrop 8000 (Thermo scientific, UK), and 500ng/sample 
of RNA was reverse transcribed using the High Capacity cDNA Reverse 
Transcription Kit following manufacturer instructions (Applied Biosystems). 
 
 
 
2.5.2 Real-time PCR assay design 
Taqman probes and primers were previously described [134] or were designed 
using Primer express 3.0 and were purchased from Applied Biosystems (UK) or 
from Eurofins MWG Operon( London, UK) or from Sigma/Aldrich (Gillingham, 
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Dorset, UK). Coding gene sequences were obtained from Genebank. Primer 
and probe sequences are shown in Table 1. 
 The primer sets flank the amplicon region and define the end points of 
the DNA probe labelled with FAM/TAMRA reporter and quencher dyes, 
respectively. The probe hybridizes with the amplicon and during PCR the 5´-3´ 
nuclease activity of taq polymerase cleaves the probe thereby separating the 
reporter and quencher, which results in fluorescence. Fluorescence is 
proportional to the quantity of cleaved probes and therefore to the amount of 
amplicons. 
 
Table 2.1 Sequences of oligonucleotide primers and probes used in Taqman real time 
PCR. All sequences are shown in 5’→3’ order. 
Gene 
Forward primer 
sequence 5’→3’ 
Probe sequence [FAM-
Tamra]5’→3’ 
Reverse primer 
sequence 5’→3’ 
mHMGCo
As 
TGGTGGATGGGAAGC
TGTCTA 
CCAAGGCCCGCAGGTAGCACTG 
TTCTTGCGGTAGGCTGC
ATAG 
mApoc3 
CCAAGACGGTCCAGG
ATGC 
CCATCCAGCCCCTGGCCACC 
ACTTGCTCCAGTAGCCT
TTCAGG 
mCPT1 
GGCTTAGTCGGGAGG
CTCTG 
AATCAACTCCTGGAAGAAACGCC
TTATTCGAA 
ACCCCTAAGGATGCCAT
TCTTG 
mFAS 
GGCATCATTGGGCACT
CCTT 
CCATCTGCATAGCCACAGGCAAC
CTC 
GCTGCAAGCACAGCCT
CTCT 
mADRP 
CAGCCAACGTCCGAG
ATTG 
TGCCAGTGCCAGAGGTGCCGT 
CACATCCTTCGCCCCAG
T 
mPPARα 
GCGCAGCTCGTACAG
GTCA 
CAAGAAGACCGAGTCCGACGCA
GC 
TCTCTTGCAACAGTGG
GTGC 
mAcox1 
TGACCGTTAAGGTCTT
TGCAGA 
AACTCCCCAAGATTCAAGACAGA
GCCGT 
AGGTTCCTCAGCACGG
CTT 
mPPARγ 
CTGACCCAATGGTTGC
TGATTAC 
AAATATGACCTGAAGCTCCAAGA
ATACCAAAGTG 
TGGAGATGCAGGTTCT
ACTTTGA 
mPPARδ 
GACCAGAACACACGTT
TCCTTC 
AGCAGCTGTGCAGACCTCTCCCA
GA 
CCATCACAGCCCATCTG
CA 
hPPARδ 
GGGACCACAGCATGC
ACTTC 
CCAGCAGCTACACAGACCTCTCC
CGG 
TGCAGTTGGTCCAGCA
GTGA 
mCD36 
TGAAAAGTCTCGGAC
ATTGAGATTC 
TTTCCTCTGACATTTGC 
AGATCCGAACACAGCG
TAGATAGA 
mUCP1 
GCAGATATCATCACCT
TCCCG 
TGGACACTGCCAAAGTCCGCCTT
C 
CCTGGCCTTCACCTTGG
AT 
mUCP2 TCCTGAAAGCCAACCT AGATGACCTCCCTTGCCACTTCAC CGATGACGGTGGTGCA
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CATGA TTCTG GA 
mUCP3 
GAAGATGGTGGCTCA
GGAGG 
CCACGGCCTTCTACAAAGGATTT
GTGC 
AAGCTCCCAGACGCAG
AAAG 
mPDK4 
GGAAGTATCGACCCA
AACTGTGA 
CACTCAAAGGCATCTTGGACTAC
TGCTACCA 
GGTCGCAGAGCATCTT
TGC 
mANGPT
L4 
GCTTTGCATCCTGGGA
CGAG 
ACTTGCTGGCTCACGGGCTGCTA
C 
CCCTGACAAGCGTTACC
ACAG 
mCDKN2
C 
GCGCTGCAGGTTATG
AAAC 
CCTGGCAATCTCCGGATTTCCA 
TTAGCACCTCTGAGGA
GAAGC 
mGAPDH 
GCCAAGGTCATCCATG
ACAAC 
CTCATGACCACAGTCCATGCCA 
GGGGCCATCCACAGTC
TTC 
 
2.5.3 Taqman quantitative Real Time PCR 
The cDNA was initially diluted 1:5 and optionally further dilutions were 
made on the basis of pilot assays which were run with single samples for each 
tissue to determine optimal dilution of the cDNA for each gene assay. The 
cDNA samples were collected into single 96 well plate and then scaled up to 
384 well daughter plates format using robot (FluidX xpp-721) (resulting in 4 
copies per each sample). A premix consisting of 3μl of 5x Taqman Master mix 
(Applied Biosystems, UK), 0.5μl forward primer (from 18μM stock), 0.5μl 
reverse primer (from 18μM stock), 0.4μl Taqman fluorogenic probe (from 5μM 
stock) and 1.6μl of water was made. Then a robotic system (Equator, Deerac 
Fluidics) was used to add 6μl of premix to 4 μl of cDNA into the 384 well plates 
making up 10μl total volume of mixture/well. The ABI Prism 7900 sequence 
detector (Applied Biosystems) was used to perform RT-PCR reaction. Cycling 
parameters were as follows: 50°C for 2 minutes, 95°C for 10 minutes, 40 cycles 
of 95°C for 15 seconds, 60°C for 1 minute. Data was acquired and processed 
with Sequence Detector 1.6.3 software (Applied Biosystems).  
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2.5.4 Gene expression normalization 
The test genes expression levels were normalized to remove possible 
differences such as RNA quality and pipetting errors that could distort the 
results. 18s RNA or mouse glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) were used as housekeeping genes. A following formula was used for 
normalizing: 
2((target gene Ct value – housekeeping gene Ct value) x (-1)) 
Where: Ct value = threshold cycle value for each sample (where fluorescence 
signal was recorded as statistically significant above background levels. 
 
2.6 Microarray analysis 
2.6.1 Samples processing 
Total RNA was harvested from liver samples using the RNeasy kit (Qiagen) 
according to the manufacturer’s instructions, including a DNase digestion step. 
Total RNA was quantified on a NanoDrop spectrophotometer (ND-8000) and 
samples were amplified and labelled using Illumina TotalPrep RNA amplification 
Kit (Invitrogen, UK). From this point samples were processed until raw data 
results in Wellcome Trust Clinical Research Facility, Western General Hospital, 
Edinburgh by Ms Louise Evenden. All samples passed quality check using 
Agilent 2100 Bioanalyser and 1.5ug/biotin-labelled sample was hybridized with 
MouseWG-6 v2.0 Expression BeadChips (Illumina,USA).  BeadChips were 
scanned using an Illumina BeadArray reader and raw data were acquired using 
GenomeStudio software. MouseWG-6 v2.0 Expression BeadChip contains 
45,281 transcripts that can be analyzed in one sample. The beadchip contains 
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the probes from the MouseRef-8 beadchip with additional probe design based 
on RIKEN FANTOM 2 database and other data sources. 
 
 
2.6.2 Analysis of the microarray data 
Expression data were normalized (average normalization) in 
GenomeStudio with background extraction. Microarray data were analyzed 
using GenomeStudio, MeV v 4.8.1 and MS Excel. False discovery rate method 
(FDR) [135] was used to correct for multiple testing effects. Differentially 
expressed genes were identified by determining the fold change and P values 
of the t-test. Genes whose expression intensity changed by >1.75 fold up or 
down with P<0.05 and FDR<0.05 were considered to exhibit differential 
expression in the microarray experiments. Correlation tests were considered to 
be significant if correlation P<0.05 and FDR<0.05 was obtained. 
 
2.7. Histological analysis of liver tissue 
2.7.1 Preparation of tissues for sectioning 
Frozen liver tissue was placed into bijous containing fix which had been cooled 
down to 4°C. Liver was fixed in 1% PFA/PBS/2mM MgCl2 for 3 hours at 4°C. 
Then tissues were washed 3 times with PBS containing 2mM MgCl2. Tissues 
were then dehydrated overnight at 4°C in PBS/2mM MgCl2 containing 30% 
sucrose. After dehydration, tissues were embedded in Optimal Cutting 
Temperature compound (OCT), mounted on the plastic moulds and placed on 
the dry ice/isopentane bath for 5-10 minutes. Moulds with tissues were stored in 
-80°C or continued with staining protocol. 
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2.7.2 Oil red O staining 
The histological mechanism of the staining of lipids is invariably a function of the 
physical properties of the dye being more soluble in the lipid to be demonstrated 
than in the vehicular solvent.  The polyazo group of dyes include the oil red 
series, the Sudan red series, and the Sudan blacks.  For negative reference 
one section was treated with a 50:50 acetone/xylene mixture for 5 minutes, 
wash in water and continued with the protocol. Frozen sections were cut (10 
microns) on cryostat and mounted on Optiplus positively charged microscope 
slides and air-dried to the slides for 30 minutes only. Then slides were 
immersed into the formalin and fixed at 4°C for 30-45 minutes. After this, slides 
were washed with running tap water for 7 minutes (or until OCT is completely 
disappeared from the slide) and they were rinse in distilled water. Subsequently 
they were placed in 60% isopropanol for 1 minute only, to remove water and 
then placed in Oil Red O (ORO) working solution for 15 minutes. ORO working 
solution was made as follows: 0.5g ORO powder was mixed with 100ml of 
isopropanol. Then 30 ml of the stock stain was mixed with 20 ml of 1% water 
dextrin solution, allowed to stand for 30 minutes, and filter through 0.2μm filter.  
After incubation with ORO slides were rinsed with 60% isopropanol and placed 
in clean 60% isopropanol for 2 minutes only. After that they were rinsed in 
distilled water and stained with Mayer’s hematoxylin for 30 sec. After this step 
slides were rinsed in distilled water and placed in running tap water for 10-12 
minutes for “bluing”. They were rinsed in distilled water and mounted with cover 
glass in glycerine jelly. Sections were viewed under a light microscope. 
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2.8 Statistical analysis 
GraphPad Prism 5.0 (Graphpad Software, Inc, CA, USA), MS Excel, 
GenomeStudio (Illumina) and MeV v 4.8.1 were used for statistical analysis. 
Two-way ANOVA with Bonferroni post tests, student t test and correlation was 
used to calculate statistical significance. P<0.05 and FDR<0.05 for multiple 
testing were considered as significant. 
 
 
2.9 Companies from which chemicals and kits were obtained 
Agilent technologies (Stockport, Cheshire, UK) 
Anachem (Bedfordshire, UK) 
Avanti Polar Lipids (Alabaster, Alabma, USA) 
Bio-Rad laboratories (Hemel Hempstead, Herts, UK) 
Charles River Ltd (Margate, Kent, UK) 
Fluka (Pool, Dorset, UK) 
GraphPad Inc. (San Diego, USA) 
Invitrogen (Paisley, Scotland) 
MWG Biotech (Ebersberg, Germany) 
New England Biolabs (Hitchin, Herdfordshire, UK) 
Nunc Brand products (Roskilde, Denmark) 
Applied Biosystems (Foster City California USA) 
Promega UK (Southampton, Hampshire, UK) 
Randox (Crumlin, Antrim, United Kingdom) 
Qiagen Ltd (Crawley, UK) 
Sigma-Aldrich (Poole, Dorset, UK) 
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VWR (Poole, Dorset, UK) 
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Chapter 3 Anti-obesity and metabolic properties of PPARδ 
agonism, in non-transgenic mice. 
 
3.1 Introduction 
Although it is generally accepted that PPARδ is expressed ubiquitously 
[136], some data indicate that its expression level in mouse skeletal muscle is 
relatively low when compared to liver, small intestine or skin [137]. Despite that 
fact, important functions have been assigned to PPARδ action in muscle 
[121,123,138]. In liver however, aspects of PPARδ activation are less 
understood. The situation becomes even more complicated because of the fact 
that there is a variety of synthetic PPAR δ ligands available, which have been 
tested in various animal models and men.  Having different potency and 
selectivity towards PPARδ, it is not surprising they can produce different results 
in diverse model organisms [139]. The aim of the following study was to show 
the effect of the PPARδ activation by one potent and up to date synthetic 
agonist available – GW501516 in wild type C57BL mice. GW501516 is more 
than 1000 times more selective for PPARδ than for the rest of the PPAR family 
members (EC50=0.001μM for PPARδ and EC50=10μM for PPARα and PPARγ 
by luciferase reporter gene transactivation assay in COS7 cells) [127]. 
So far GW501516 use in animal models produced variety of results. In 
general it is accepted that in rodents GW501516 causes weight loss or prevents 
body mass gain [81,122,140]. The other aspects of GW501516 treatment vary 
and may be dependent on experimental design, animal model used etc. 
Whereas some studies shown promotion of steatosis in rodent liver after 
GW501516 treatment [124] others suggest it even as a drug candidate to treat 
NASH [129,141]. This issue needs to be clarified as long as PPARδ synthetic 
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ligands are considered to be use therapeutically in humans for treating aspects 
of metabolic syndrome. This chapter aims to assess the short and long-term 
effect of PPARδ ligand administration on body mass, hepatic and plasma lipid 
profiles and gene expression in wild type mice.   
 
3.2 Results 
 
30 female C57BL/6 background mice were divided into two branches: 
one fed standard chow (RMI diet) and the second - chow supplemented with 
0.005% of GW501515 (7mg/kg/day). 10 animals (5 per each group) were 
sacrificed at 2, 4 and 8 weeks time. Mice were 10 weeks old at the beginning of 
experiment. Before the sacrifice, animals were fasted to ensure adequate 
plasma lipids measurements.  
Throughout the duration of experiment, treated animals showed no sign 
of obvious ill health. After introduction of GW501516 into the diet, treated mice 
started to lose weight in the first 2 weeks of experiment. After that time point, 
the weight loss trend reversed and weight gain was seen until the end of the 
experiment (Figure 3.1A). Control mice were gaining weight steadily throughout 
the whole 8 weeks (Figure 3.1A). After 4 weeks difference in weight gain 
between control and treated group was 10.3 fold (Figure 3.1B). And the weight 
difference in terminal weights reached 2.6 fold (Figure 3.1B). Thus influence of 
PPARδ ligand on weight gain after 4 and 8 weeks was considered as very 
statistically significant (P<0.01). 
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Figure 3.1 GW501516 treatment prevents diet induced obesity. (A) Body mass change 
throughout 8 weeks of feeding with PPARδ agonist. (B) Percentage weight difference 
between control animals and fed GW501516-supplemented diet. Significance is 
indicated as (** p<0.01; *** p<0.001), n=5mice/group. Data are expressed as means  ± 
SEM. 
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In parallel experiment, with exactly the same experimental design, but 
without fasting the mice, results show the same trend of weight loss (data not 
shown). Additionally, food consumption was monitored. Although changing over 
time, an average food intake throughout the whole experiment in animals fed 
diet supplemented with PPARδ ligand was lower than in the control group fed 
plain chow (Figure 3.2). GW501516 at dose of 7mg/kg/day (0.005%; w/w) has 
led to reduction in food consumption by 8%. This decrease in appetite was 
statistically significant (p=0.0322). 
 
Figure 3.2 Food intake in animals fed normal chow and diet supplemented in 
GW501516. n=15mice/group. Data are expressed as means  ± SEM. 
 
 
Plasma levels of GW501516 concentration in treated animals was found 
to be at the level of 1μmol/L, with no measurable amount detected in animals 
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fed control diet (Figure 3.3 A). Blood levels of triglyceride were significantly 
lower in mice fed diet supplemented with PPARδ ligand at every measured time 
point (Figure 3.3 B). Although GW501516 treatment significantly increased, the 
levels of plasma total cholesterol (at 4 and 8 weeks time; Figure 3.3 C), the 
High Density Lipoprotein (HDL) levels showed the same trend (Figure 3.3 D). 
 
Figure 3.3.  Effects of PPARδ agonism on the serum lipid profile of C57/BL6 mice. (A) 
Plasma GW501516 concentration. (B) Improvement in blood triglyceride profiles in 
treated animals. (C) Increase in total plasma cholesterol and (D) HDL levels. 
Significance is indicated as (*p<0.05; ** p<0.01; *** p<0.001), n=5mice/group. Data are 
expressed as means  ± SEM. 
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Plasma Free Fatty Acids (FFA) and glucose plasma levels showed no 
significant differences between groups at any time point (data no shown). 
Plasma glucose levels were significantly lower after 4 weeks (P<0.05; data not 
shown), with no difference between groups after 2 and 8 weeks time. 
In the plasma derived from non-fasted animals, insulin levels had no 
significant differences between groups or throughout the experiment duration 
(Figure 3.4A). Another hormone levels, leptin, had tendency to be at lower level 
in treated groups, when compared to controls.  However, only differences at 2 
and 8 week time points were significant (P<0.05; Figure 3.4B). 
 
Figure 3.4. Plasma insulin and leptin levels in non-fasted animals fed control diet or diet 
supplemented with 0.005% GW501516 – a PPARδ agonist. n=5 mice/group. Data are 
expressed as means  ± SEM. 
 
 
After 2 weeks, levels of hepatic fat (triglyceride) showed no variation 
between groups. However, after 4 weeks, mice fed diet supplemented with 
PPARδ ligand had accumulated 70% more triglyceride than control group 
(P<0.01; Figure 3.5). At the end of the experiment though, the fatty liver 
phenotype was reversed, with control group having 70% more intrahepatic fat 
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when compared to treated group (P<0.001). Level of liver triglyceride after 8 
weeks in treated group was comparable to level found in the same group after 2 
weeks. When comparing 4 and 8 weeks time points, hepatic fat level within 
treated groups was down by 62% at the end of the experiment (P<0.001; Figure 
3.5). Level of liver cholesterol showed no changes between groups or 
throughout the duration of experiment (data not shown). 
 
Figure 3.5 Levels of hepatic triglyceride in non-transgenic mice fed diet supplemented 
with PPARδ ligand. 4 weeks treatment increases the hepatic triglyceride content 
(P<0.01), whereas 8 weeks was protective against GW501516-induced liver steatosis 
in non-transgenic mice (P<0.001). n=5 mice/group. Data are expressed as means  ± 
SEM. 
 
 Oil red O staining of frozen liver sections revealed and confirmed 
deposition of the triglyceride inside hepatocytes. The size and the manner of 
infiltration of triglyceride droplets indicate microvescicular rather than 
macrovescicular type of fat deposition in livers of mice fed diet supplemented 
with GW501516. 
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Figure 3.6 Oil Red O staining of liver sections. Each picture represents typical example 
of hepatic fat deposition in separate group. Magnification: 400X, scale bar = 50μm. 
 
Gene expression analysis revealed that mRNA expression of the three 
PPAR isoforms in liver and muscle showed no variability between groups and 
throughout the length of experiment with the exception of PPARδ mRNA 
expression in muscle (Figure 3.7).  
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Figure 3.7. Expression of messenger RNA of PPAR receptors in liver and muscle. Only 
PPARδ expression in muscle showed difference after GW501516 treatment after 2 and 
4 weeks time (P<0.05 and P<0.01 respectively). Samples derived from fasting animals. 
White bars – mice fed control diet, black bars - mice fed diet supplemented with 
GW501516. n=5 mice/group. Data are expressed as means  ± SEM. 
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Bearing in mind that PPARδ transcriptional activity targets genes which 
participate in fatty acid processing and utilization, mRNA expression of several 
marker genes was measured. Adipophilin (Adipose Differentation-Related 
Protein: ADRP) a protein that coats intracellular lipid droplets is a marker of 
triglyceride accumulation, and direct downstream target of PPARδ receptor. 
Although the presence of intrahepatic fat was clearly shown before the real 
time, surprisingly, PCR did not reveal major changes throughout time of the 
experiment and between groups (Fig 3.8A). Apolipoprotein C3 (Apoc3), an 
inhibitor of lipoprotein lipase and thus marker of hypertriglyceridemia was down-
regulated in livers of GW501516 treated animals when compared to controls. 
The trend was visible after each time point, although only after 4 (down by 32%) 
and 8 weeks time (down by 29%) difference turned out to be significant (P<0.05 
and P<0.01 respectively) (3.8B). Change in this gene expression levels is 
consistent with lower plasma triglyceride levels found in mice treated with 
GW501516 (Fig 3.3A). 
Considering the fact that the plasma cholesterols levels were higher in 
PPARδ agonist treated groups, HMG-CoA synthase  (HMG-CoAS), which 
catalyzes the reaction to form 3-hydroxy-3-methylglutaryl-CoA and therefore is 
important enzyme in cholesterol synthesis pathway was chosen for the marker 
gene. Enzyme’s mRNA was up-regulated in treated group after 4 weeks (by 
68%; P<0.01) and at 8 weeks time. However, this was not statistically significant 
at the final time point (Fig 3.8 C). 
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Figure 3.8 Levels of hepatic mRNA of Adipophilin (ADRP) with no treatment or time 
related changes (A); Apolipoprotein C3 (Apoc3) with tendency to drop in GW501516 
treated mice (B) and HMG-CoA synthase  (HMG-CoAS) (C), were up-regulation is 
consistent with plasma total cholesterol levels (Fig 3.3C). White bars – mice fed control 
diet, black bars - mice fed diet supplemented with GW501516. Two-way ANOVA, 
significance is indicated as (*p<0.05; ** p<0.01), n=5 mice/group. Data are expressed 
as means  ± SEM. 
 
Based on gene expression by real time PCR no evidence was found that 
presence of excessive liver triglyceride in PPARδ agonist treated group after 4 
weeks was caused by fatty acid synthesis de novo.  The level of hepatic PPARγ 
mRNA, a master of adipocyte differentiation and fatty acid anabolism, had not 
changed at any time point (Fig 3.7C). The level of mRNA of protein directly 
involved in fatty acid synthesis, Fatty acid synthase (FAS) in liver after 4 weeks 
was actually lower in treated group by 60%, when compared to untreated group 
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from the same period. However, after reduction of the lipid content in livers of 
treated animals at 8 weeks time (Fig 3.5) the level of FAS has risen by 333% 
when compared to the same group from 4 weeks time point (Fig 3.9A). In 
muscle, the level of FAS mRNA was found only significantly different after 8 
weeks, where it was 3.7 fold higher in treated animals, when compared to 
controls (Fig 3.9B). 
 
 
Figure 3.9. Level of Fatty acid synthase (FAS) in livers (A) and muscle (B) in animals 
fed control diet (white bars) and animals fed diet supplemented with PPARδ agonist. In 
both organs no positive correlation was found between increased triglyceride levels 
after 4 weeks and up-regulation of FAS. Test used: two-way ANOVA, significance is 
indicated as ( ** p<0.01; ***p<0.001), n=5 mice/group. Data are expressed as means  ± 
SEM. 
 
 Although PPARδ agonism is generally responsible for induction of lipid 
catabolism, an impaired β-oxidation process could promote fat accumulation 
and as a result, liver steatosis. Several β-oxidation and fat catabolism marker 
genes were chosen for testing that hypothesis. Expression of peroxisomal acyl-
coenzyme A oxidase 1 (Acox1), which is the first enzyme of the fatty acid beta-
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oxidation pathway, was not changed substantially between groups or over the 
time of experiment (Fig 3.10A). On the other hand, mRNA levels of carnitine 
palmitoyltransferase I (CPT1), which mediates the transport of long chain fatty 
acids across the mitochondrial membrane, was increased 5 fold in steatotic 
livers (4 weeks, treated animals)  (Fig 3.10B).  Also hepatic expression of 
mRNA of uncoupling protein 2 (UCP2), which decreases reactive oxygen 
species production during lipid oxidation was increased at 2, 4 and 8 weeks 
time in GW501516 treated mice (by 65%, 74% and 163% respectively) (Fig 
3.10C). 
 
Figure 3.10. Examples of regulation of the genes involved in lipid oxidation upon 
PPARδ agonist treatment. Acox1 expression shows no changes in the livers of animals 
with increased fat content (4 weeks, treated group) (A). Hepatic CPT1 expression is 
up-regulated by PPARδ ligand in livers of treated animals (4 weeks) (B). UCP2 mRNA 
levels are elevated significantly at every time point by GW501516 treatment.  White 
bars – mice fed control diet, black bars - mice fed diet supplemented with GW501516. 
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Test used: two-way ANOVA, significance is indicated as (*p<0.05; ***p<0.001), n=5 
mice/group. Data are expressed as means  ± SEM. 
 
Using muscle-derived mRNA, more global expression pattern of lipid 
oxidation genes were examined. CPT1 expression after 4 weeks increased by   
53% in treated group, when compared with control (Fig 3.11A). Uncoupling 
protein 3 (UCP3), which plays role in neutralization of protein oxidation (and 
therefore is usually correlated with lipid oxidation) was up-regulated in treated 
group after 2 and 4 weeks time points (by 143% and 123% respectively) (Fig 
3.11B). Additionally, pyruvate dehydrogenase kinase isozyme 4 (PDK4), which 
inhibits carbohydrate metabolism in favour of lipid based metabolism in muscle, 
had similar pattern of expression in skeletal muscle as mentioned UCP3. Up-
regulation of the isoenzyme was significantly different in treated groups at 2 
(68%) and 4 (217%) weeks time (Fig 3.11C). 
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Figure 3.11 Up-regulation of the genes involved in fatty acid oxidation in muscle. CPT1 
(A) mRNA levels were higher in treated animals after 4 weeks. UCP3 (B) and PDK4 (C) 
reached significantly higher levels after 2 and 4 weeks.  White bars – mice fed control 
diet, black bars - mice fed diet supplemented with GW501516. Test used: two-way 
ANOVA, significance is indicated as ( ** p<0.01; ***p<0.001), n=5 mice/group. Data are 
expressed as means  ± SEM. 
 
3.3 Discussion 
This chapter proceeded to investigate phenotypic and transcriptional 
aspects of using GW501516 as a selective PPARδ activator in non-transgenic 
mice.  Consistent with many reports published before [121,142,143], activation 
of PPARδ led in this study to prevention of body mass increase and 
improvement of plasma lipid profile.  
 
PPARδ role in modulation of appetite and plasma lipid profile 
As the main function of this transcription factor is to switch from 
carbohydrate-based metabolism to lipid-based metabolism, activation of PPARδ 
enhances lipid catabolism in various tissues, thereby retarding weight gain. The 
reduced appetite of mice fed diet supplemented in GW501516 might contribute 
to overall weigh reduction found in these animals. Although it is difficult to say 
whether reduced food intake is a direct result of PPARδ activation or rather a 
side effect of pharmacologically-provoked lipid catabolism. A similar finding was 
discovered in study done by Perreault et al [144]. In their work, diet-induced 
obese and ob/ob mice were fed diet supplemented with a PPAR pan agonist 
(compound 4), which caused appetite suppression along with body weight loss. 
Although PPAR pan agonist activates all three subtypes of PPAR family, 
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authors associated mainly activation of PPARα as the main contributor to 
reduced food intake. In our study, however, the agonist used, GW501516 (as it 
was mentioned before in introduction to chapter 3) is more than 1,000-fold 
selective for PPARδ over the other subtypes of PPAR family [127], suggesting 
that PPARδ might also play role in this phenomenon. 
 As previously reported in human and primate studies [116,127], 
GW501516 treatment was also capable of reducing plasma triglyceride in mice. 
On the other hand, raised HDL levels were not observed in studies in men, 
whereas in primates and in our study in C57BL mice, this HDL raising is 
apparent. Although rise in HDL could be partially explained by increased 
concentration of total plasma cholesterol also found in our study, nevertheless, 
ability to modify HDL levels is still important feature of PPARδ agonism in the 
context of its metabolic action.  
 In this study, lack of influence of GW501516 on insulin levels was in 
contrast to its action on leptin levels, where PPARδ agonist was capable of 
lowering leptin significantly almost at every measured time point. Similar results 
was described in work done by Chen et al, where GW501516 was able to 
improve hyperleptinaemia in monosodium l-glutamate metabolic syndrome mice 
[122]. Generally accepted evidence suggests that leptin has a role within the 
central nervous system to modulate food intake and thermogenesis [62].  It is 
assumed that leptin concentrations are, in general, proportional to body fat 
mass. However, circulating leptin levels tend to drop sharply e.g. during fasting. 
Considering the fact that PPARδ is particularly active during states of exercise 
or restriction of energy intake, pharmacological activation of PPARδ could have 
similar effect as mentioned physiological conditions on this hormone levels.  
67 
 
 
 
Role of PPARδ agonists in liver lipid metabolism in wild-type mice  
 Several of the previous studies have suggested some role of synthetic 
PPARδ agonists in promoting hepatic lipid accumulation [124,128], whereas 
other considered it neutral or even negative [116,130]. In our work, we show 
evidence that in non-transgenic mice treated with GW501516 there was time 
dependent liver fat fluctuation. Animals fed control diet steadily gained body 
mass, which eventually after 8 weeks resulted in increased hepatic lipids. In 
contrast, the mice fed diet supplemented with GW501516 after 4 weeks had 
significantly higher liver triglyceride content, while still not gaining any body 
mass. However, at the end of the experiment, treated group had less 
triglyceride in the liver than control group. It is possible that PPARα subtype 
might be responsible for clearance of the hepatic lipids in the long term. 
Although GW501516 selectivity for PPARδ was quoted before, PPARα to 
PPARδ proportions in rodent liver are well in favour for the former. Non-
selective activation of PPARα by GW501516 accumulating in the liver or by 
PPARδ downstream activity on PPARα could be possible explanation of hepatic 
triglyceride fluctuation, in spite of stable GW501516 blood plasma’s 
concentrations.  
Lee et al [124] proposed promotion of fatty acid synthesis as an 
explanation for observed fat accumulation in livers of mice fed GW501516 to 
allow the utilisation of glucose and providing fuel for fat burning in muscle. 
However, in contrast to their finding, we show that in our study, fatty acid 
synthase (FAS) was not induced by GW501516 and was not positively 
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correlated with level of hepatic triglyceride. Therefore with this evidence it is 
difficult to say whether PPARδ is truly involved in promoting synthesis of the 
additional fat. Nevertheless, presence of additional hepatic triglyceride in 
GW501516 treated groups after 4 weeks was real and it could be also due to 
weakened β-oxidation processes in the liver. Still, no evidence was found to 
support this hypothesis. The pattern of hepatic expression of lipid oxidation 
marker gene suggested enhanced metabolism as shown by increases in the 
mRNA encoding CPT1 and UCP2.     More global fatty acid catabolism upon 
feeding the animals with diet supplemented with GW501516 was also 
supported by examples of genes expression in skeletal muscle. Taking under 
consideration that PPARδ agonist action is not limited to liver, as the expression 
of PDK4 and UCP3 shows, and the fact that there is no solid proof for de novo 
lipogenesis or impaired β-oxidation in the liver in this study, it might be 
concluded that presence of additional fat in livers of GW501516 treated animals 
can come from peripheral sources like adipose tissue, which is highly likely due 
to the rapid weight loss in these animals. The possibility of shifting the 
distribution of fatty acids from adipose tissue to ectopic accumulation upon 
various stimuli was recently supported  in work done by Zhong et al [145]. They 
showed evidence for contribution of alcohol-provoked adipose tissue lipolysis to 
hepatic steatosis. Rapid free fatty acids release from subcutaneous or visceral 
fat stores upon powerful stimulus might be actual cause or significant 
contribution to fatty liver phenotype. 
 These experiments were carried out to gain global picture on action of 
the GW501516 in non-transgenic mice and test hypothesis whether PPARδ 
agonist might promote fat accumulation in the mouse liver. However, to get 
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more insight into the actual cause of this phenomenon and determine if PPARδ 
receptor is solely responsible for the observed hepatic fat fluctuations in 
response to GW501516, we proceeded to utilise a transgenic animal models 
that would allow genetic alterations of PPARδ activity.  
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Chapter 4 Effects of dietary GW501516 administration in non-
transgenic or human PPARδ or dominant negative derivative of 
human PPARδ mice on fatty liver phenotype. 
 
4.1 Introduction 
Rodent models for studying peroxisome proliferator activated receptors 
biology have been so far both useful and troublesome [146]. Carcinogenicity 
and hepatomegaly found in rodents treated with synthetic PPARα ligands is in 
contrast to primates and especially to men, since humans do not exhibit the 
liver toxicities associated with the rodent models treated with PPARα ligands. 
Therefore, it is essential to find suitable animal models as close as 
possible in drug response to men, to foresee potential outcomes in humans. 
Since the primate model is not widely available and the rodents are prone to 
their species related differences in drug response, transgenic humanized mice 
or rats could turn out to be a promising alternative. In the study shown in the 
previous chapter we found that the PPARδ was the least abundant subtype of 
the whole PPAR family expressed in the liver of non-transgenic mice, with 
PPARα expression overwhelming the remaining 2 members of PPAR family 
(data not shown). Ideally, a humanized transgenic mouse model should reflect 
proportions of PPAR family found in the human liver, where there is no such 
disproportion in expression of PPARα over PPARδ [93]. Recently, 2 such 
models have appeared, including one used in the following study. Two 
approaches have been utilized when making the mouse transgenic model for 
human PPARδ. First in the work done by Gross et al [147] and second by our 
group [117,140]. In the first case, mouse endogenous PPARδ was simply 
replaced by human counterpart. The authors termed the model PPARδ knock-in 
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(PPARδ KI), which reflects genetic alternation done in the mouse. Summarizing 
the phenotype of their humanized mouse model for PPARδ, they show the 
ability of human PPARδ to replace the function of mouse PPARδ. Using the 
PPARδ other available specific activator, GW0742, they have shown that 
mouse and human PPARδ have overlapping functions in lipid and lipoprotein 
metabolism due to regulation of similar gene pool. However, the level of 
expression of the swapped receptor in livers of PPARδ KI animals was actually 
lower than endogenous PPARδ in non-transgenic mice. Although as they claim 
functionality of this nuclear receptor subtype between these 2 species was 
similar, it still doesn’t reflect the proportions between PPARs found in human 
liver.  
Our model of human PPARδ (hPPARδ) used in the following study 
(described in detail in methods chapter), not only allowed tracking of the 
physiological and transcriptional response of human gene in mouse model, but 
also mimicked more closely proportions of PPARs in human liver. Additionally, 
the dominant negative version of hPPARδ (hPPARδΔAF2) was used. This  
classical dominant negative deletion of the Activation Function 2, AF2, domain 
of PPARδ shows both constitutive transcriptional repression in addition to 
enhanced repression of PPRE signalling in the presence of a PPARδ agonist 
[148]. It serves as a loss of function or parallel-reversed model (when compared 
with the hPPARδ expressing mice) to help to decipher involvement of PPARδ 
receptor in hepatic steatosis observed in non-transgenic mice upon stimulation 
with GW501516 and described in previous chapter. 
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4.2 Results 
Seventy 10-week old C57BL/6 background (30 non-transgenic mice; 10 
mice expressing human PPARδ, and 30 mice expressing a dominant negative 
derivative of PPARδ (hPPARδΔAF2) – 30 mice) were placed on control 
(repelleted RMI + 0.25% I3C) or GW501516 (repelleted RMI + 0.25% I3C + 
0.0025% GW) supplemented diet. 
After two weeks, 30 mice (10 from each genetic group – 5 on control, 5 
on GW501516 diet) were sacrificed. Then after 4 weeks from beginning of the 
experiment 20 mice (non-transgenic and hPPARδΔAF2) were taken. After 8 
weeks of the experiment remaining 20 mice (non-transgenic and hPPARδΔAF2) 
were sacrificed.  
All animals were sacrificed using increasing concentration of CO2. Blood 
were removed using cardiac puncture, followed by organ removal (liver, 
muscle). Before the kill, animals were fasted to ensure adequate serum lipids 
measurements. 
hPPARδ over-expressing animals were only included in the experiment 
for the first 2 weeks due the development psoriasis-like skin disease with more 
prolonged treatment with GW510516 [117,119].  
After 14 days of treatment, weight measurements demonstrated that 
ligand treated hPPARδ animals lost 15% of the body weight in 2 weeks, when 
compared to untreated controls (P<0.001). Non-transgenic mice fed diet 
containing GW501516 and animals conditionally over-expressing hPPARδΔAF2 
with GW501516 in diet, had no significant changes in body mass in relation to 
their control groups or maintained normal weight gain within 2 weeks time 
(Figure 4.1A). In the later stages of the experiment, involving this time only non-
transgenic and hPPARδΔAF2 animals, wild type mice fed diet supplemented 
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with GW501516 had similar pattern of weight gain (Figure 4.1B) described in 
experiment from previous chapter, were animals were having no I3C in the diet. 
On the other hand, the animals over-expressing hPPARδΔAF2 were completely 
immune to GW501516-induced weight loss throughout the duration of 
experiment (Fig 4.1C). However, when comparing control mice only, the 
hPPARδΔAF2 animals had slightly lower weight gain than the non-transgenic 
mice in 8 weeks study (Fig 4.1 B and C), although the overall effect was not 
statistically significant. 
 
 
Figure 4.1 Body mass change in non-transgenic, hPPARδ and hPPARδΔAF2 mice. 
Comparison of body weight gain after 2 weeks, in all 3 genotypes (A). Differential 
weight gain in non-tg animals throughout the experiment (B). No mass change was 
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found between groups in hPPARδΔAF2 animal branch (C). Two-way ANOVA, 
significance is indicated as (*p<0.05; ** p<0.01; *** p<0.01), n=5 mice/group. Data are 
expressed as means  ± SEM. 
 
 In similar a experiment with identical animal numbers and design, but 
ending after 12 days and done exclusively to obtain data from Medical 
Resonance Imaging (MRI), identical pattern of body mass change was found in 
all 3 genotypes as in 2-weeks time point (Fig 4.2A).  
 
 
Figure 4.2 Results from whole body MRI scans of non-tg and transgenic animals fed 
control or diet supplemented in GW501516. Body mass change in 12 days of treatment 
(A). Percentage change in fat mass (B). Percentage change in lean mass (C). Two-way 
ANOVA, significance is indicated as *** p<0.001, n=5 mice/group. Data are expressed 
as means  ± SEM. 
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 MRI scans of the whole live animals revealed major changes in fat and 
lesser changes in lean mass compositions between first and last day of the 
experiment. Whereas all control groups increased body fat mass, non-
transgenic animals fed diet supplemented GW501516 lost 12% of the body fat, 
hPPARδ mice on the same diet lost 64% of the body fat, while hPPARδΔAF2 
animals fed diet with GW501516 gained 23% in fat (Fig 4.2B). There was 
virtually only one group, which had notable loss in lean mass, hPPARδ animals 
fed diet enriched in GW501516, which showed a 12% reduction of body lean 
mass. High association was found between body mass changes and fat or lean 
mass fluctuation. Although the correlation between lean mass and fat mass was 
lower, than seen for  body mass vs lean mass ( R2=0.5566 vs R2=0.9035), tests 
for correlation turned out to be extremely significant for both cases (P<0.0001) 
(Figure 4.3). 
 
 
Figure 4.3 Correlations between total body mass vs fat mass (A) and between total 
body mass vs lean mass (B). Each point on the graph represents an individual animal 
used in this experiment (total number = 30) (12 days study). 
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Figure 4.4. Food intake in 12 days experiment in non and transgenic mice. 
Consumption of food by non-transgenic mice (A); Food consumption by hPPARδ 
animals (B); Food intake by hPPARδΔAF2 mice (C). Comparison of food intake by 
controls of all 3 genotypes (D), and by treated mice (E), n=5 mice/group. 
 
Food intake monitoring in the 12-days experiment showed that in non-
transgenic animals, mice fed diet enriched in GW501516 only marginally 
consumed less than the control animals (Fig 4.4A). hPPARδ mice fed diet 
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supplemented with GW501516 initially consumed more than their controls 
without the ligand in the food, but at the end of the experiment situation has 
reversed (Fig 4.4B). The food intake levels in hPPARδΔAF2 animals was 
similar to that observed the hPPARδ animals (Fig 4.4C), despite striking 
differences in weight gain between these two genotypes upon GW501516 
treatment.  
Blood lipid measurements in 14-days experiment across all three 
genotypes have shown similar pattern as that seen in the study conducted in 
non-transgenic mice only.  Total cholesterol was generally higher in non-
transgenic and hPPARδ treated animals than in the controls, however, none of 
the differences turned out to significant (Figure 4.5A). No significant effect on 
plasma triglyceride was noticed in any of the genotypes although in hPPARδ 
there was tendency for lower triglyceride levels in treated mice (Fig 4.5B). 
Significant difference was found in HDL plasma levels derived from hPPARδ 
animals (Fig 4.5C). Treated mice had 52% higher levels of HDL than controls. 
No changes were observed in HDL levels in hPPARδΔAF2 animals. In non-
transgenic mice treated with GW501516, HDL levels were still higher than in 
controls, but the difference was not statistically significant. Plasma free fatty 
acids (FFA) were higher in non-transgenic treated mice and control 
hPPARδΔAF2 animals when compared to their control or treated groups 
respectively. However, none of these changes were statistically meaningful (Fig 
4.5D).  
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Figure 4.5. Plasma lipid profiles in non-transgenic and transgenic animals, after 14 
days of GW501516 treatment. Plasma total cholesterol tendencies to rise upon 
GW501516 treatment in non-transgenic and hPPARδ animals were not found to be 
significant (A). No differences after 2 weeks was found in triglyceride levels (B). 
Extremely significant rise in HDL levels were detected in hPPARδ in mice fed diet 
enriched in GW501516 (C). Fluctuations in FFA were not translated into statistical 
significance despite observed tendencies (D). Two-way ANOVA, significance is 
indicated as *** p<0.001, n=5 mice/group. Data are expressed as means  ± SEM. 
 
Plasma leptin levels showed high variation among the genotypes. In non-
transgenic PPARδ ligand treated animals lower levels of this adipose tissue-
borne hormone were observed, although there was no statistical difference in 
this group. In hPPARδ mice fed diet supplemented with GW501516 leptin levels 
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were barely detectable when compared to controls fed normal diet and the 
difference turned out to be extremely significant (P<0.001). On the other hand 
the GW501516-treated hPPARδΔAF2 animals showed no decrease in blood 
leptin levels comparing to their controls (Fig 4.6A). Insulin (Fig 4.6B) and 
glucose (Fig.4C) levels showed no variation across genotypes or treatment 
groups. 
 
Figure 4.6.Blood hormones and glucose levels in 3 different genotypes treated with 
PPARδ ligand. Plasma leptin was almost eliminated in hPPARδ animals by GW501516 
treatment (A). Insulin levels were not changed upon PPARδ agonist (B). No glucose 
variations between treatment groups were found (C), n=5 mice/group. Data are 
expressed as means  ± SEM. 
Following sacrificing the mice after two weeks, dissection of the animals 
revealed pale colour of the livers of hPPARδ and hPPARδΔAF2 mice.  
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Figure 4.7 Examples of typical livers derived from mice fed for 14 days control diet or 
diet supplemented with GW501516.   
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Direct measurements of triglyceride in liver tissue showed that after 2 
weeks non-transgenic mice fed diet enriched with GW501516 had slightly 
elevated hepatic triglyceride content when compared to their controls, although 
the difference turned out to be not significant. In mice over-expressing hPPARδ 
and fed diet supplemented with GW501516 liver fat content increased by 202% 
in comparison to their controls (P<0.001).  Mice over-expressing a dominant 
negative form of hPPARδ (hPPARδΔAF2) with the ligand in the diet, 
accumulated 52% less fat in the liver, than control animals, (P<0.001). 
However, hPPARδΔAF2 control mice had hepatic fat content comparable to 
hPPARδ GW501516-treated group (Fig 4.8A). When comparing only treatment 
groups, hPPARδ mice had 109% more liver triglyceride than non-transgenic 
(P<0.001) and 85% more than hPPARδΔAF2 mice (P<0.01). (Fig4.8A). 
Cholesterol liver content after 14 days of experiment was only significantly 
elevated in hPPARδ animals fed diet containing GW501516 were difference 
between controls and treated animals reached 94% (P<0.001) (Figure 4.8B). 
Non-transgenic mice and hPPARδΔAF2 animals have revealed further 
fluctuations in hepatic fat content in later stages of the study, after 4 and 8 
weeks. Wild type animal’s hepatic lipid response to PPARδ ligand across all 3 
time points resembled the one shown in previous chapter. There was a build-up 
of liver fat after 4 weeks in treated group, when compared to controls, with 
situation being reversed after 8 weeks of GW501516 treatment. In livers of 
hPPARδΔAF2 animals, triglyceride were at lower level in treated mice than in 
the animals fed control diet at all time point, however only at 2 and 8 weeks the 
difference was significant (P<0.001 and P<0.01 respectively) (Fig 4.8C). 
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Figure 4.8 Hepatic lipid response in wild type and mice transgenic for hPPARδ and 
dominant negative hPPARδΔAF2 after feeding the control diet or diet supplemented 
with GW501516. Hepatic triglyceride after 14 days study in transgenic and non-
transgenic mice (A). Liver total cholesterol was only significantly elevated in hPPARδ 
animals fed diet enriched in PPARδ agonist (B). Hepatic triglyceride across all 3 time 
points in non-transgenic and mice over-expressing hPPARδΔAF2. Two-way ANOVA, 
significance is indicated as ** p<0.01; *** p<0.001, n=5 mice/group. Data are 
expressed as means  ± SEM. 
 
RT-PCR quantification has shown that the expression of the transgene in 
transgenic animals in this particular experiment was significantly higher in the 
liver when compared to muscle expression (Figure 4.9), with no detection in 
tissues of non-transgenic animals. GW501516 availability did not affected 
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transgene expression pattern. Full data on transgene distribution across tissues 
and its inducibility was published before [140]. 
 
Figure 4.9 Human PPARδ and hPPARδΔAF2 induction in liver and muscle after 2 
weeks feeding the diet supplemented with 0.25% Indole-3-carbinol. n=5 mice/group.  
 
Patterns of hepatic expression of the members of PPAR family showed 
no significant differences between treatment groups, with exception of PPARγ 
being 3.5 fold up-regulated in hPPARδ control mice over treatment group 
(P<0.01). In muscle however, PPARγ showed no statistical variation in 
expression across the genotypes or treatment groups. This was in contrast to 
PPARα and PPARδ expression where there was significant difference between 
control and treatments groups in hPPARδ mice. PPARδ receptor was also up-
regulated in hPPARδΔAF2 control mice, when compared to treatment group 
(Figure 4.10 A-F).  
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Figure 4.10 PPAR family expression in liver and muscle. PPARα in liver (A) and muscle 
(B), PPARγ in liver (C) and in muscle (D) and PPARδ expression pattern in liver (E) 
and muscle (F), n=5 mice/group. Data are expressed as means  ± SEM. 
 
Apolipoprotein C3 (Apoc3) levels, which are known to positively correlate with 
plasma triglyceride, across the genotypes after 2 weeks did not reach any 
significant difference between groups (Figure 4.11A). Similarly, HMG-CoA 
synthase, although showing trends involving PPARδ ligand and genotype in the 
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pattern of expression, none of these changes reached statistical significance 
(Figure 4.11B). Another PPARδ target gene PDK4, although primarily limited in 
tissue distribution to muscle, was also expressed in the liver where highly 
expressed in GW501516 treated group, however only in non-transgenic group. 
An almost identical pattern could be observed in muscle (Figure 4.11 C and D). 
Angiopoietin-related protein 4 (ANGPTL4) gene, which encodes a protein that 
functions as lipoprotein lipase inhibitor, has pronounced role in lipid metabolism, 
where it modulates triglyceride uptake and it is believed that it serves to protect 
a cell against cellular lipid overload by reducing extracellular TAG hydrolysis 
and consequent fatty acid uptake [149]. It is also known PPARδ target gene. 
However, it this experiment, in liver it was not differentially expressed between 
groups or genotypes and in muscle samples it was several fold induced by 
GW501516 in non-transgenic mice only (Figure 4.11 E and F). 
 Almost identical pattern of expression was observed in mRNA of ADRP 
in liver and muscle. The two Way ANOVA indicated a significant difference  
between the control and treated groups (Figure 4.12 A and B). Additionally 
expression of ADRP in the liver was highly associated with hepatic levels of 
triglyceride (Figure 4.13). Group means for liver TAGs and group means for 
ADRP showed high correlation regardless genotype or treatment status 
(P=0.0073 and R2=0.8636). Another marker of lipid uptake, CD36 (Cluster of 
Differentiation 36) is a membrane associated protein and its mRNA was several 
fold over-expressed in livers of hPPARδ animals (Figure 4.12 C) and in muscle 
in non-transgenic and hPPARδ mice, however in the latter the difference was 
not considered significant (Figure 4.12D). 
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Figure 4.11 PPARδ target genes expression in liver and muscle. Apoc3 in liver (A), 
HMGCoA in liver  (B), PDK4 in liver (C) and muscle (D) and ANGPTL4 in liver (E) and 
muscle (F). White bars – control groups, black bars -  groups fed diet supplemented 
with GW501516. Two-way ANOVA, significance is indicated as * p<0.05; *** p<0.001, 
n=5 mice/group. Data are expressed as means  ± SEM. 
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Figure 4.12 Expression of genes involved in lipid droplets coating and fatty acids 
uptake between the genotypes and treatment groups. ADRP in liver (A) and muscle (B) 
and CD36 in liver (C) and muscle (D). White bars – control groups, black bars -  groups 
fed diet supplemented with GW501516. Two-way ANOVA, significance is indicated as * 
p<0.05; *** p<0.001, n=5 mice/group. Data are expressed as means  ± SEM. 
 
 
Figure 4.13 Expression of ADRP a protein marker of TAGs accumulation and direct 
PPARδ responsive gene, is significantly correlated with hepatic triglyceride levels. 
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Each point on the graph represents mean value of each group (control and treated) for 
ADRP relative expression vs mg/g of hepatic triglyceride. 
 
Fatty acid synthase mRNA levels in liver showed no significant up-regulation in 
mice over-expressing human PPARδ; in fact, there was marked several fold 
down-regulation in non-transgenic and no effect of the GW501516 treatment on 
hPPARδΔAF2 mice.  However in muscle, hPPARδ animals FAS mRNA levels 
indicated increased transcription of this gene in GW501516-treated animals 
when compared to their controls or to the wild type or  hPPARδΔAF2 mice, 
regardless the groups status (Figure 4.14 A and B). 
 
Figure 4.14. Fatty acid synthase expression across treatments groups and genotypes 
in liver (A) and in muscle (B). White bars – control groups, black bars -  groups fed diet 
supplemented with GW501516. Two-way ANOVA, significance is indicated as *p<0.05; 
** p<0.01, n=5 mice/group. Data are expressed as means  ± SEM. 
 
How the transgenes expression influences ß-oxidation process in this animal 
model is shown on the examples of 3 genes. Acox1 mRNA was increased by 
214% in liver of GW501516-treated hPPARδ animals when compared to control 
group (P<0.01), and in muscle with trend to be GW501516-dependent 
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excluding hPPARδΔAF2 mice were the situation was reversed (Fig 4.15 A and 
B respectively). Additionally, hepatic expression levels of levels of CPT1 were 
not changed during the treatment in hPPARδ animals, but up-regulated in 
muscle upon agonist treatment (Fig4.15 C and D respectively). Uncoupling 
protein 2 (UCP2) is mitochondrial anion carrier and its function is to decrease 
reactive oxygen species production, it is also target of PPARs [150]. It can also 
serve as marker of energy turnover. In steatotic livers of hPPARδ mice it was 
markedly up-regulated (Fig 4.15 D) and in muscle also non-transgenic mice  
turned out to be responsive to PPARδ ligand. Only hPPARδΔAF2 animals were 
not affected by GW501516 in terms of of UCP2 mRNA levels. 
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Figure 4.15 Expression markers of β-oxidation genes in  non-transgenic, hPPARδ and 
hPPARδΔAF2 mice. Acox1 liver (A) and muscle (B) levels. CPT1 expression in liver 
(C) and muscle (D). And UCP2 hepatic E) and muscular (F) expression. White bars – 
control groups, black bars - groups fed diet supplemented with GW501516. Two-way 
ANOVA, significance is indicated as *p<0.05; ** p<0.01, n=5 mice/group. Data are 
expressed as means  ± SEM. 
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4.3 Discussion 
 
We wished to examine the role of PPARδ in the action of GW501516 that we 
observed in our studies in Chapter 1.  In order to this we used both gain and 
loss of function strategies in transgenic mice.  For a gain of function approach 
we used transgenic mice conditionally over-expressing human PPARδ and for a 
loss of function approach we used transgenic mice conditionally over-
expressing dominant negative derivative of human PPARδ.  
 
PPARδ receptor is responsible for GW501516-induced weight loss 
 Confirming our hypothesis, weight loss was particularly evident when hPPARδ 
animals were fed a diet containing GW501516 (Fig 4.1 A). And the dominant 
negative hPPARδ over-expression completely prevented weight reduction by 
GW501516.  This convincingly confirmed the leading role of the PPARδ 
receptor in GW501516-related effects. Although fat disappearance was the 
main contributor to total body weight loss in non-transgenic and hPPARδ mice, 
lean mass was reduced too (Fig. 4.2 C). It might suggest role of the transgene 
activity in this process, however, hPPARδ was not induced in muscle of these 
animals [140] (Fig. 4.9). The evidence from semi-starvation experiments in 
humans also show that muscle mass loss is initiated in parallel to fat mass 
reduction from the very beginning of the reduction of caloric intake, although the 
latter is lost at much faster rate [33].  The correlation was stronger between total 
mass reduction and lean mass reduction rather that between total body mass 
versus fat mass in both transgenic models and the control animals. This 
imbalance comes from the fact that, hPPARδΔAF2 animals fed diet enriched 
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with GW501516 failed to mobilize their fat deposits, but in 12 days, they were 
still retarding the lean mass gain in the presence of PPARδ agonist (Fig 4.2 C).  
 
Activity of PPARδ plays an important role in energy homeostasis 
regulation  
Interestingly, while control non-transgenic mice in the current study had the 
trend to reduce the food intake when GW501516 was available in the diet, 2 
weeks of studying physiological response to PPARδ agonist in transgenic mice 
showed no significant differences in food consumption, when compared to their 
genetic controls. This is also in contrast to what was described in previous 
chapter, where wild type mice had diminished appetite when GW501516 was 
added into the diet. It is not surprising considering the hPPARδΔAF2 mice, 
which represent the dominant negative model of the PPARδ receptor. However, 
regardless of the mechanism of appetite suppression by PPARδ agonist in wild 
type mice, it is not strongly pronounced in the hPPARδ animals. It is possible 
that basal reduction in food consumption is compensated by extensive nutrient-
demanding metabolic state and therefore enforced increase in food intake, 
created by over-expression and activation of hPPARδ. PPARδ is the most 
abundant isoform in the central nervous system and is enriched in the 
hypothalamus, a region of the brain involved in energy homeostasis regulation. 
In study performed by Kocalis et al, neuronal deletion of PPARδ resulted in a 
susceptibility to diet induced obesity in animal model [151]. Their findings and 
our results on the involvement of GW501516 on appetite suppression, indicate 
that PPARδ plays an important role in energy homeostasis regulation which is 
independent of PPARδ-induced WAT lipolysis. Adipose born hormones like 
leptin, may play a significant role in this mechanism. There was virtually no 
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leptin in the plasma derived from hPPARδ animals fed diet enriched with 
GW501516 (Fig 4.6 A) and the leptin is known to play great role in modulating 
the appetite, with low blood levels stimulating the food intake [62].  Therefore 
we would expect the food intake of the GW501516 treated hPPARδ mice to 
increase. Extremely low levels of leptin in blood of hPPARδ mice, could be 
explained directly by significant reduction in adiposity preceded by over-
expression of the transgene and activation by PPARδ ligand. Leptin was not 
affected by GW501516 treatment in hPPARδΔAF2 mice, which confirms 
potential of this receptor to modulate leptin levels [122]. Insulin levels in 
transgenic mice were consistent in not being influenced by PPARδ activity, 
similarly to what was found in wild type animals in previous chapter.  
 
Lipid metabolism is regulated by PPARδ 
Surprisingly, there was no decrease in plasma triglyceride in hPPARδ, nor in 
the wild-type mice in 2 weeks time. In previous experiment, this GW501516-
associated effect was observed after 14 day of treatment in non-transgenic 
animals (Fig 3.3B). The interference of I3C signalling might not be excluded. 
Although the recent report shows that I3C itself possesses triglyceride lowering 
capability [152]. On the other hand, the effect on the HDL levels seemed to be 
pronounced in animals conditionally expressing hPPARδ, where only 2 weeks 
were enough to reach the levels of HDL, which in wild type animals, were only 
achieved after 4 weeks (Fig 3.3 D and Fig 4.5 C respectively).   
 In non-transgenic mice 2-weeks feeding with diet enriched in 
PPARδ agonist provoked only minor fluctuations in liver triglyceride (Fig. 3.5 
and Fig. 4.8A), while in mice transgenic for hPPARδ, this time was sufficient for 
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accumulation significant amount of lipids in the liver. Higher level of hepatic 
triglyceride was also found in hPPARδΔAF2 animals on normal chow diet, but 
not in hPPARδΔAF2 mice with GW501516 in the diet. It might be rather 
surprising, as PPARδ in this case was not functional, because of lack of ligand-
activated AF2 domain. However, recent findings [148,153] suggest that PPARδ 
main role could be a repressor function. Gustafsson et al concluded that genetic 
ablation of PPARδ will remove the intrinsic role that PPARδ has in the 
tempering of signalling of PPARα and PPARγ. Similar conclusion was drawn by 
already cited Adhikary et al study. On the other hand, findings described in this 
chapter show that hepatic fat level was reduced in hPPARδΔAF2 mice with the 
PPARδ agonist in the diet, being comparable to those found in non-transgenics 
after 2 weeks treatment. Exactly the same pattern could be seen in mRNA 
expression of ADRP in liver in 2 weeks (strong correlation with liver triglyceride, 
Fig 4.13) and also in other genes expressed in liver and in muscle (Figure 4.12 
and 4.14). And animals over-expressing hPPARδΔAF2, which were fed for 8 
weeks diet supplemented with GW501516 had minor fluctuations in hepatic fat, 
but the levels of fatty acids were always lower in this group, than in the control 
animals within the same phenotype. The non-transgenic animals in this 
experiment have shown consistency in the hepatic fat levels with the findings 
from previous chapter.  
Concluding, ligand binding to AF2 domain-deficient PPARδ, restores 
repressing function of this nuclear receptor. In this case, agonist bound to AF2-
incomplete hPPARδ, works in antagonist fashion, efficiently competing with 
endogenous mouse PPARδ for PPRE binding sites.  This model of PPARδ 
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expression provides an additional tool, confirming association between PPARδ 
signalling and hepatic fat accumulation.   
 
Liver is the key organ for PPARδ-associated effects  
Endogenous PPARδ is expressed ubiquitously in most of the body 
organs [137]. Therefore, it is difficult to determine, which of them could be 
crucial for PPARδ-agonist linked regulation of plasma lipids, weight loss and 
liver steatosis. In our animal model however, the basal hPPARδ transgene 
expression was very low in range of tissues and highly inducible in the liver 
(Figure 4.9), [140]. Consequently, the pronounced weight loss and hepatic lipid 
accumulation in mice conditionally-expressing hPPARδ fed diet supplemented 
with GW501516, might lead to the conclusion that liver is vital for generation of 
this phenotype.  
Despite the well established induction of the transgene in the liver, in this 
organ, PPAR family members did not show noticeable and significant relation to 
the genotype or treatment status. Unlike the liver, muscle PPARs, especially 
PPARα and PPARδ demonstrate pattern of expression, which is also evident in 
other genes. Namely, pronounced expression in wild type, hPPARδ treated with 
PPARδ agonist and hPPARδΔAF2 control animals. Examples of such pattern of 
expression can be found in ADRP and HMGCoAs in liver or CPT1, UCP2 and 
Acox1 in muscle. This set of the genes reflects more closely the repressor 
function of PPARδ, where ligand binding to endogenous mice receptor or 
hPPARδ or negative dominance of hPPARδΔAF2 relieves the repression, which 
drives the transcription of the target genes. Not all genes shown in this chapter 
however, manifest the repressor function of the PPARδ, which is consistent with 
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findings of Adhikary et al, where 3 differing modes of target gene regulation by 
PPARδ have been described. In these studies PPARδ was shown to control 
gene expression by; (a) type 1 response: up-regulation of the target genes by 
siRNA knock down of PPARδ, but not by GW501516, (b) type II response: up-
regulation by knock down of PPARδ and by GW501516 binding, (c) type III 
response: down-regulation by PPARδ siRNA, but not by GW501516 binding 
[153]. 
As previously have been shown in wild type animals model, in hPPARδ 
mice the hepatic gene expression of fatty acid synthase (FAS) (Fig 4.14 A) or 
genes involved in β-oxidation (Fig 4.15) do not support the hypothesis that the 
origin of the additional fat in the livers in animals treated with PPARδ ligand 
comes from fatty acid de novo synthesis or crippled fatty acid burning and 
turnover. Some new light is shed on causes of observed massive hepatic lipid 
accumulation in animals treated with GW501516 by parallel substantial 
reduction of adipose tissue deposits and CD36 expression in liver. CD36, which 
supports transport of fatty acids across the cellular membrane, was markedly 
up-regulated in hPPARδ livers fed diet enriched with GW501516. The presence 
of additional hepatic fat in control hPPARδΔAF2 animals is however neither 
consistent with weight loss or CD36 up-regulation in these animals. Possibly, 
hPPARδΔAF2 transgene induction in this model is enough to release amount of 
fatty acids from adipose cells to cause hepatic steatosis, but insufficient to 
deplete the body of its adipose tissue, as it was found in mice over-expressing 
full length human PPARδ receptor and activated by the agonist.  
All of the experimental mice used in this chapter, were healthy 10 weeks 
old animals fed normal diet. Since the PPARδ agonists are hoped to be used to 
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correct some aspects of the metabolic syndrome, it is important to gain a better 
understanding of hPPARδ activity in different metabolic contexts such as high 
fat diet and obesity. The next chapter aims to address this. 
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Chapter 5 Effects of chronic high fat dietary intake in mice 
conditionally expressing human PPARδ or dominant negative 
derivative of human PPARδ on body weight and hepatic 
triglyceride accumulation. 
 
5.1 Introduction 
One of the contributors to non-alcoholic fatty liver disease (NAFLD) is 
diet [36]. In general, saturated fat and fructose contribute to hepatic lipid 
accumulation, whereas unsaturated fat, choline, antioxidants and high-protein 
diets rich in isoflavones seem to have a more preventive effect [37,129]. 
Unsaturated fatty acids are also one of the activators of PPARδ [154]. 
Recommend consumption of fat by clinicians is defined as a diet deriving less 
than 30% of the energy from fat [33]. The typical laboratory experimental high 
fat diets (HFD) for rodents, have higher than 30% energy from fat, but usually 
contain balanced fatty acid composition. The one used in this study derives 
60% of the daily calories from fat and has a ratio of total saturated fatty acids to 
monounsaturated fatty acids approximately equal to 1. In normal wild-type 
animals, long term feeding with HFD eventually leads to relative increase of 
adipose tissue mass, total body weight gain and possibly, liver fat accumulation 
[155,156]. Bearing in mind that monounsaturated fatty acids or their derivatives 
can activate PPARδ, serving as its partial agonists and on the other hand high 
content of saturated fat in HFD, feeding the mice over-expressing hPPARδ 
using this diet can have two possible effects. One would be the usual over-
nutrition resulting in body mass gain and possibly liver steatosis, and 
alternative, protective role against diet induced obesity. Using our transgenic 
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model, we tested the role of hPPARδ in long term HFD feeding in obesity and 
liver steatosis.   
 
5.2 Results 
 9-13 week old C57BL/6 mice (6 per group -3 males, 3 females) were 
placed on high fat diet (60% energy from fat) or on high fat diet + transgene 
inducer - I3C (0.25%(w/w)). Wild type control mice and two strains of transgenic 
mice were used: transgenic for human PPARδ receptor (hPPARδ) and 
dominant negative PPARδ receptor with blocked activation domain 
(hPPARδ∆2AF). GW501516 was not used in this study. After 18 weeks all mice 
were sacrificed.  During the experiment, hPPARδ mice in the treated group did 
not develop symptoms of psoriasis-like skin disease that was seen in hPPARδ 
animals treated with GW501516. Throughout the experiment, wild-type mice 
and wild type mice fed diet supplemented with I3C had comparable weight gain 
rate with the I3C group in last 3 weeks putting on less weight (Fig 5.1 A). 
Nevertheless at the end of the experiment the difference in weight gain between 
the I3C and non I3C groups in wild type mice was not significant (Fig 5.2). In 
contrast, hPPARδ mice fed HFD with I3C after 4 weeks of study have stopped 
gaining weight reaching the plateau, which lasted almost to the last week of 
experiment (Fig 5.1 B). After 18 weeks on HFD, control group had 4.5 fold 
increase in percentage of weight gain over the normal chow group (P=0.0015) 
(Fig 5.2). The third branch of the experiment, hPPARδ∆2AF mice when fed  
HFD without I3C maintained steady weight gain throughout the time of 
experiment until the last week, but the HFD+I3C group had significantly lower 
weight gain rate starting from the second week of experiment  (Fig 5.1 C). 
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Figure 5.1 Weight gain of non-transgenic mice (A), hPPARδ mice (B) and 
hPPARδΔAF2 mice (C) fed plain HFD (D) or HFD supplemented with I3C serving as a 
transgene inducer (E). n=6 mice/group 
 
At the end of the study, hPPARδ∆2AF animals fed HFD+I3C had significantly 
lower weight gain when compared to their genotypic controls (Fig 5.2), and also 
lower than non-tg animals fed HFD+I3C, but statistically higher than hPPARδ 
mice fed HFD+I3C (Fig 5.1E). 
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Figure 5.2 Weight gain data from last day of experiment of non-transgenic, hPPARδ 
and hPPARδΔAF2 mice fed plain HFD (D) or HFD+I3C. Pictures show the proportion 
of the body size in relevant mice in all three genotypic groups. Mice presented on the 
pictures from left hand side are examples of control animals, right hand side – mice 
from I3C groups. n=6 mice/group. Data are expressed as means  ± SEM. 
 
The weekly food consumption was also measured throughout the duration of 
the experiment. Surprisingly, the food intake could not be treated as an indicator 
or explanation of weight gain, as in the case of non-transgenic and hPPARδ 
mice, animals with the I3C in the diet periodically consumed more than those on 
plain HFD. hPPARδ∆2AF animals dietary groups had no difference in food 
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intake, although like the rest of the animals there was clearly noticeable trend in 
decreasing food consumption over time (Fig 5.3). 
 
 
Figure 5.3. Food consumption in high fat diet experiment among non-transgenic (A), 
hPPARδ (B) and hPPARδ∆2AF mice. n=6 mice/group 
 
 
After dissection of the hPPARδ animals, enlarged, visceral fat pads were 
exposed in animals fed HFD only. In hPPARδ fed HFD supplemented with I3C, 
visceral fat was still visible, although not well-defined as those seen in control 
animals (Fig 5.4). The visceral adiposity of wild type animals and hPPARδ∆2AF 
was comparable to the one found in hPPARδ mice fed plain HFD (data not 
shown). 
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Figure 5.4 Visceral fat pads exposed post-mortem in hPPARδ mice fed plain HFD (left 
hand side picture) and fed HFD I3C (right hand side picture). 
 
Plasma lipids including triglyceride, total cholesterol and HDL did not show any 
noticeable differences between dietary groups or between genotypes (Figure 
5.5), although when corrected for gender, hPPARδ males in HFD+I3C group 
had significantly higher HDL levels than the control group fed plain HFD (data 
not shown).  
After 18 weeks, hepatic triglyceride levels in non-tg animals groups were 
comparable.  In mice conditionally-expressing hPPARδ, hepatic triglyceride in 
HFD+I3C group were lower by 68%, when compared to control group fed plain 
HFD (P=0.001). Animals over-expressing the dominant negative hPPARδ, also 
had a lower amount of liver fat than their controls, but the difference was not 
considered statistically significant (Fig. 5.6A). Interestingly, hepatic cholesterol 
was on equal level in all but one group. hPPARδ mice fed HFD+I3C, had 
elevated levels of intrahepatic cholesterol, but this phenomenon was gender 
specific with only 2 females (per 3 females per 6 animals in the group). 
Therefore statistical test did not considered this finding significant (Fig 5.6B). 
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Figure 5.5 Plasma lipids in mice fed HFD or HFD+I3C. n=6 mice/group. Data are 
expressed as means  ± SEM. 
 
Figure 5.6 Hepatic triglyceride (A) and hepatic total cholesterol (B) in wild type and 
transgenic animals fed HFD or HFD+I3C for 18 weeks. n=6 mice/group. Data are 
expressed as means  ± SEM. 
To test whether the observed important inter-genetic changes in rate of 
weight gain and hepatic lipid accumulation were indeed caused by induction, 
105 
 
and subsequent activity of the transgenes, key metabolically active tissue were 
screened using RT-PCR for expression of the hPPARδ and hPPARδΔAF2. The 
basal levels of the transgenes were very low in every screened organ. White 
adipose tissue (WAT), brown adipose tissue (BAT) and muscle did not show 
signs of any induction of transgenes. In liver, contrary to the three first organs, 
although basal levels of the hPPARδ and hPPARδΔAF2 were low, with 
magnitude comparable to previous 3 organs, in presence of I3C, the transgene 
expression was induced 321 and 434 fold (hPPARδ and hPPARδΔAF2 
respectively), when compared to animals fed plain HFD (Fig 5.7). 
 
 
Figure 5.7 Transgene expression in white adipose tissue (WAT), brown adipose tissue 
(BAT), muscle and liver in transgenic mice fed plain HDF or HFD + 0.25% I3C. n= 6 
mice/group. 
 
Surprisingly, in lean animals over-expressing hPPARδ, hepatic gene expression 
after 18 weeks did not show obvious signs of increased fatty acid oxidation. For 
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example: CPT1 and Acox1 expression in hPPARδ animals was lower in mice 
fed HFD+I3C, than in their control group (Fig 5.8 A and B). Whereas FAS 
mRNA levels had lower values in non-transgenic and hPPARδ mice in groups 
fed HFD+I3C. It could be concluded that I3C has FAS-inhibiting properties, 
however, in hPPARδΔAF2 fed HFD+I3C FAS levels were actually higher than in 
their control groups eating plain HFD (Fig 5.8 C). 
 
 
Figure 5.8 Expression of CPT1 (A), Acox1 (B) and FAS (C) in non-transgenic, hPPARδ 
and  hPPARδΔAF2 mice fed HFD (white bars) or HFD+I3C (black bars) for 18 weeks. 
Two-way ANOVA, significance is indicated as (*p<0.05), n=6 mice/group. Data are 
expressed as means  ± SEM. 
 
Liver PPARδ and PPARγ expression did not reveal any major changes in 
expression across the genotypes or treatment groups (Fig 5.9 B and C). Unlike 
107 
 
these 2 mentioned members of PPAR family, the third, PPARα was significantly 
down-regulated in hPPARδ mice fed HFD+I3C and when compared to control 
and considerably up-regulated in hPPARδΔAF2 animals fed HFD+I3C 
comparing to their plain HFD fed controls (Fig 5.9 A). 
 
Figure 5.9 PPARs expression in liver in non-transgenic, hPPARδ and  hPPARδΔAF2 
mice fed HFD (white bars) or HFD+I3C (black bars) for 18 weeks. Two-way ANOVA, 
significance is indicated as (*p<0.05), n=6 mice/group. Data are expressed as means  
± SEM. 
Genes traditionally accepted as direct or not indirect PPARδ targets like 
HMGCoAs or ADRP in hPPARδ mice showed down-regulation in mice fed 
HFD+I3C rather than increasing their levels (Fig 5.10 A and C). ADRP 
expression reflected the liver triglyceride content rather than being quantitatively 
responsive to hPPARδ over-expression. On the other hand, such genes like 
Apoc3 and PDK4, in previous chapter reported to be responsive to PPARδ 
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activation, in wild type or hPPARδ mice conditionally expressing transgene 
were not responsive to HFD-activated hPPARδ (5.10 B and D). This was in 
contrast to mice with induced hPPARδΔAF2 transgene, which have shown 
several fold increase in mRNA abundance of these two genes over their 
controls fed pure HFD (Fig 5.10). 
 
 
Figure 5.10 Liver PPARδ target genes expression in non-transgenic, hPPARδ and  
hPPARδΔAF2 mice fed HFD (white bars) or HFD+I3C (black bars) for 18 weeks. Two-
way ANOVA, significance is indicated as (*p<0.05), n=6 mice/group. Data are 
expressed as means  ± SEM. 
 
Expression of PPARδ genes such as ANGPTL4, PDK4, UCP1, UCP2 or UCP3 
and Acox1 in white and brown adipose tissue did not show any statistical 
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difference between groups or genotypes with the exception of PDK4 and UCP2 
in WAT where these two genes were several fold up-regulated in control 
hPPARδ group (data not shown). However, hPPARδ mice fed HFD+I3C had 
comparable levels of expression of these genes to the non-transgenic and 
hPPARδΔAF2 groups. 
 
 
5.3 Discussion 
In previous chapter, mice conditionally over-expressing hPPARδ, when fed diet 
supplemented with GW501516 demonstrated rapid weight loss and subsequent 
hepatic steatosis, which was reversed in mice over-expressing dominant 
negative hPPARδ treated with GW501516. In this chapter’s study the 
GW501516 was eliminated from chow in favour of high fat diet (HFD). Lack of 
GW501516 in the diet allowed keeping the experiment going for longer than 2 
weeks, which before, was usually the maximum time of treatment with 
GW501516 before this genotype develops psoriasis-like skin disease [117,119].  
 
Over-expression of the hPPARδ transgene prevents from HFD-induced 
obesity 
Feeding the hPPARδ animals with normal RMI diet supplemented with I3C 
serving as a transgene inducer did not cause weight loss in 2 weeks time (Fig. 
4.1A and Fig. 4.2A). In contrast, mice fed HFD+I3C from the first week of 
experiment started to retard the body growth rate in relation to the mice fed 
plain HFD. Although I3C has been reported to prevent diet-induced obesity 
[152], the effects of this compound on weight gain in this study were small and 
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the effects of modulating hPPARδ activity in these mice was much more 
substantial (Fig 5.1 B). The effect of transgene induction on body weight gain in 
hPPARδ mice did not appear to depend on increased food or energy intake, as 
there were no significant differences observed in food intake among the groups. 
The only explanation of prevention from increasing the body mass in hPPARδ 
animals fed diet +I3C was induction of the transgene and subsequent activation 
of it by dietary fatty acids. Which HFD-derived fatty acids were directly 
responsible for activation of hPPARδ is unknown, however, 13.46% of the total 
ingredients of the HFD were composed of monounsaturated fatty acids, which 
were identified as PPARδ regulators [154]. One of the fatty acids present in 
HFD was linolenic acid. Although it only contributed up to 0.18% of the total 
HFD composition used in this study, it was reported before as an efficient 
activator of the PPARδ, but not PPARα or PPARγ [157]. The more challenging 
dilemma is the fact that hPPARδΔAF2 mice fed HFD+I3C had significantly 
retarded body mass gain, when compared to their genetic counterparts fed plain 
HFD or to the non-transgenic mice fed HFD+I3C. In previous chapter, it was 
shown that hPPARδΔAF2 animals fed normal chow + I3C in 8 weeks had 
noticeable but not statistically relevant lower body mass gain rate when 
compared to non-transgenic mice fed normal chow + I3C. In this experiment 
HFD makes the difference significant. If the PPARδ function when not activated 
is in large part repression, then over-expression of dominant negative hPPARδ, 
possibly relives the repression of certain set of the target genes. It could be 
possible that group of these gene is responsible for observed retarded body 
weight gain in hPPARδΔAF2 with the HFD lipids being not efficient enough to 
bring back the full repression of the  hPPARδΔAF2 as GW501516 is capable of, 
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which was found in previous chapter’s study. Nevertheless, the relieving of 
repression of PPARδ target genes by negative dominance of human version of 
the receptor is not the equivalent to of the over-expression and activation of the 
full-length receptor. The weight gain between hPPARδ and hPPARδΔAF2 fed 
HFD+I3C mice was still significantly different, with the first being almost 
completely zero (Fig 5.1 E). It is interesting that HFD-induced obesity in non-
transgenic animals (Fig 5.1A) was completely abolished in mice over-
expressing hPPARδ. What is even more striking is that effect is mainly due to 
the transgene being expressed in the liver and not in WAT, BAT or muscle.  
Still, hPPARδ transcriptional activity in the liver has important systemic 
implications. The pictures showing post-mortem ventral views of hPPARδ mice 
fed HFD or HFD+I3C clearly indicate that WAT was largely mobilized upon 
hPPARδ hepatic over-expression.  
 
Effect of over-expression of the transgene is not a direct equivalent of 
GW501516 signalling 
Although PPARδ activity was not directly reflected in a modulation of plasma 
lipids, where were no obvious distinctions between treatments groups or 
genotypes, the liver fat was found to be evidently dependent on I3C availability 
interacting with genotype. After 18 weeks of study the low levels of hepatic 
triglyceride were found in parallel to induction of the hPPARδ and to lesser 
extent, to over-expression of hPPARδΔAF2. This finding is consistent with data 
from studying GW501516 effects in non-transgenic animals treated with the 
agonist for 8 weeks described in chapter 3 and 4, where the chronic dietary 
supplementation of GW501516 turned out to be protective against diet-induced 
hepatic liver accumulation. It is also in accordance with studies performed by 
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Lee et al where authors did not observe signs of fatty liver with GW501516 
treatment up to 6 months in wild-type C57BL/6 mice, but they found short term 
hepatic fat accumulation [124]. The non-transgenic control mice also clearly 
show that the protection against HFD-induced liver steatosis in not due to I3C 
activity (Fig 5.6 A). Unlike the triglyceride, the liver cholesterol presence seems 
to be promoted by hPPARδ over-expression. However, this effect is entirely 
gender specific with females the main contributors to the hepatic cholesterol 
accumulation effect. In studies performed by Meng et al and Auborn et al 
authors found that indole 3 carbinol used in our study as a transgene inducer is 
a negative regulator of oestrogen [158,159]. And Gao et al have shown that 
genetic ablation of oestrogen slulfotransferase, responsible for inactivation of 
estrogens, decreases several fold liver total cholesterol in female ob/ob mice 
[160]. Therefore the female-specific increase in hepatic cholesterol could be 
due to impaired oestrogen signalling linked with hPPARδ over-expression. 
 Taking into account that hPPARδ over-expression had such a profound 
effect on prevention of diet-induced obesity, it is rather surprising that this 
metabolic state was not reflected noticeably in hepatic gene expression. In fact, 
CPT1 and Acox 1 markers of fatty acid oxidation indicated a lower level of fat 
oxidation when compared with plain HFD controls. It is possible that these 2 
markers were reflecting simply the availability of substrate for fatty acid 
oxidation. That seems to be confirmed by PPARα mRNA transcripts which were 
found to be less abundant in mice over-expressing hPPARδ. On the other hand 
mice conditionally expressing hPPARδΔAF2 had elevated levels of PPARα 
mRNA, which is consistent with the hepatic PPARα mRNA expression data in 
hPPARδΔAF2 fed normal diet + I3C, shown in previous chapter. Traditionally 
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accepted PPARδ target genes like ADRP, HMGCoAs or PDK4, also shown 
down-regulation or turned out to be non-reactive to hPPARδ over-expression in 
presence of HFD. This might indicate a limited availability of substrate for β-
oxidation as already mentioned. 
 In summary HFD feeding promotes diet-induced obesity and hepatic lipid 
accumulation in C57BL/6 wild type mice. These effects however were tempered 
efficiently by long term over-expression of hPPARδ in the liver. In the two 
previous chapters, we presented evidence for PPARδ-promoted hepatic 
accumulation in wild-type and transgenic mice. The mechanism of clearance of 
liver fat in long-term period in study involving wild-type animals and possibly in 
animals used in this chapter's experiments needs further investigation. The next 
chapter aims to address this. 
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Chapter 6 Effect of genetic ablation of PPARα or PPARδ on PPARδ-
driven hepatic lipid accumulation. Study of PPARα-KO and 
PPARδ-KO mice. 
 
6.1 Introduction  
As shown in previous chapters, PPARδ pharmacological activation using 
the potent synthetic ligand GW501516 promotes liver lipid accumulation 
accompanied by weight loss. This effect is markedly enhanced by conditional 
over-expression of human PPARδ. However, regardless of stable GW501516 
blood levels or hPPARδ over-expression and despite still available peripheral 
fat deposits hepatic triglyceride disappear in long-term treatment. It might 
suggest steady build up or activation of a hepatic fat-burning factor. One of the 
main transcription factors governing fat oxidation is PPARα, abundantly 
expressed in liver. Recent evidence [17] shows identification of an endogenous  
PPARα ligand, which production as the authors suggest, is dependent on fatty 
acid synthase activity. Generation of this ligand was suggested by Barroso et al 
as an explanation of the beneficial effect of GW501516 in lowering plasma 
triglyceride in HFD-fed mice [161]. On the other hand, Terada et al shows some 
evidence that GW501516 can be efficient PPARα activator. The authors of this 
study speculated on whether the GW501516 is a direct activator of PPARα or 
that it may activate PPARα through an indirect mechanism such as by the 
production of an endogenous ligand of PPARα [162].   
 While our results using the PPARδ transgenic animals confirm a role for 
PPARδ in the action of GW501516 these experiments do not address the 
possibility of an additional contribution of PPARα to the process. In order to 
assess the requirements for PPARα and PPARδ in the action of GW501516 we 
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used of PPARα knockout (PPARα-KO) and PPARδ knockout mice (PPARδ-
KO). PPARα-KO mice were shown to be resistant to fibrate-promoted 
hepatomegaly, observed in wild type-animals treated with these compounds 
[95]. However, they are susceptible to fasting-induced fatty liver, showing the 
important role of PPARα in liver fat oxidation and processing [25,163].  
By treating PPARα-KO mice with GW501516 we investigated if PPARα 
activation and signalling is directly involved in long-term clearance of PPARδ-
promoted liver triglyceride accumulation. Additionally, by studying the PPARδ-
KO animals fed GW501516, we tested the hypothesis if weight loss and liver 
steatosis shown in the experiments presented in previous chapters, can be 
solely attributed to PPARα’s cross-reaction with GW501516. 
 
 
6.2 Results  
To first present how PPARα is important in the liver rodent as a major 
driving force of β-oxidation, here we show the influence of fasting on hepatic 
lipid response and to lesser extent on plasma lipid profile in wild type and 
PPARα-KO mice. Thirty 10-15 week old male non-transgenic and PPARα-KO 
mice (3 per group) were fasted for 0, 6, 16 and 24 hours. Interestingly, after 6 
hours of fasting the initial rise in hepatic triglyceride was noticeable in non-
transgenic, but not in PPARα-KO animals. However, after 16 and 24 hours of 
food deprivation the hepatic triglyceride levels in PPARα-KO exceeded those 
found in the wild type mice by 2.5 and 6.3 fold respectively and this effect was 
considered as very significant (Fig 6.1).  
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Figure 6.1 Fasting induced hepatic lipid accumulation in non-transgenic and PPARα-
KO animals. Two-way ANOVA, significance is indicated as: ** p<0.01; *** p<0.001, n=3 
mice/group. Data are expressed as means  ± SEM. 
 
The lipid response in the liver was partly reflected in plasma triglyceride 
profile, where in PPARα-KO mice blood triglyceride were only significantly 
elevated after 16 hours of fasting (Fig 6.2 A). On the other hand, a very similar 
profile of lipid fluctuation was revealed after measurements of free fatty acids 
(FFA) in plasma, where FFA levels mostly overlapped with hepatic triglyceride. 
It suggests indirectly, that the source of hepatic fat was blood borne (Fig 6.2 B) 
as main lipid export from the liver is in lipoprotein conjugated form and not as 
FFA.  
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Figure 6.2 Plasma triglyceride (A) and FFA (B) in fasted non-transgenic (white bars) 
and PPARα-KO mice (black bars). Two-way ANOVA, significance is indicated as: * 
p<0.05 ** p<0.01; *** p<0.001, n=4 mice/group. Data are expressed as means  ± SEM. 
 
After confirming how PPARα is important for processing hepatic lipids 
during short time food deprivation, we proceeded to examining long-term effect 
of hepatic lipid reaction to chronic pharmaceutical activation of PPARδ receptor 
in PPARα-KO animals. 
24 10-week old PPARα-KO mice ((B6.129S4-Pparatm1Gonz/J), 2 females, 2 
males per group) were placed on control or a diet containing GW501516 
(0.0025% w/w). After two weeks, 4 mice (4 from each group) were sacrificed. 
Then after 1 month from beginning of the experiment a further 8 mice were 
taken with the remaining mice being sacrificed after 2 months. Before the 
sacrifice mice were not fasted to avoid interference from the phenotype 
described above. 
Unexpectedly, in the first weeks of feeding mice with the diet 
supplemented with GW501516, PPARα-KO animals did not show any sign of 
weight loss (Fig 6.3A) or reduced adiposity when sacrificed after 2 weeks (data 
not shown), when compared to their controls fed plain chow. What is more, 
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animals fed a diet enriched with GW501516 after two weeks put a more on 
weight than their controls and this effect was significant (2.1 fold, P=0.02) (Fig 
6.3 A and B). 
 
Figure 6.3 Weight gain (A and B) and food intake (C) in PPARα-KO mice fed PPARδ 
selective agonist GW501516. T-test and two-way ANOVA, significance is indicated as: 
* p<0.05, n=4 mice/group. Data are expressed as means  ± SEM. 
 
As might be expected, there was also no difference in food intake 
between both treatment groups (Fig 6.3 C). The beneficial effect of lowering 
plasma triglyceride upon GW501516 treatment also disappeared in PPARα-KO 
mice (Figure 6.3 A), although the correction must be made for measuring non-
fasted animals. Plasma total cholesterol had a trend to be noticeably higher in 
GW501516 treated animals but the overall effect was not significant (Fig 6.3 B). 
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Despite the lack of functional PPARα, the rise in plasma HDL levels upon 
GW501516 treatment was still detectable. At 4 and 8 weeks time points HDL 
levels were higher in treated groups, when compared to controls, however, with 
only 4 weeks time measurement difference being statistically significant 
(P<0.05) (Figure 6.3 C). 
 
 
Fig 6.3 Plasma lipids in PPARα-KO mice fed normal or diet supplemented in 
GW501516. White bars – mice fed normal chow, black bars - animals fed diet enriched 
in GW501516. Two-way ANOVA, significance is indicated as: * p<0.05, n=4 
mice/group. Data are expressed as means  ± SEM. 
 
As expected with the lack of weight loss in GW501506-treated mice, the 
levels of plasma insulin and leptin were not modulated by GW501516 in 
PPARα-KO animals (Fig 6.4), which shows indirect influence of PPARδ ligand 
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on especially leptin levels as it was seen in wild type animals and animals over-
expressing hPPARδ. 
 
Figure 6.4 Leptin (A) and insulin (B) levels in mice fed normal chow (white bars) or fed 
diet supplemented with GW501516 (black bars), n=4 mice/group. Data are expressed 
as means  ± SEM. 
 
Measurements of liver triglyceride have revealed no difference in hepatic 
fat, including total cholesterol between the treatment groups (Fig 6.5). This is in 
total contrast to the observations found in wild type or in animals transgenic for 
hPPARδ in previous chapters, where GW501516 had profound role in 
promoting liver steatosis in these animals. 
 
Figure 6.5 Hepatic triglyceride (A) and hepatic cholesterol (B) levels are not affected by 
GW501516 treatment in PPARα-KO mice. White bars – mice fed normal chow, black 
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bars - animals fed diet enriched in GW501516, n=4 mice/group. Data are expressed as 
means  ± SEM. 
Although a fatty liver phenotype and PPARδ-dependent weight loss were 
completely abolished in PPARα-KO mice fed PPARδ agonist, gene expression 
in that group showed that many direct PPARδ target genes were not only still 
up-regulated, but their expression levels were markedly more pronounced.  
For example, liver ADRP mRNA levels were significantly higher at every time 
point (3 - 5.5 fold) (P<0.001) (Figure 6.6 A). Consistent with lack of liver 
steatosis in GW501516 treated animals, no correlation was found between 
ADRP and hepatic triglyceride (data not shown). The angiopoietin-related 
protein 4 (ANGPTL4) is involved in lipid metabolism and is the target of PPARδ. 
Hepatic ANGPTL4 mRNA levels were also elevated in treatment group 23.5, 
2.5 and 6.7 fold (at 2, 4 and 8 weeks respectively) (Figure 6.6 C). Also 
HMGCoAs and UCP2 have shown evident expression upon GW501516 
treatment (Figure 6.6 B and D).  
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Figure 6.6 Gene expression pattern of PPARδ target genes in livers of PPARα-KO 
mice fed normal chow (white bars) or diet supplemented in GW501516 (black bars). 
Two-way ANOVA, significance is indicated as: * p<0.05; ** p<0.01; *** p<0.001, n=4 
mice/group. Data are expressed as means  ± SEM. 
  
In addition, muscle mRNA levels of pyruvate dehydrogenase kinase isozyme 4 
(PDK4) (inhibition of carbohydrate metabolism), ANGPTL4 (lipid metabolism), 
UCP2 and UCP3 (proteins uncoupling) were profoundly increased in mice fed 
diet enriched in GW501516. All of them are PPARδ target genes (Fig 6.7 A-D). 
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Figure 6.7 Expression of PPARδ target genes in muscle of PAPRα-KO mice fed normal 
chow (white bars) or diet supplemented in GW501516 (black bars). Two-way ANOVA, 
significance is indicated as: * p<0.05; ** p<0.01; *** p<0.001, n=4 mice/group. Data are 
expressed as means  ± SEM. 
 
In previous chapters, genes such as CPT1, Acox1 Apco3 were found to 
be significantly dependent on GW501516 treatment. In PPARα-KO animals 
however, excluding the case of Acox1, which have revealed some trend rising 
trend in presence of PPARδ agonist, the overall hepatic expression of these 
genes were not significantly dependent on GW501516 availability (Fig 6.8). 
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Figure 6.8 CPT1 (A), Apoc3 (B) and Acox1 (C) expression in livers of PPARα-KO mice 
fed normal chow (white bars) or diet supplemented in GW501516 (black bars), n=4 
mice/group. Data are expressed as means  ± SEM. 
 
FAS mRNA levels, in general, turned out to be non-reactive to PPARδ 
agonist in PPARα-KO mice. Only muscle after 4 weeks treatment have shown 
noticeable increase in mRNA abundance in GW501516 treated animals (Fig. 
6.9). 
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Figure 6.9 Fatty acid synthase levels in liver (A), muscle (B) and white adipose tissue 
(C) of PPARα-KO mice fed normal chow (white bars) or diet supplemented in 
GW501516 (black bars). Two-way ANOVA, significance is indicated as: * p<0.05, n=4 
mice/group. Data are expressed as means  ± SEM. 
 
Although in the PPARα-deficient mice we used in this study the PPARα 
mRNA is still expressed, the transcript is aberrant and no functional protein is 
made [77]. Therefore only PPARδ and PPARγ mRNAs expression levels were 
screened.  Interestingly, PPARα ablation caused observable trend in decrease 
of PPARδ mRNA levels in WAT and muscle in mice fed diet supplemented with 
GW501516, although only some time points have reached statistical 
significance. PPARγ expression showed no signs of variability between 
treatments groups in liver and muscle, but in muscle the tendency to drop of 
mRNA level of this PPAR family member in WAT was noticeable (Fig 6.10). 
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Figure 6.10 PPARδ and PPARγ expression in liver, muscle and WAT of PPARα-KO 
mice fed normal chow (white bars) or diet supplemented in GW501516 (black bars). 
Two-way ANOVA, significance is indicated as: ** p<0.01; *** p<0.001, n=4 mice/group. 
Data are expressed as means  ± SEM. 
 
A similar experiment was conducted using PPARδ knockout animals. For 
two weeks time C57/BL6 PPARδ-KO male and female mice (5 mice per group) 
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were fed normal chow or diet enriched in 0.0025% GW501516 (w/w). In this 
time, PPARδ agonist treatment did not cause weight loss when compared to 
control group (Fig 6.11 A), neither changed food intake, which was typical to the 
previous experiments conducted in wild-type animals or conditionally- 
expressing hPPARδ (Figure 6.11 B).  
 
 
Figure 6.11 Weight gain of PPARδ-KO mice fed normal chow and diet supplemented 
with GW501516 in 2 weeks. n=5 mice/group 
 
No differences were found in hepatic lipid content between both groups 
(P=0.203) and in hepatic cholesterol (Figure 6.12A). PPARδ-KO mice turned 
out to be non-responsive to GW501516, therefore the experiment was 
discontinued. 
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Figure 6.12 Hepatic steatosis was not present in PPARδ-KO mice fed GW501516 in 
two weeks although total liver cholesterol difference between treatment groups reached 
significance, n=5 mice/group. Data are expressed as means  ± SEM. 
 
 With the available liver lipids specimens from PPARδ-KO mice and the 
proposed explanation of PPARα involvement of long-term clearance of hepatic 
fat, the hypothesis that PPARδ activation leads to steady build-up of 
endogenous PPARα ligand now could be tested. Hepatic lipids from PPARδ-KO 
mice were compared with lipids extracted from wild-type animals fed 
GW501516 from the experiment described in chapter 5.  The proposed PPARα 
endogenous activator: 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
(POPC) [17] was detected in whole hepatocyte lipid extracts using LC-MS 
analysis. Basal hepatic levels of POPC from 2 weeks time point in PPARδ-KO 
were significantly higher than in non-transgenic mice (Fig 6.13). The time was 
also a key factor in increasing levels of POPC in livers of animals fed diet 
enriched in GW501516 throughout the length of the study, where the difference 
within the treatment groups between 2 versus and 4 and 8 weeks was 3 fold in 
favour of the latter ones (P=0.0065 and P<0.001 respectively). This data shows 
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that disappearance of hepatic lipids seen in GW501516 treated groups between 
4 and 8 weeks in non-transgenic animals (Figure 3.5) co-exists with 
accumulation of POPC over the same time period, supporting the hypothesis 
that this is a bona fide endogenous PPARα ligand that may provide the 
downstream activation of PPARα in response to activation of PPARδ. 
 
 
Figure 6.13 Endogenous PPARα ligand abundance in livers of PPARδ-KO mice and 
non-transgenic mice fed normal chow or diet supplemented with GW501516. T-test 
and two-way ANOVA, significance is indicated as: ** p<0.01, ***p<0.001, n=4 
mice/group. Data are expressed as means  ± SEM. 
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6.3 Discussion  
This chapter’s main objectives were to investigate impact of null 
mutations on both PPARα and PPARδ on the physiological actions of 
GW501516.  In previous chapters we had demonstrated that modulation of 
PPARδ activity profoundly affected response to GW501516, however other 
studies have suggested a role for PPARα in the response to this drug, and our 
results had suggested a potential temporal interplay between these two 
receptors in hepatic lipid regulation.  
 
PPARα is involved in modulation of body mass in mice 
 The main surprising finding was that PPARα-KO animals did not lose 
weight in response to GW501516, demonstrating an absolute requirement for 
this receptor in the weight loss response to this drug.  
We confirmed the profound role for PPARα in the mobilization of adipose tissue 
deposits upon fasting. The knockout mice displayed an exaggerated fasting 
response after 16 hours with increases in plasma levels of FFA and liver 
triglyceride, as has been previously published.  However, elevated plasma free 
fatty acids and hepatic lipid accumulation was evident in wild-type animals after 
only 6 hours of fasting, but not in PPARα-KO animals. The mobilization of 
peripheral fat deposits was evidently delayed in KO animals.  This is a novel 
and surprising observation.  It suggests a role for PPARα  not only in governing 
the genes involved in oxidation of fatty acids but also in controlling the rate of 
release of fatty acids from adipose cell. Hormone sensitive lipase (HSL) one of 
the “gatekeepers” of lipolysis is activated predominantly by phosphorylation, 
triggered by low insulin levels or catecholamines and is active in low blood 
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glucose state, which is typical to fasting. It is a rate-limiting enzyme for adipose 
triglyceride lipolysis [15]. The observed delayed release of FFA in PPARα-KO 
mice might be due to possible PPARα participation in controlling this process. 
One of the first indications that PPARα activity might include involvement in 
adipose tissue lipid stores mobilization was work done by Perreault et al. In his 
study he showed that in the absence of PPARα, the PPAR pan agonist 
(compound 4) was not able to induce drug-promoted weight reduction [144]. 
However, the author’s conclusion was that compound 4 treatment weight 
reduction capabilities come mainly from the fact of suppressed appetite, which 
is provoked by intermediates generated during oxidation of fatty acids, which 
then regulate food intake in treated mice, and not by stimulating lipolysis. 
Indeed, the PPAR agonist has the potential to reduce the appetite,  as it was 
shown in experiment in wild-type animals fed GW501516 described in chapter 
3, however, mice conditionally over-expressing hPPARδ and fed diet enriched 
in GW501516 did not show diminished appetite, but in the same time lost 
significant proportion of total body weight (chapter 4).  
 
PPARα and PPARδ co-ordinately modulate body weight gain 
The role of PPARα in mobilizing adipocyte fat stores is becoming more 
evident when analyzing action of PPARδ selective ligand in PPARα-KO mice. 
These mice fed GW501516 did not exhibit any weight loss in spite of massive 
up-regulation of the PPARδ target genes involved in lipid oxidation like UCP2 
and UCP3, genes involved in generation of ketone bodies like HMGCoAs or 
inhibitors of carbohydrate metabolism like PDK4. The fact that GW501516 was 
inefficient in causing weighs loss in PPAR-KO mice was not due to absence of 
132 
 
up-regulation of the genes involved of whole process of lipid utilization. It was 
rather the result of failure of the PPARα-KO mice to mobilize its peripheral white 
adipose tissue stores in presence of PPARδ ligand.  Similar dependence of 
PPARδ activity on PPARα presence and signalling was revealed in study done 
by Faiola et al. In their work, authors have found that increases in liver weights 
and clinical chemistry indicators of skeletal muscle damage and/or liver injury 
were more pronounced in wild-type mice compared with PPARα-KO mice 
administered toxicological doses of selective PPARδ agonist GW0742 [164]. 
However, they concluded that absence of PPARα eliminates the cross-
activation of this receptor with PPARδ ligand. Similar hypothesis was 
constructed by Terada et al, where he found that the effect of GW501516 on 
several PPAR target genes in primary hepatocytes and the in vivo liver studies 
depends on the expression of PPARα. The conclusions was that that activation 
of PPARα by GW501516 can be explained by two mechanisms: either by direct 
activation by binding of GW501516 to PPARα or by indirect activation through 
direct binding and activation of PPARδ [162]. Our experiment with PPARδ-KO 
mice shows that theoretical cross-activation of GW501516 with PPARα is not 
sufficient to induce body mass reduction through peripheral fat mobilization. 
This is the condition as we assumed based on experiments shown in previous 
chapters, for the major cause of observed liver fat accumulation observed in 
non-transgenic and especially in mice over-expressing hPPARδ. In Terada et al 
study the authors however, do not show phenotypic observation of GW501516 
action in PPARα-KO mice, focusing rather solely on transcriptional regulation 
patterns. Nevertheless, there are some important differences in their finding and 
our observations. For example we have shown that PDK4 is still up-regulated in 
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muscle of PPARα-KO mice in the presence of GW501516 (Fig 6.7 A) and PDK4 
expression in liver shows trend for up-regulation after treatment with 
GW501516, although it was not statistically significant (data not shown). 
However, in Terada et al work, authors present data showing down-regulation 
of this gene in livers of PPARα-KO mice fed diet enriched in GW501516.  
 
PPARδ activation leads to generation of PPARα endogenous ligand 
Consistent conclusion from studies performed by Terada et al and 
Barroso et al and also from our work was that PPARδ pharmacological 
activation might lead to generation of endogenous PPARα ligand. So far only 
Barroso et al have presented some evidence supporting this hypothesis, where 
they have shown that mice fed high fat diet and treated with GW501516 had 
elevated hepatic levels of 16:0/18:1- phosphocholine, previously identified as 
endogenous PPARα ligand [17], when compared to mice fed normal chow or 
plain HFD [161]. Here we present that generation of this ligand is dependent on 
presence of functional PPARδ or related to GW501516 treatment and time 
dependent (Fig 6.13). The elevated levels of this phosphocholine molecule in 
PPARδ-KO mice are consistent with the hypothesis that physiologically un-
liganded PPARδ works as a repressor and with ligand binding or genetic 
ablation of the receptor the repression is relieved and sets of target genes is up-
regulated or down-regulated [148,153]. It is possible that among these genes, 
are the one involved in process of generation of 16:0/18:1- phosphocholine 
specimens. The original work of Chakravarthy et al associating this particular 
phosphocholine specimen with endogenous PPARα ligand suggests strong 
involvement of fatty acid synthase in production of this molecule. Unlike their 
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findings, our work only shows evidence for up-regulation of FAS in the livers of 
wild-type animals at the latest stage of experiment (Fig 3.9). Our data would 
suggest that PPARδ modulates the production of POPC via an alternative 
pathway other than through FAS activity, although the nature of this remains 
unknown. 
 
PPARδ activity promotes white adipose tissue lipolysis  
The steady build up of PPARα ligand through chronic PPARδ activation 
does not however explain the inability of PPARα-KO animals to mobilize their 
white fat peripheral deposits in the presence of GW501516, so well documented 
in non-transgenic and mice over-expressing hPPARδ in previous chapters. 
Moreover, the exact mechanism how pharmacological PPARδ activation leads 
to adipose tissue lipolysis is still not well deciphered. Some evidence was 
provided by Staiger et al, where in their work they have shown that plasma 
ANGPTL4 positively correlated with fasting free fatty acids and adipose tissue 
lipolysis [165]. ANGPTL4 is well known PPARδ target gene and other studies 
like one performed by Gray et al report it as a crucial element of lipolysis 
induction [166]. The authors of the latter study place ANGPTL4 function as 
crucial for fasting, glucocorticoids, and catecholamines stimulated triacylglycerol 
hydrolysis in murine fat. Fasting lowers the insulin levels, which is known HSL 
repressor [15] and together with glucocorticoids, and catecholamines leads it to 
activation of HSL. Still, these conditions are not met in pharmacological 
induction of adipocyte lipolysis and subsequent weight reduction observed in 
wild-type mice treated with GW501516 or hPPARδ over-expressors. These 
mice were not exercised or semi-starved and after sacrifice the insulin levels 
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were not different between treatment groups. Additionally, in the study 
performed by Narkar et al there was no increase in HSL transcripts in the 
quadriceps of GW501516 treated mice, although they have shown that co-
treatment with AICAR,  the AMP-activated protein kinase (AMPK) agonist, does 
induce HSL transcription in muscle [121]. The potential explanation how the fat 
is mobilised by PPARδ activity without or with minimal induction of HSL, could 
lie in activation of another lipase present in WAT – adipose triglyceride lipase 
(ATGL) [167]. ATGL is now considered to be the major triglyceride lipase in 
adipose tissue, hydrolyzing triacylglycerol to diacylglycerol and a FFA [168]. 
The increase of transcripts of ATGL, were found in Staiger et al study, where 
C2C12 myocytes were treated with GW501516. They have also shown the 
mRNA of ATGL was co-expressed with ANGPTL4 transcripts in the same cell 
line. Additionally, recent report from Fuchs et al shows that ATGL knockout 
mice have lower levels of hepatic endoplasmic reticulum stress compared to 
wild-type mice, which is typical in non-alcoholic fatty liver disease [169]. Also 
the work done by Mandard et al shows that over-expression of ANGPTL4 in 
peripheral tissues increases significantly levels of ATGL, but not HSL, in 
adipocytes [170]. Taken together, the importance of secretory protein ANGPTL4 
and ATGL activation might indicate the right direction how pharmacological and 
in particular hepatic PPARδ activation promotes WAT lipolysis. However, this 
effect is completely abolished in PPARα-KO mice despite massive up-regulation 
of ANGPTL4 mRNA in muscle and liver upon GW501516 treatment (Fig 6.6C 
and 6.7B respectively). Evidently, PPARα presence is essential for induction of 
triglyceride hydrolysis by PPARδ pathway. Most likely through preventing ATGL 
induction and/or activation, but not through HSL, which is still active in PPARα-
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KO animals because it was shown they are still prone to fasting-induced fatty 
liver. The delayed appearance of elevated plasma FFA in fasted PPARα-KO 
mice seems to support this hypothesis as the ATGL is the lipase, which first 
hydrolyses  triacylglycerol to diacylglycerol and FFA [171]. Summarizing, 
genetic PPARα knockout deprives the mouse body an important factor, which 
enables PPARδ agonist-dependent weight loss and subsequent liver lipid 
accumulation. Equally probable is also that ablation of PPARα frees the 
potential repressor-like factor, which interferes with PPARδ-related WAT 
lipolysis, in normal condition repressed by PPARα presence. Such pattern of 
regulation was presented by Adhikary et al, where they have shown that 
inhibition of PPARδ transcripts using siRNA, de-represses defined set of genes. 
Therefore, necessity arises to explore and expose the complex 
transcriptional relationship between PPARδ and PPARα in relation to regulation 
of body weight and hepatic lipid accumulation by these receptors. In the next 
chapter we have assessed genome-wide transcriptional profiles of GW501516 
effects in the livers of various mouse genetic models, in order to provide some 
overview of these complex interactions. 
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Chapter 7 Genome-wide transcriptional profiling of PPARα and 
PPARδ cooperation in regulation of gene expression. 
 
7.1 Introduction 
The evidence from previous chapters shows that signalling from both 
PPARα and PPARδ is crucial for GW501516-induced physiological effects such 
as white adipose tissue lipolysis and subsequently weight loss and hepatic 
triglyceride accumulation. There are other recent reports on close cooperation 
between orphan receptors. For example, nuclear receptors Rev-erbα and Rev-
erbβ regulate circadian rhythm and metabolism. Depletion of both Rev-erbα and 
Rev-erbβ causes marked hepatic steatosis, in contrast to relatively subtle 
changes upon loss of either subtype alone [172]. As previously discussed 
Adhikary et al proposed several modes of transcriptional regulation by PPARδ. 
One is the classical ligand-dependent relief of repression of target genes. Two 
additional patterns of transcriptional regulation described in that work revealed 
that PPARδ presence is required for stable expression of a defined set of genes 
and second is that siRNA-mediated depletion of PPARδ up-regulates groups of 
genes, which are normally ligand non-responsive [153]. If we add another factor 
to the equation like presence or absence of PPARα, the situation can 
complicate even further as the results from previous chapter suggest. 
Furthermore, in our published work we have shown that expression of both 
hPPARδ and hPPARδΔAF2 abolish bezafibrate-induced hepatomegaly and 
PPARα target genes expression in liver [140]. With the availability of the 
multiple genetic mice models (wild type, hPPARδ, hPPARδΔAF2, PPARα-KO 
and PPARδ-KO) it was be possible to show how the genetic ablation of the two 
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of the PPAR subtypes or over-expression of human PPARδ or dominant 
negative affect the transcriptional response of PPAR target genes in a genome 
wide manner. 
 
7.2 Results 
9-11-week old male and female C57BL/6 background mice (5 animals/group) 
were placed on different diets. The groups are presented in table 7.1.  
 
Table 7.1 Genetic and treatment groups for microarray experiment. 
 Genotype 
Diets 
groups 
non-
transgenic 
non-
transgenic 
hPPARδ hPPARδΔAF2 
PPARα-
KO 
PPARδ-
KO 
Control RMI 
RMI + 0.25% 
I3C 
RMI + 
0.25% I3C 
RMI + 0.25% 
I3C 
RMI RMI 
Treatmen
t 
RMI + 
0.0025 
GW501516 
RMI + 0.25% 
I3C + 0.0025 
GW501516 
RMI + 
0.25% I3C 
+ 0.0025 
GW50151
6 
RMI + 0.25% 
I3C + 0.0025 
GW501516 
RMI + 
0.0025 
GW50151
6 
RMI + 
0.0025 
GW5015
16 
 
After 5 days of treatment, mice were sacrificed, livers harvested and 
gene expression from this organ analyzed utilizing microarrays. Out of 30854 
genes (consisting of 45281 probes) available on the microarray chips, 9548 
reached intensities higher from background with a mean P value over the 60 
samples of <0.1.  This broad selection was required to not exclude genes that 
were non-expressed in specific samples eg. the knockouts, or where expression 
was only significantly detectable in the induced samples.  
Several distinct patterns of transcriptional cooperation between PPARα 
and PPARδ were found when analyzing microarray data. The first pattern of 
transcriptional regulation was revealed where hPPARδ or PPARα-KO 
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genotypes mediate marked change of expression of 119 genes out of 9548 
upon GW501516 treatment (P value <0.01, FDR <0.05), from which 61 were 
significantly up-regulated and 58 down-regulated. In this group, the change of 
proportion in the abundance of these two PPARs was in favour of PPARδ, 
through over-expression of hPPARδ or genetic KO of PPARα relieves or 
strengthens the transcriptional repression, Therefore for these genes PPARα is 
working as a gatekeeper of PPARδ target genes. Typical examples of these 
genes and one of the top hits are: cyclin-dependent kinase inhibitor 1A 
(Cdkn1a) regulating cyclin-dependent protein kinase involved in cell cycle 
regulation (Fig 7.1 A), G0/G1 switch gene 2 (G0s2), which plays role in positive 
regulation of apoptotic process (Fig7.1 B) or regulator of G-protein signalling 16 
(Rgs16) (Fig 7.1 C). 
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Figure 7.1 Three selected genes presenting how hepatic change of proportion in 
PPARs in favour of PPARδ, influences the expression of the target genes upon 
GW501516 treatment. n=5 mice/group. Data are expressed as means  ± SEM. 
 
 A second mode of regulation was found when sets of genes were 
identified where their expression was significantly dependent on GW501516 
treatment but not influenced by PPARα ablation. From 25 genes altogether 
only, 18 were up-regulated and 6 down-regulated by GW501516 treatment, 
including PPARα-KO genotype mice (P value <0.01, FDR <0.05). The genes 
which were up-regulated were usually more pronounced in hPPARδ mice, but 
normally also reactive to GW501516 in wild-type mice. In this group, knocking 
out PPARδ and prevented GW501516 from invoking transcriptional response. 3 
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examples of up-regulated genes include: carnitine acetyltransferase (Crat), a 
mitochondrial protein involved in fatty acid beta-oxidation (Fig 7.2 A), 
Angiopoietin-related protein 4 (Angptl4), secretory protein, well known PPARδ 
target gene, which plays essential role in triglyceride homeostasis (Fig. 7.2 B) 
and ST3 beta-galactoside alpha-2,3-sialyltransferase 5 (St3gal5) engaged in 
carbohydrate metabolic process (Fig. 7.2 C). This group could be described as 
PPARδ dependent, but PPARα independent genes.  
 
 
Figure 7.2 Examples of the genes reactive to GW501516 treatment, but not affected by 
PPARα knock out. The hPPARδΔAF2 generally blocked the GW501516 response in 
this class of genes. n=5 mice/group. Data are expressed as means  ± SEM 
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The third pattern of transcriptional regulation emerged when ablation of 
PPARα caused down-regulation of the basal levels of genes, which are reactive 
to the PPARδ agonist. In this case, removal of PPARα from the “system”, works 
stronger than simple antagonism, where typical antagonist generally only 
prevents the activation of the transcription factor preventing the up or down 
regulation of the target genes, leaving the basal levels of given transcriptome 
unchanged. Here, PPARα genetic ablation, causes even reduction of the basal 
levels of the target mRNA. 530 genes were identified (P value <0.01, FDR 
<0.05), which have reached more than 0.75 fold reduction in the basal level 
expression in PPARα-KO mice, when compared to wild-type or humanized 
mice. One of the top 3 genes with greatest reduction of its mRNA levels when 
PPARα was knocked out were: galactose-3-O-sulfotransferase 1 (Gal3st1), 
involved in glycolipid biosynthetic processes (Fig. 7.3 A), serine incorporator 2 
(Serinc2), a L-serine transmembrane transporter (Fig. 7.3 B) and AMP-activated 
protein kinase, gamma 2 (Prkag2), which plays role in regulation of fatty acid 
metabolic processes (Fig. 7.3 C). 
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Fig 7.3. PPARα genetic knock out down-regulates the basal levels of the defined sets 
of genes. n=5 mice/group. Data are expressed as means  ± SEM 
The fourth pattern found is paralleled with the previous one, but in this 
case the PPARδ knockout affects the basal levels of defined sets of genes. 
1564 genes were found to be significantly affected by down-regulation caused 
by genetic removal of PPARδ (P value <0.01, FDR <0.05, more than 0.75 fold 
reduction in the basal level expression). Typical examples include: zinc finger 
and BTB domain containing 7a (Zbtb7a), which plays role in regulation of 
transcription (Fig. 7.4 A), essential meiotic endonuclease 1 homolog 2 (Eme2) 
with its role in DNA recombination and repair (Fig. 7.4 B) and T-cell lymphoma 
invasion and metastasis 2 (Tiam2) involved in apoptotic processes (Fig. 7.4 C). 
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Figure 7.4 PPARδ genetic knock out down-regulates the basal levels of the defined 
sets of genes. n=5 mice/group. Data are expressed as means  ± SEM 
 
In summary in this group, PPARδ functional protein is working as 
constitutive transcription factor for a relatively large group of genes, but 
interestingly, these genes are not generally reactive to GW501516.  
Another pattern, the fifth, was revealed when analysis have shown that 
both PPARα and PPARδ are essential for defined set of genes expression. 853 
were identified (P value <0.01, FDR <0.05, more than 0.75 fold reduction in the 
basal level expression). Most of these genes were not reactive to GW501516 
treatment, but their levels were highly dependent on simultaneous presence of 
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both receptors. Typical examples of this transcriptional collaboration include: 
glutathione S-transferase, alpha 2 (Gsta2) encoding xenobiotic metabolizing 
protein (Fig. 7.5 A), phosphatidic acid phosphatase type 2C (Ppap2c), which its 
product is involved in sphingolipid biosynthesis (Fig. 7.5 B) and heat shock 
protein 8 (Hspb8), induced as a response to stress (Fig. 7.5 C). These genes, 
although in the examples shown not reactive to GW501516 require functional 
proteins of both receptors for stable, basal levels of their transcription. 
Interestingly, only part of this gene group overlaps with two previous groups 
were PPARα or PPARδ were needed for basal expression. 
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Figure 7.5  Both PPARα and PPARδ are needed for target gene expression. Ablation 
of both receptors causes down-regulation of transcription. n=5 mice/group. Data are 
expressed as means  ± SEM 
 
The last, sixth group identified with the distinctive pattern of expression 
indicate that both PPARα and PPARδ are required in the normal condition for 
repression of the defined set of gene. Elimination of these both receptors from 
the hepatic environment, causes marked up-regulation of 275 genes (minimum 
1,5 fold up-regulation, P value <0.01, FDR <0.05). The three examples of this 
pattern are: abhydrolase domain containing 1 (Abhd1), possessing 
carboxylesterase activity (Fig. 7.6),  ATPase, H+ transporting, lysosomal V1 
subunit G1 (Atp6v1g1) with its product involved in transmembrane transport 
(Fig. 7.6 b) and acetyl-Coenzyme A acetyltransferase 3 (Acat3), with its protein 
working as a part of cellular response to fatty acid (Fig. 7.6 C). In this group of 
genes in normal condition, PPARα and PPARδ work as powerful repressors.  
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Figure 7.6 PPARα and PPARδ both needed for repression of the genes, which are 
generally non-responsive to GW501516 treatment. n=5 mice/group. Data are 
expressed as means  ± SEM 
 
Summary of PPARα and PPARδ coordination in regulation of gene expression 
is shown in table 7.2 
 
Table 7.2 Modes of PPARα and PPARδ cooperation in regulation of gene expression 
in the liver. 
Mode Description Figure 
PPARα as a repressor for 
PPARδ target genes 
hPPARδ over-expression or PPARα-knockout 
mediate marked change of expression of defined 
set of genes 
7.1 
148 
 
PPARδ-only specific 
gene targets 
Gene expression dependent on GW501516 
treatment but not influenced by PPARα ablation 
7.2 
PPARα as a “co-
activator” for PPARδ 
target genes 
Ablation of PPARα caused down-regulation of 
basal levels of the genes, which are reactive to 
PPARδ agonist 
7.3 
PPARδ repressive action 
needed for stable 
expression 
PPARδ knockout down-regulates basal levels of 
defined sets of genes 
7.4 
PPARα and PPARδ as  
cooperative “promoters” 
of gene expression 
Both PPARα and PPARδ are essential for 
defined set of genes expression 
7.5 
Both PPARα and PPARδ 
as copperative 
constitutive repressors 
Both PPARα and PPARδ are in normal condition 
required for repression of the defined set of gene 
7.6 
 
Apart from using microarray data for deciphering transcriptional 
relationship and collaboration between PPARα and PPARδ in regulation of 
gene expression, the hepatic expression profile was also used to predict 
prospective weight loss or hepatic steatosis in mice as a response to 
GW501516 treatment.  Group means for weight gain (% of initial body mass) 
and hepatic triglyceride levels at point of 2 weeks were formed from data from 
earlier experiments described in previous chapters. They reflected exactly the 6 
groups shown in this chapter. In details: non-transgenic mice fed control or diet 
supplemented in GW501516, non-transgenic, hPPARδ and hPPARδΔAF2 fed 
control + 0.25% I3C or diet supplemented with 0.25% I3C + 0.0025% 
GW501516; PPARα-KO and PPARδ-KO fed control or diet supplemented in 
GW501516 (w/w).  Phenotypic group means from the experimental 2 weeks 
time point were then correlated with hepatic gene expression data obtained 
from 5 days microarray experiment. 
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29 genes were identified, whose pattern of expression was significantly 
correlated with rate of weight gain established from previous independent 
experiments, however, no genes were found (FDR below 0.05), which would be 
significantly correlated with level of hepatic steatosis. Several genes involved in 
transmembrane transport were identified such as Abcc3 (Fig. 7.7 A), which 
plays role in bile acid and bile salt transport and has been reported in diabetic 
phenotype, Slc19a1 (Fig. 7.7 B) encoding folate transporter and Slc25a10 (Fig. 
7.7 C), the mitochondrial malate and succinate carrier. Other examples involve 
genes involved in lymphocyte differentiation like Ly6d (Fig. 7.7 D), which has 
been previously associated with the degree of hepatic steatosis in mice. 
Member of perilipin family S3-12, (Fig. 7.7 E), involved in coating intracellular 
lipid droplets and an adipogenic marker, gene expression governing genes such 
as Taf1d or cell growth factors like Igf1 (Fig. 7.7 F). All, but Igf1 turned out to be 
negatively correlated with weight gain. Full list of the genes is presented in 
Table 7.3. Examples of pattern of expression and correlation graphs of chosen 
genes are shown in Figure 7.7 
 
 
Table 7.3 List of the genes involved in promoting or assisting weight loss altered by 
GW501516 treatment in mouse liver and identified through correlation tests between 
microarray hepatic expression data from 5 days vs weight gain rate (% of initial body 
mass) after 2 weeks from several independent experiments.  
Gene symbol 
Enterez 
gene ID 
Pearson 
R 
P value 
False 
discovery 
rate 
Gene description Biological process 
Abcc3 76408 -0.9649 3.97E-07 0.003 
ATP-binding cassette, sub-family C 
(CFTR/MRP), member 3 
transmembrane 
transport 
Slc19a1 20509 -0.9355 7.91E-06 0.021 
Solute carrier family 19 
(sodium/hydrogen exchanger), 
member 1 
transmembrane 
transport 
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Slc25a10 27376 -0.9211 2.10E-05 0.034 
Solute carrier family 25 
(mitochondrial carrier, 
dicarboxylate transporter), 
member 10 
transmembrane 
transport 
Abcc4 239273 -0.9096 4.07E-05 0.033 
ATP-binding cassette, sub-family C 
(CFTR/MRP), member 4 
transmembrane 
transport 
Slc16a5 217316 -0.9003 6.53E-05 0.035 
Solute carrier family 16 
(monocarboxylic acid 
transporters), member 5 
transmembrane 
transport 
Srd5a3 57357 -0.9229 1.88E-05 0.038 Steroid 5 alpha-reductase 3 steroid catabolism 
Cbr1 12408 -0.9055 5.04E-05 0.034 Carbonyl reductase 1 redox recations 
Grpel1 17713 -0.8953 8.31E-05 0.035 
GrpE-like 1, nuclear gene 
encoding mitochondrial protein 
protein anabolism 
Ripk4 72388 -0.9023 5.94E-05 0.034 
Receptor-interacting serine-
threonine kinase 4 
phosphorylation 
Serhl 68607 -0.9201 2.24E-05 0.03 
Serine hydrolase-like (Serhl), 
mRNA. 
peroxisome function 
Atxn10 54138 -0.8938 8.87E-05 0.034 Ataxin 10 
nervous system 
development 
Chchd6 66098 -0.8978 7.38E-05 0.033 
Coiled-coil-helix-coiled-coil-helix 
domain containing 6 
mitochondrial 
function 
Ly6d 17068 -0.9099 4.02E-05 0.036 
Lymphocyte antigen 6 complex, 
locus D 
lymphocyte 
differentiation 
Unc119 22248 -0.9030 5.75E-05 0.035 Unc-119 homolog (C. elegans) 
lymphocyte 
differentiation 
S3-12 57435 -0.8770 0.00018 0.048 
Plasma membrane associated 
protein, S3-12 
lipid droplets coating 
Gns 75612 -0.8952 8.33E-05 0.033 
Glucosamine (N-acetyl)-6-
sulfatase 
glycosaminoglycan 
metabolic process 
Gal3st1 53897 -0.8796 0.000163 0.05 Galactose-3-O-sulfotransferase 1 glycolipid synthesis 
Cpsf1 94230 -0.8935 8.99E-05 0.033 
Cleavage and polyadenylation 
specific factor 1 
gene expression 
Taf1d 75316 -0.8913 9.93E-05 0.033 
TATA box binding protein (Tbp)-
associated factor, RNA 
polymerase I, D (Taf1d), transcript 
variant 2, mRNA. 
gene expression 
Sox12 20667 -0.8786 0.000169 0.05 SRY-box containing gene 12 gene expression 
S100a13 20196 -0.9524 1.78E-06 0.007 S100 calcium binding protein A13 cytokine secretion 
Igf1 16000 0.8777 0.000175 0.048 Insulin-like growth factor 1 cell growth 
Nrg4 83961 -0.8991 6.95E-05 0.033 Neuregulin 4 Cell growth 
Pmm1 29858 -0.9147 3.08E-05 0.035 Phosphomannomutase 1P 
carbohydrate 
metabolism 
Prune 229589 -0.8866 0.000122 0.039 Prune homolog (Drosophila) 
carbohydrate 
metabolism 
Tmem120a 215210 -0.9082 4.40E-05 0.032 Transmembrane protein 120A 
 
C230029F24Rik 442837 -0.9141 3.19E-05 0.032 
PREDICTED: Mus musculus RIKEN 
cDNA C230029F24 gene  
1600032L17Rik 
 
-0.9001 6.62E-05 0.033 
PREDICTED: Mus musculus RIKEN 
cDNA 1600032L17 gene  
2410012H22Rik 69747 -0.8784 0.00017 0.049 
PREDICTED: Mus musculus RIKEN 
cDNA 2410012H22 gene  
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Figure 7.7 Genome-wide transcriptional profiling of GW501516 effects in various 
genetic models reveals strong correlation between liver gene expression after 5 days 
and successive weight gain rate after 2 weeks. Pattern of hepatic gene expression 
across the experimental genotypes in 5 days (bars graphs) and 2 weeks weight gain vs 
5-days  expression data for Abcc3 (A), Slc19a1 (B), Slc25a10 (C), Ly6d (D), S3-12 (E), 
Igf1(F) (scatter graphs). Each point on the scatter graph represents mean value of 
each group (control or treated vs expression value) for given gene. n=5 mice/group. 
Data are expressed as means  ± SEM 
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7.3 Discussion 
In vivo model for investigation of PPARα and PPARδ cooperation in 
transcriptional regulation of gene expression. 
In nuclear receptor biology, initial activity of these transcription factors, translate 
subsequently into metabolic and physiological changes. Although the time 
course of the experiment was 5 days only, too short to induce major 
physiological alterations seen in the longer studies in previous chapters, it 
turned out to be sufficient enough to expose important gene expression 
mechanisms. The other advantage of 5 days study only was also preservation 
of nuclear-receptor-based transcriptional activity of whole sets of genes, not 
influenced yet by various physiological feedback loops and homeostatic 
mechanisms, which are likely to occur in later stages of chronic ligand 
treatment. One of the aims of this chapter was to show elaborate cooperation 
between PPARα and PPARδ in transcriptional regulation of their target genes. 
Indeed, several distinctive ways have emerged how these two receptors in 
close collaboration regulate mRNA synthesis of defined set of genes.  One of 
the most intriguing was when over-expression of hPPARδ or deletion of PPARα 
had a similar and profound effect on mostly up-regulation of a certain set of 
genes. In both cases PPARδ signalling was becoming dominant over PPARα 
activity. Clearly it is not only the activation status of these receptors that 
determines the transcriptional outcome of target genes, but also relative 
proportion of the subtypes that is present in the system. In contrast to the 
mouse, human liver is known to have PPARδ dominating over PPARα 
quantitatively [93,125]. As the figure 7.1 shows, for given sets of genes, over- 
expression of hPPARδ might indeed “humanize” rodent liver, at least in relation 
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to PPARs abundance proportion. Although in the liver of non-transgenic mice 
the level of expression of PPARα is higher than PPARδ expression [12], during 
fasting the situation changes quantitatively even more in favour of PPARα [118]. 
Interestingly Escher et al showed that this physiological/nutritional change of 
proportion is due to the PPARδ, which is down-regulated in the liver in 
prolonged fasting. After an overnight fast, the authors observed a similar 
decrease in hepatic PPARδ mRNA expression in wild-type and PPARα null-
mutant mice by up to 80% [173]. Thus, they concluded that nutritional regulation 
of hepatic PPARδ mRNA expression by fasting is independent of the activity of 
PPARα. Here we show that although the level of expression of PPARδ mRNA 
might be might be not dependent on PPARα presence or activity in the liver, the 
target genes for PPARδ are highly influenced by absence of PPARα. One might 
speculate that physiological decreases in the levels of PPARδ in the rodent and 
possibly in human liver during fasting might be a metabolic adaptation for 
“sensitizing PPARα” and subsequently facilitating its transcriptional activity 
along with ligand availability and abundance of its nuclear-receptor protein. It is 
equally possible that an analogous mechanism exists for PPARδ being 
“sensitized” by PPARα absence (KO animals) or great reduction in proportions 
(hPPARδ over-expression), that he have just shown using DNA microarrays. 
However, such hypothesis would assume that at least in certain range of genes 
and molecular events, these two receptors have antagonistic properties. The 
work done by Gustafsson et al seems to confirm this, by showing that genetic 
ablation of PPARδ removes its role in retarding of PPARα and PPARγ signalling 
[148]. 
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Summarizing, the expression patterns shown in groups 1 and 2  (Fig 7.1 
and Fig 7.2 respectively), are quite similar and partly overlap, with the main 
difference that the first set of  genes is not reactive to GW501516 in non-
transgenic animals, unlike the latter group, where their up or down-regulation is 
clearly noticeable in wild-type animals as well. 
 Expression patterns 3 and 4 (Fig 7.3 and Fig 7.4 respectively), where 
PPARα or PPARδ genetic ablation causes marked down-regulation of mRNA of  
specific groups of genes is fully consistent with the findings described in work 
performed by Adhikary et al [153]. The authors clearly find that siRNA silencing 
of PPARδ down-regulates given sets of genes, but these genes are normally 
not reactive to PPARδ ligand. It is tempting to speculate whether therapeutic 
implementation of such mechanism of transcriptional control would not provide 
stronger effects than simple use of specific antagonist, which only prevents the 
receptor from activation, stabilizing its basal transcriptional activity [174]. 
 Even more pronounced effect of transcriptional regulation highly 
dependent on close PPARα and PPARδ cooperation emerges from expression 
patterns 5 and 6 (where basal level of specific groups of the genes was down-
regulated or up-regulated, respectively) after simultaneous genetic ablation of 
both receptors.  Already cited in the introduction for this chapter recent report 
from Bugge et al shows similar phenomenon. In short: genetic KO of nuclear 
receptors Rev-erbα together with closely related Rev-erbβ in mouse embryonic 
fibroblasts, renders circadian clock proteins Bmal1 and Cry1 expression 
arrhythmic. It was in contrast to the mild effect on these clock genes, when only 
single deletion of Rev-erbα or Rev-erbβ was present. The  authors conclude 
that this subtype collaboration is unusual among nuclear receptors but common 
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among core clock proteins [172]. In our work we show that this cooperation 
extends also to peroxisome proliferator-activated receptors. It is also 
characteristic that genetic ablation of PPARα or PPARδ causes always two-way 
transcriptional reaction: up-regulation and down-regulation of given sets of 
genes. It is certainly individual case for each gene what is exact mechanism 
how this is achieved. This subject was partly discussed in the previous chapter, 
but without doubt it consists of complex interaction between various co-
repressors and co-activators for which nuclear receptor in normal condition is 
either a constitutive direct repressor or repressor of repressors. Summarizing, 
the picture which emerges from our data shows that abundance of nuclear 
receptor in “unliganded”, dormant state is equally important for gene expression 
as ligand binding and its subsequent downstream signalling. However, the 
subsets of the genes controlled and modulated by dormant nuclear receptor do 
not overlap fully with groups controlled by agonist activity. 
 
Early hepatic gene expression predicts rate of subsequent weight loss 
upon GW501516 treatment. 
 Genome-wide transcriptional profiling has also demonstrated that early 
transcriptional actions in the liver involving PPARα-PPARδ tandem activities, 
translates directly into phenotypic events in later stages. By comparing 
transcriptional profile of various strains of mice fed GW501516 for 5 days we 
were able to correlate it directly with weight loss or gain phenotype from two-
weeks. However, significant correlation failed to occur with the hepatic 
triglyceride profiles defined for mice from previous experiments. It confirms the 
already mentioned hypothesis that reduction in peripheral fat deposits and 
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therefore consequent weight loss precedes and is essential for hepatic lipid 
accumulation observed in our mice genetic models upon GW501516 treatment. 
The most numerous group of the genes significantly correlated with the weight 
loss turned out to be transmembrane transporters. Abcc3 was one of the most 
significantly associated genes. In study done by Hardwick et al hepatic mRNA 
for Abcc3 was found to be elevated in human liver samples with confirmed non-
alcoholic liver fatty live disease (NAFLD). However in the same study 
immunohistochemical staining of Abcc3 revealed no alterations in cellular 
localization during NAFLD progression [175]. Additionally, More et al found that 
mRNA for Abcc3 and Abcc4 transporters in livers of obese db/db mice (genetic 
deletion of leptin receptor) were expressed more than 2 fold higher, than in 
C57BKS wild-type mice [176]. Abcc3 transporter along with Slc19a1, which was 
also highly associated with forthcoming weight loss in our data, is also a 
significant drug transporter, an important factor in response to methotrexate, a 
drug used for treatment of juvenile idiopathic arthritis [177]. Another member 
from our transporter hits:  Slc25a10 was found to be facilitating de novo fatty 
acid synthesis in white adipose tissue [178]. Slc25a10 supplies malate for 
citrate transport. Citrate is required for forming acetyl-CaA a key component of 
lipogenesis [178]. Although in our model of hepatic triglyceride accumulation the 
expression of fatty acid synthase plays a minimal role, and FAS is considered 
the rate limiting step in de novo lipogenesis in the liver, it remains a possibility 
that some aspects of lipogeneis are raised in our model; However, this 
transmembrane transporter is also involved in glucose metabolism. Slc25a10 
was shown to be essential for glucose stimulated insulin secretion (GSIS). In 
work published by Huypens et al, an adenovirus expressing a siRNA against 
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Slc25a10 inhibited GSIS [179].   S3-12 was also identified as being highly 
correlated with weight loss.  S3-12 is a member of perilipin family with function 
similar to ADRP. This is very interesting as we demonstrated that, whereas 
ADRP expression was highly correlated with the level of hepatic lipids in non-
transgenic, hPPARδ and hPPARδΔAF2 mice, it was still highly inducible in 
PPARα-KO livers where lipid accumulation was absent (Fig 6.5A and Fig 6.6A). 
On the other hand, S3-12 expression was tempered efficiently by genetic KO of 
both receptors (Fig. 7E). S3-12 was previously shown to be involved in fatty 
liver phenotype when PPARγ1 was over-expressed in transgenic mouse [180], 
is induced by fasting in PPARα null mice [12], and in our study, we also 
demonstrate it as a PPARδ target gene in the mouse liver.  
Another strong candidate for fatty liver phenotype, although not directly 
associated with triglyceride accumulation is Ly6d a part of lymphocyte antigen 
complex. In microarray analysis of liver transcriptome from apoE-deficient mice 
fed a western-type diet enriched with linoleic acid isomers (known to promote 
fatty liver in mice), the Ly6d was found among other 9 genes highly associated 
with the degree of steatosis [181]. The mentioned study’s duration was 12 
weeks and our experiment was performed for 5 days only. It shows how 
consistent the elevated expression of Ly6d is in molecular events leading to 
liver triglyceride accumulation. If future studies confirm up-regulation of Ly6d in 
the early stages  of  hepatic steatosis, it might serve as a solid biomarker for 
fatty liver.   
The only significantly negative correlation of expression of a gene with 
subsequent weight loss was Igf1. Low levels of insulin growth factor 1 were 
found in sera of patients with hepatic steatosis and the authors concluded that 
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this association was independent of alcohol consumption [182]. Also Estep et al 
reported that miRNA specimens associated among others to IGF1, were 
differentially expressed in white adipose tissue between NASH and non-NASH 
patients. [183].  
In summary, utilizing microarray technique we were able to identify a 
group of hepatic genes in which expression was strongly correlated with future 
metabolic events leading to GW501516-induced reduction in body weight and 
consequent triglyceride accumulation in the mouse liver. Additionally, close 
transcriptional mutual collaboration and antagonistic properties were revealed 
between PPARα and PPARδ in the control of gene expression in the liver. 
 
 
159 
 
Chapter 8 Conclusions 
 
The work shown in this thesis has focused on deciphering the role of 
peroxisome proliferator activated receptor delta in the control of body weight 
and hepatic lipid homeostasis. The results of this analysis will contribute to the 
overall assessment of the drug safety profile of a new generation of drugs that 
selectively target PPARδ. 
Up to date, there are still no drugs available on the market, which 
selectively target PPARδ receptor. However, synthetic agonists for PPARδ were 
shown to attenuate multiple metabolic abnormalities normally associated with 
the metabolic syndrome in humans, by lowering fasting and postprandial 
plasma triglyceride, LDL cholesterol, FFA and increase HDL cholesterol 
[116,184]. At the molecular level PPARδ activation has been shown to modulate 
the expression of a number of genes in muscle, which are involved in lipid 
uptake, storage and metabolism and also in glucose homeostasis 
[22,113,123,124,185]. Apart from its important role in skeletal muscle 
metabolism, evidence is accumulating that PPARδ, plays equally vital role in the 
management of lipid turnover also in the liver [129,130,186,187]. 
At the beginning of this work there were contradicting reports on PPARδ 
agonism promoting or protecting from fatty liver phenotype. Giving the 
promising role of PPARδ agonists in improving of some aspects of metabolic 
syndrome and susceptibility of individuals with this syndrome or type 2 diabetes 
to fatty liver steatosis, this thesis along with the newest published reports will 
add to understanding of the less characterized, but essential from toxicological 
perspective role of selective PPARδ synthetic agonists in liver lipid response.  
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Effect of PPARδ agonism on body weight 
 
PPARδ synthetic agonists retard the rate of weight gain in rodent models 
of high-fat diet–induced obesity [81,123,188] and the experimental approach 
presented in this thesis focused on in vivo pharmacological studies using 
various genetic models of mice including humanized animals. 
However, unlike in the rodent model, 4-month treatment of obese rhesus 
monkeys with different doses of GW501516 did not affect body weight [127]. 
Therefore it is still an open question, if long-term delivery of drugs based on 
PPARδ ligands will control body weight in primates. For example in a recent 
study conducted in men, in 12 weeks of administration of GW501516, loss in 
body weight was not apparent. Although an increase in body reduction was 
seen for the highest dose group (10 mg), the data collected did not allow 
characterization of the weight change composition, which potentially includes 
fat, muscle mass, glycogen storage, or water [184]. The importance of body 
composition change upon GW501516 action was revealed when examining 
body fat and lean mass in transgenic and non-transgenic mice shown in chapter 
4. The greatest input to total weight reduction in hPPARδ mice was white fat 
mass decrease, which is consistent with findings from Wang et al, where WAT 
and BAT-specific expression of constitutively active VP16-PPARδ protein 
caused almost complete reduction in adipose tissue mass [81]. Although 
PPARδ is expressed ubiquitously in rodents and in humans, its expression in 
skeletal muscle is 10 and 50-fold higher levels compared with PPARα and 
PPARγ, respectively [189]. Also, muscle accounts for approximately 80% of 
insulin-stimulated glucose uptake, therefore it might be assumed that the main 
energy requirement for lipids, when glucose is low, is coming from the muscle. 
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And therefore the signalling from muscle partly stimulated by PPARδ 
transcriptional activity in this organ will be the main cause to drive adipose 
tissue lipolysis. However, I3C-induced over-expression of hPPARδ in our 
transgenic mice was almost exclusively restricted to liver (Fig. 4.9) and partly to 
other organs [140], but in the muscle, transgene expression was extremely low 
when compared to mentioned organs. Additionally, the endogenous mouse 
PPARδ was still active in muscle of transgenic mice, but the difference in weight 
loss between hPPARδ and wild-type animals was still very significant (Fig. 4.1A, 
4.2 A and B). And the lack of body mass reduction in hPPARδΔAF2 animals 
treated with GW501516, which also had expression of the transgene mostly 
confined to liver, seems to confirm importance of liver. Therefore, liver emerges 
as a key organ in PPARδ-stimulated reduction in weight gain. The hypothesis 
suggested by Perreault et al [144] that PPAR agonists might suppress the 
appetite and therefore this is one of the primary reasons for weigh gain 
reduction was partly confirmed in wild-type animals, but not supported in 
experimental evidence from hPPARδ animals in this thesis.  
In most cases, the WAT lipolysis occurs upon hormonal stimulation [15]. 
But the pharmacological stimulation of weight reduction by use of PPARδ 
synthetic agonists does not necessarily absorb hormonal-induced initiation of 
triglyceride hydrolysis and release. A proposed candidate factor linking hepatic 
PPARδ activity and the nutrient and hormone dependent and independent WAT 
lipolysis, is ANGPTL4. A wealth of evidence from in vivo studies shows that 
ANGPTL4, a glycoprotein that is secreted by the WAT and liver, plays a 
fundamental and essential role in not only preventing the uptake of triglyceride 
rich lipoproteins by WAT, but also in adipocyte lipolysis [149,166]. As it was 
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shown by Grey et al ANGPTL4 positively modulates the activity of cAMP-
dependent protein kinase A (PKA). And the phosphorylation by this kinase is 
essential for activation of triglyceride hydrolytic enzymes [166]. Recently, 
ANGPTL4 supportive role in mediating triglyceride hydrolysis and release of 
FFA from adipocytes was linked with PPARδ activity [12,157,165], which is not 
surprising as ANGPTL4 is PPARδ target gene. By using RT-PCR we 
demonstrated PPARδ-mediated up-regulation of ANGPTL4 in livers of wild-type 
animals after 2 weeks or PPARα-KO mice at every measured time point (Fig. 
4.11E and Fig. 6.6 C respectively), but this change was absent in mice 
expressing hPPARδ after 2 weeks (Fig. 4.11E). However, microarray data 
evidently show that hPPARδ animals fed GW501516 along with the wild-type 
animals and PPARα-KO, but not the hPPARδΔAF2 and PPARδ-KO mice had 
significantly up-regulated levels of ANGPTL4 (Fig. 7.2 B). These findings also 
indicate that ANGPTL4 expression is not dependent on PPARα signalling, but 
as it was shown using PPARα-KO animals, PPARα presence is required for 
GW501516-stimulated lipolysis nevertheless. Therefore PPARδ regulation of 
ANGPTL4 is not sufficient to account for GW501516 mediated lipolysis.  
Together these findings suggest that PPARδ activation can not only 
induce efficient fat burning [31], but also seems to initiate white adipose tissue 
lipolysis in hormone-independent way through ANPTL4 up-regulation. 
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Modulation of hepatic lipid homeostasis by PPARδ agonists 
 
As demonstrated in this thesis, PPARδ activity leads to triglyceride 
accumulation in the liver of non-transgenic and especially in mice over-
expressing hPPARδ. This phenomenon is transient, at least in wild-type 
animals, but the question remains if this pharmacologically-induced temporary 
liver steatosis is still toxicologically relevant phenomenon. There is still much to 
be known about the progression from “simple” liver steatosis to non-alcoholic 
steatohepatitis (NASH) or from NASH to cirrhosis. These steps are crucial. 25-
75% type 2 diabetic patients develop fatty liver phenotype [190]. Influx or 
synthesis of additional fat may trigger or speed up the progression to more 
advanced disease level in patients with metabolic syndrome or type 2 diabetes 
[38].  
Although earlier reports indicate that PPARδ can be down-regulated in 
rodent liver after fasting [173], this nuclear receptor activity is responsible for 
fasting and exercise-induced metabolic transcriptional changes, which lead to 
major alteration in glucose and lipid metabolism and the liver is key organ in this 
process [31,142,191,192]. Therefore systemic delivery of potent PPARδ ligands 
will have profound influence on hepatic physiology either direct or indirect [10]. 
Stannard et al showed that 72 hours fasting increases intramyocellular lipid 
content in non-diabetic, physically fit men [193] and Moller et al demonstrated 
that intrahepatic lipid content in human subjects measured by 1H-magnetic 
resonance, increased significantly after the 36 h fasting period by 156% [51]. 
Rodent fasting physiology is also comparable with human. For example, 12–
18h fasting in voles results in livers displaying steatosis with characteristic 
accumulation of triacylglycerols, while fatty acids prevalent in membrane 
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phospholipids decreases in proportion [194]. Additionally van Ginneken reports 
that 24h starvation in mouse leads to significant rise in hepatic triacylglycerols 
by 456% [195]. And other reports shows similar phenomenon [19,196]. Another 
metabolic area where PPARδ is particularly important is physical activity. 
PPARδ agonists were even proposed as exercise mimetics [121]. In work done 
by Hu et al, the authors demonstrated that after one bout of exercise in mice 
hepatic triglyceride species were found to be more abundant in the recovery 
phase, while phosphatidylcholines species were decreased [197]. The same 
authors also show that muscle triglyceride content was decreased during 
exercise presumably due to increased muscle fatty acid oxidation. This is in 
accordance to our findings where we were able to show promotion of pro-lipid 
oxidative transcriptional changes in muscle of non-transgenic and especially 
hPPARδ animals treated with GW501516. 
In natural physiological state, PPARδ is being activated upon increased 
energy demands, governing a number of pathways, which lead to utilization of 
fat as an energy substrate [191,198]. Pharmacological activation of PPARδ 
using highly selective, potent, but artificial ligands like GW501516, initiates 
whole metabolic sequences without the actual energy demand. In such case, 
adipose tissue releases fatty acids, which are not immediately required to power 
the body organs. In work published by Berge et al, the authors demonstrated 
that tetradecylthioacetic acid (TTA) a PPARα and PPARδ dual agonist helps to 
improve blood hyperlipidemia in rats. They formed the hypothesis that free fatty 
acids (FFA) will be drained from the plasma into the liver, and oxidized at the 
expense of triglyceride accumulation in the hepatocytes. And draining of FFA by 
the liver will relieve the fatty acid pressure on adipose and muscle tissue where 
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glucose uptake and oxidation is inhibited by fatty acids [10]. Similar conclusion 
were drawn by Liu et al where they have shown that adenovirus-mediated liver 
restricted PPARδ activation reduces fasting glucose levels in normal and high 
fat diet - fed mice. This effect was however accompanied by hepatic glycogen 
and lipid deposition [128]. On the other hand however, still reasonable evidence 
supports the hypothesis that PPARδ agonism is protective against hepatic 
steatosis. In recent work by Lee et al, rats treated with GW0742 from 26 to 36 
weeks showed improvement in fatty infiltration of the liver [199]. And in the 
MCD-diet induced mouse model of NASH, treatment with GW501516 
ameliorates hepatic steatosis and inflammation by improving lipid metabolism 
and inhibiting inflammation [129]. Our observation and other reports [124] 
indicate that time of treatment is the key factor.  The mechanism by how this is 
achieved is a matter of availability of substrate to infiltrate the liver (abundance 
of WAT deposits being lipolysed by PPARδ pharmacological activation) and 
production and steady build up of particular inducer of hepatic fatty acid 
oxidation. Experimental evidence shown in this thesis suggest that despite 
availability of WAT deposits, fat is cleared from the liver, as was demonstrated 
in wild-type animals in chapter 3. Liu et al proposed that PPARδ agonism 
protective role against hepatic steatosis relies on generation of protective mono-
unsaturated and lowering lipotoxic saturated fatty acid levels [128]. Our findings 
showing time-depended increase in PPARα endogenous ligand (POPC) fully 
confirm and strengthen this hypothesis.  
Together these data support a beneficial role for PPARδ ligands in the 
improvements of diabetes, but care need to be taken when considering 
treatment of patients with defined NASH with PPARδ agonists. 
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PPARα-PPARδ interaction 
 
The successful use of the fibrates class of drugs as an efficient treatment 
for dyslipidemia, was attributed to activation of PPARα receptor [99]. 
However, in one of the first reports of using PPARδ ligands in PPARα-
null animals, which came from DeLuca et al work [200], the authors found that 
administration of PPARδ agonists to mice lacking PPARα induces peroxisome 
proliferation in the liver a phenomenon formerly solely credited to PPARα 
activity. It opened up the question of functionality overlaps and mutual 
interactions. The findings presented in chapters 6 and 7 from this thesis unravel 
the complex system of interaction between these two receptors in controlling 
transcription of multiple sets of genes. Alterations in gene expression in PPARα-
KO mice treated with the PPARδ agonist are also reflected in lack of phenotypic 
changes traditionally attributed to PPARδ agonism like mobilization peripheral 
lipid stores and subsequent weight reduction. On the other hand, we observed 
that the ability of PPARδ agonists of raising HDL levels could be still evident in 
PPARα-KO animals. Previous [127] and more recent [184] findings shown that 
PPARδ agonists may be effective drugs to increase reverse cholesterol 
transport and we have now demonstrated that PPARα signalling is not 
necessary in this process.  
One of the important question which remains to be answered is whether 
small molecule agonism or antagonism of PPARα could have the same 
consequences for PPARδ-agonism as genetic ablation of PPARα had, as 
shown in this thesis. As we demonstrated, absence of PPARα blocks efficiently 
some important PPARδ agonistic attributes in relation to its anti-obesity 
properties.  Adhikary et al also shown that for transcription of certain set of 
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genes siRNA-mediated removal of PPARδ protein is equal to ligand binding to 
existing receptor [153]. We confirmed that removal of PPARα or PPARδ has 
always two way consequences of up and down-regulations of whole group of 
genes. De-repression mechanism by removal of the functional nuclear protein 
from the system was also evident, when levels of POPC in PPARδ-KO animals 
were found to be elevated, when compared to wild-type animals. PPARδ 
agonist treatment had similar effect (Fig. 6.13).  If the fibrate-responsive genes 
at least in part, belong to the group where ligand binding and ablation of the 
receptor causes the same transcriptional event, simultaneous therapeutic use of 
fibrate class of drugs and specific potent PPARδ agonists could prove counter-
productive in medical application of PPARδ ligands. On the other hand, 
research from use of pan activators of PPARs such as punicic (PUA), jacaric 
acid (JAA) catalpic (CAA), and eleostearic acids (ESA) shows that all have 
demonstrated some promising health effects by acting as dual or pan agonists 
of PPARs [86]. In addition we demonstrated that mutual cooperation between 
PPARα and PPARδ in clearance of hepatic fat relies on generation of POPC, 
and endogenous PPARα ligand.  However, care needs to be taken as evidence 
is constantly growing that PPARs can have mutual antagonistic effects and 
interaction between three subtypes of PPARs is important for understanding 
biology of these transcription factors. For example, Gustafsson et al found that 
dominant negative form of PPARδ will have positive and pronounced effect on 
PPARα and PPARγ signalling [148] and one of the recent report from Kocalis et 
al shows that neuron-specific deletion of PPARδ causes up-regulation of 
PPARγ and target genes of both PPARα and PPARγ, as well as genes of fatty 
acid oxidation [151]. The complex interplay between the isoforms of PPARs is 
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illustrated by the regulation of expression of cyclooxygenase-2 (COX-2) in rat 
brain astrocytes. The authors discovered that thiazolidinediones increase COX-
2 expression via a PPARγ-dependent increase of PPARδ receptors [201]. 
Furthermore, they found that positive influence of PPARγ and negative 
influence of PPARα on PPARδ transcriptional activity occurs via regulation of 
the expression level of PPARδ. Additionally, the PPARδ-activation resulted in 
an increase of PPARα expression level, thus forming a positive/negative 
feedback loop [201]. PPARδ signalling serves as a connection of PPARγ and 
PPARα-dependent signals to target genes. A crossroad between PPARs was 
suggested previously. Zuo et al found that linoleic acid activates PPARδ and 
subsequently inhibits PPARγ activity [202]. And Shi et al showed that even 
stable expression of PPARδ isoform is sufficient to repress the induction of 
PPARα target genes [203]. In this way, not only the absolute levels of any one 
PPAR isotype but also the ratio of the PPAR isotype levels will control the 
activity of each member of PPAR family. Summarizing, when considering 
therapeutic use of PPARδ agonists or antagonists one needs to bear in mind 
that PPARδ can be also considered as regulator and gatekeeper of other PPAR 
subtypes for which clinically drugs are in use and therefore possible 
antagonistic interaction is likely to occur, when co-used with prospective PPARδ 
potent modulators. 
 
Concluding remarks and future directions 
Although the biology of PPARδ has not been fully deciphered, here we show 
the evidence that liver specific over-expression of human PPARδ in mouse liver 
promotes hepatic steatosis conferred through extensive peripheral adipose 
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tissue lipolysis and consequently an influx of fatty acids into the liver. As a 
result, PPARδ emerges not only as a master controller of lipid oxidation genes, 
but also as a modulator of transmembrane transport and WAT lipolysis possibly 
through ANGPTL4 activity, one of the key PPARδ target genes. This effect 
however, requires PPARα signalling regardless the levels of ANGPTL4. The 
mechanism by which the absence of PPARα inhibits PPARδ-induced lipolysis of 
adipose tissue is worth exploring, taking into consideration the importance of 
this mechanism in anti-obesity related drug research. Findings in this thesis also 
provide evidence for tight interplay between members of PPAR family. 
Investigation of the exact role the PPARδ has in controlling the two other PPAR 
subtypes would be also significant, bearing in mind that thiazolidines as ligands 
for PPARγ and fibrates for PPARα have been both useful and troublesome. 
Using PPARδ as indirect modulator of PPARα and PPARγ when challenging 
pathological aspects of metabolic syndrome could be promising way of 
improving mode of actions of these drugs. 
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